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ABSTRACT  
 
Synthesis of cyclodextrin derivatives for organocatalysis 
 This doctoral thesis examines the preparation of new cyclodextrin (CD) derivatives suitable 
for organocatalysis. The aim of this work is to prepare monosubstituted and disubstituted CD 
derivatives as organocatalysts for different types of enantioselective reactions potentially performed in 
water. In addition, disubstituted CD derivatives require considering the potential mixture of 
regioisomers and pseudoenantiomers. Thus, this thesis is divided into several sections – preparation of 
CD precursors and derivatives for organocatalysis, preparation of pure regioisomers and 
pseudoenantiomers of disubstituted CDs and final application of CD derivatives in enantioselective 
reactions. Furthermore, this thesis also focuses on the molecular modeling of the prepared CD 
derivatives and on their catalytic activity in silico. 
The first section covers the preparation of new disubstituted CD precursors as pure 
regioisomers for organocatalysts, specifically to develop a new method for the preparation of 
heterodisubstituted AC regioisomers on the primary rim of α-CD. This section also includes the 
determination of the regioisomer ratios of common α-CD intermediates disubstituted on the primary 
rim to evaluate their potential as precursors in organocatalysis.   
The second section of this thesis focuses on the preparation of new monosubstituted and 
disubstituted CD derivatives (of native and permethylated CDs) with Cinchona alkaloids (cinchonine, 
cinchonidine, quinine and quinidine), their application as organocatalysts in enantioselective reactions 
and the evaluation of their catalytic activity also in water.   
The third section includes the molecular modeling of Cinchona alkaloids and CDs. The 
inclusion complex of quinine and native β-CD in water was investigated as a model system. Moreover, 
all monosubstituted Cinchona-CD derivatives were geometric-optimized and equilibrated, and their 
spatial arrangement with substrates in enantioselective reactions was predicted based on these 
calculations. 
 
Keywords: Cyclodextrins, catalysis, Cinchona alkaloids, regioisomers, molecular modeling 
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ABSTRAKT  
 
Syntéza cyklodextrinových derivátů pro organokatalýzu 
Tato disertační práce se zabývá přípravou nových cyklodextrinových (CD) derivátů vhodných 
pro organokatalýzu. Cílem této práce je připravit monosubstituované a disubstituované CD prekurzory 
a deriváty jako organokatalyzátory, které by bylo možné použít v různých enantioselektivních 
reakcích, provedených potenciálně ve vodě. V případě disubstituovaných CD derivátů bylo též 
nezbytné uvažovat o případných regioisomerech a pseudoenantiomerech těchto derivátů. Práce je tedy 
rozdělena do několika částí – příprava CD prekurzorů a derivátů pro organokatalýzu, příprava a 
separace regioisomerů a pseudoenantiomerů disubstituovaných CD derivátů a finální aplikace CD 
derivátů v různých enantioselektivních reakcích. Navíc je tato práce doplněna o molekulové 
modelování připravených CD derivátů a jejich katalytické aktivity in silico.   
První část práce se zabývá přípravou nových disubstituovaných CD prekurzorů jako čistých 
regioisomerů pro organokatalýzu, zejména se zabývá vývojem metody pro přípravu 
heterodisubstituovaného AC regioisomeru na primární straně α-CD. Tato část také zahrnuje stanovení 
poměru jednotlivých regioisomerů běžně používaných disubstituovaných α-CD intermediátů 
s ohledem na jejich možné využití jako prekurzorů v organokatalýze.  
Druhá část se zabývá přípravou nových monosubstituovaných a disubstituovaných CD 
derivátů (od nativních a permethylovaných CD) s chinolinovými (Cinchona) alkaloidy, jejich aplikací 
jako organokatalyzátorů v enantioselektivních reakcích a zhodnocením jejich katalytické aktivity 
v těchto reakcích proveditelných ve vodě. 
Třetí část zahrnuje molekulové modelování chinolinových alkaloidů a CD. Nejdříve byl 
zkoumán vznik inkluzního komplexu chininu a nativního β-CD ve vodě pro ověření podmínek 
použitých v molekulárně-dynamických simulacích. Dále byly CD deriváty monosubstituované 
chinolinovými alkaloidy optimalizovány metodami molekulové dynamiky a na základě těchto výpočtů 
bylo zkoumáno jejich prostorové uspořádání se substráty v enantioselektivních reakcích.  
 
Klíčová slova: Cyklodextriny, katalýza, chinolinové alkaloidy, regioisomery, molekulové modelování  
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1. INTRODUCTION 
Cyclodextrins1 (CDs), synthetic compounds known for more than 120 years, have become key 
compounds in the industry and in research in recent decades. These non-toxic molecules prepared 
from starch have a hydrophobic cavity which determines their applications in the pharmaceutical and 
food industries. Accordingly, considerable research effort has been put into synthesizing new CD 
derivatives with enhanced properties and into applying them in different fields (pharmacy, food, 
agriculture and toiletry, among others), in addition to catalysis.   
As catalysts, CDs show promising properties by enabling (new) organic reactions in water, 
they are quite easily removed and recovered from reaction mixtures and enhance the stereoselectivity 
and enantioselectivity of products.2 In comparison, asymmetric organocatalysis3 has become important 
research field in organic synthesis thanks to the preparation of various enantiomer-enriched 
compounds. Creating new efficient catalytic systems (non-toxic, without metal) has made it possible 
to prepare a wide range of new chiral compounds for the pharmaceutical and other industries.  
However, systems combining organocatalytic groups and CDs for asymmetric synthesis are 
still scarce. Furthermore, only a limited number of organic reactions have been catalyzed with CDs 
with a good enantiomer excess thus far. Furthermore, research has also focused on developing water-
soluble new CD derivatives for different purposes, which is the key step in green chemistry.4 
CD derivatization is crucial step to improve the properties of CDs (solubility, catalytic groups) 
and thus, to widen the applications of CDs in research and in the industry. Derivatizations of the CD 
skeleton can be performed either randomly or selectively. For some applications, only randomly 
substituted CD derivatives can be used, requiring no method for the selective modification of CD 
skeleton. One of these examples is randomly-methylated β-CD (RAMEB). Although the methyl 
groups are not selectively attached to CD anchor in this derivative, its preparation is highly 
reproducible.5 These randomly substituted CDs are directly used as mixtures of derivatives in some 
applications, but the preparation of selectively modified CD derivatives is often required in other 
applications. Nevertheless, a range of different selectively modified CD derivatives has been already 
prepared, but the similar reactivity of hydroxyl groups of the CD skeleton remains a problem; thus 
preparation of selectively substituted CD derivatives is a leading challenge for synthetic chemists.  
Concurrently, molecular modeling and simulation studies have helped experimental synthetic 
chemists to visualize molecules easily without any experimental background and to predict chemical 
phenomena. Moreover, using relatively inexpensive computational equipment, the arrangement of the 
molecules and thus, the catalytic activity of (not only) CD derivatives can be predicted in order to 
confirm or disprove hypotheses of synthetic chemists. Based on the above, computational simulation 
accelerates chemical research and helps us propose and design better and more efficient catalysts.  
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2. OBJECTIVES 
The main goal of this thesis was to prepare new CD precursors and derivatives for asymmetric 
organocatalysis and to evaluate them in enantioselective reactions.  
 
This general goal encompasses the following partial goals: 
a) to prepare different regioisomers on the primary rim of disubstituted CD derivatives as 
precursors for heterodisubstituted CD organocatalysts for enantioselective reactions 
b) to investigate the regioisomer ratio of commonly used primary-rim disubstituted CD 
precursors for their future use as pure regioisomers and pseudoenantiomers  
c) to develop a method for attaching the CD skeleton to catalytic groups commonly used in 
asymmetric synthesis - Cinchona alkaloids 
d) to prepare a series monosubstituted Cinchona alkaloid-CD derivatives (non-methylated 
and permethylated) using the method  developed in c) 
e) to evaluate the prepared CD derivatives in various asymmetric reactions investigating the 
possible use of water as a solvent 
f) to simulate the catalytic behavior of Cinchona-CD derivatives with various substrates in 
silico 
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3. STATE OF THE ART 
3.1.  Cyclodextrins  
Cyclodextrins (CDs) are cyclic oligosaccharides consisting of a 4C1 chair conformation of 
α-(1→4)-D-glucopyranoside units. The most common CDs are α-, β- and γ-CDs with 6, 7 and 8 
glucose units (Figure 1).  The cyclic arrangement of glucose units creates the cone shape of these 
molecules. Because of this truncated cone, the inner space termed cavity is mainly hydrophobic 
(mainly C-H bonds and glycosidic oxygens), whereas the outer part of the CD with hydroxyl groups is 
hydrophilic.1  
 Figure 1. Graphical representations of the most common α-, β-, γ-CDs used in this work 
CDs were discovered in 1891 by French scientist Antoine Villiers (1854 – 1932), who 
identified new compounds after heating starch with Bacillus amylobacter. Nearly a century later, CDs 
entered their renaissance in the 1980s when researchers found breakthrough applications and new 
approaches for the mass production of these compounds. The pioneer of this period was József Szejtli 
(1933 – 2004), who reviewed the knowledge on CDs in a seminal paper of this field5 and also founded 
a private company focused on CDs – Cyclodextrin Research and Development Laboratory (CycloLab) 
in Budapest, Hungary. Moreover, numerous research groups worldwide focus on CDs and on their 
applications in different research and industrial fields, and international (European and global) 
conferences on CDs are held every year.1,5   
 Currently, CDs are produced as white crystalline powders by enzymatic degradation of starch 
(amylose, respectively) using Bacillus macerans. This degradation results in a mixture of linear and 
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cyclic dextrins, which are usually separated by complexation with suitable agents (toluene, 1-decanol, 
cyclohexadecenol). With the fast development of this technique, the yield of β-CD has become 
virtually quantitative and thus, the price and availability of this compound is appropriate for their mass 
use in the industry.6,7 
Due to the cyclic shape of CDs and to the 4C1 conformation of glucose units, all secondary 
hydroxyl groups are situated on one (wider) edge, whereas all primary hydroxyl groups are situated on 
another (narrow) edge, as previously shown in Figure 1. Thus, the CD skeleton contains hydroxyl 
groups on primary (narrow) and secondary (wide) rims. Furthermore, hydrogen bonds between 
hydroxyl groups of C-2 and C-3 on the secondary rim of the CD skeleton create a “belt” which most 
likely explains the low solubility of β-CD in water. Conversely, one glucose unit of α-CD is distorted, 
and γ-CD is larger and more flexible molecule than β-CD, and thus, these properties could not allow 
creating a rigid belt, as outlined in Table 1.5  
Table 1. Characteristic parameters (solubility, cavity diameters) of α-, β- and γ-CDs.5 
 α-CD β-CD γ-CD 
Number of units 6 7 8 
Cavity diameter (Å) 4.7-5.3 6.0-6.5 7.5-8.3 
Height of torus (Å) 7.9 7.9 7.9 
Specific optical rotation ([α]25D) 150.0 162.5 177.4 Aqueous solubility (g/100 mL) 
at 25 °C 14.5 1.85 23.2 Crystal water (wt, %) 10.2 13.2-14.5 8.1-17.7 
Diameter of outer periphery (Å) 14.6 15.4 17.5 
 
Thanks to their hydrophobic cavity and hydrophilic outer shell, CDs are crucial for better 
solubility of organic molecules (drugs, respectively) in water. For example, some groundbreaking CD 
derivatives, such as 2-hydroxypropyl-β-CD (HPBCD), have been used in the pharmaceutical industry 
by improving the properties of drugs through encapsulation.8 Encapsulating molecules (not only 
organic) into CD cavity causes the formation of “inclusion complexes” and thus, the solubilization of 
otherwise insoluble molecules or slow releasing of molecules from CD cavity.9 Since then, numerous 
CD-based drug systems have also been tested and launched in the market.10 Moreover, CDs are not 
used only as drug carriers or solubilizers; for example, sugammadex11 is widely used as a 
neuromuscular reversal drug, reversely binding the muscle relaxants rocuronium and vecuronium to 
prevent the side effects of these relaxants during anesthesia. 
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3.1.1. Inclusion complexes of CDs 
The ability to form inclusion complexes is a key property of CD molecules. Generally, the 
cavity of CD is filled with water molecules in aqueous solution, which is an unstable system (polar 
water molecules - slightly apolar CD cavity). However, the addition of non-polar (organic) molecules 
(guests) to the solution causes their inclusion into CD (host) cavity, thereby expelling the water 
molecules from the cavity (Figure 2).5  
 
Figure 2. Graphical representation of an inclusion complex of host (CD) and guest (G)  
This host-guest interaction represented in Figure 2 can be expressed using the following 
equations (eq. 1, 2) 
    CD + G ⇆ CD ⋯ G                                                        (eq. 1) 
                                                   𝐾 = [CD⋯G]
[CD][G]
                                                             (eq. 2)  
wherein CD is cyclodextrin (host), G is the guest and K is the complex stability constant. The host-
guest ratio is usually 1:1, but 2:1, 1:2 or 2:2 inclusion complexes have also been prepared. Usually, 
guest inclusion into the cavity can be confirmed by NMR measurements5,12, by ITC analysis13 or by X-
ray analysis14.  
3.2.  Synthesis of CD derivatives 
Although native CDs (α-, β- and γ-) have outstanding properties as mentioned above, the 
preparation of CD derivatives is necessary for several reasons; to increase the solubility of CDs in 
water and in other solvents, to improve their complexation properties and to prepare target CD 
derivatives by attaching various functional or catalytic groups to CD, among others.15 
The methods for the derivatization of CD skeletons can be divided into two groups: random 
and selective substitution. A specific method is chosen depending on the final purpose of the 
derivative. In some applications, only randomly substituted derivatives can be used and the methods 
applied for their preparation are highly reproducible, although these randomly substituted derivatives 
contain a mixture of isomers, for example, RAMEB or HPBCD, which are important in the 
pharmaceutical industry, specifically enhancing the membrane permeability of poorly soluble drugs 
and properties of anesthetics, respectively.16,10 In other applications, new methods for the preparation 
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of selectively substituted CD derivatives must be developed based on the desired properties of the 
target CD derivatives. 
Currently, several research groups are trying to develop new methods for the selective 
substitution of CD anchors. Although all hydroxyl groups of CDs have similar reactivities which 
generally leads to mixtures of products and positional isomers, small differences in reactivity were 
observed depending on the positions of hydroxyl groups in the CD molecule (Figure 3).17  
 
Figure 3. General differences in the reactivity of hydroxyl groups of CD skeleton17 
 As shown in Figure 3, the hydroxyl groups at position 6 (OH-6) are the most sterically 
accessible, the most basic and the most nucleophilic. In contrast, the hydroxyl groups at position 3 
(OH-3) are the most sterically hindered and the most difficult to access; however, the advantage of CD 
inclusion complexes with suitable agents is the introduction of selectivity at this position, similarly to 
the monocinnamylation of β-CD.18 The hydroxyl groups at position 2 (OH-2) are the most acidic, and 
some approaches have resulted in preparation of these selectively substituted CD derivatives, albeit 
with very low yields.17  
These differences in reactivity have enabled the preparation of selectively mono-, di- and 
persubstituted CD derivatives on positions C-2, C-3 or C-6.17 Considering the purpose and scope of 
this thesis, only selective monosubstitution and disubstitution on the primary rim of CD skeletons (C-6 
atoms) will be discussed herein.  
3.2.1. Monosubstituted CD derivatives 
Monosubstitution of a CD skeleton is one of the most common types of derivatization which is 
commonly used to prepare a wide range of derivatives for different purposes, as previously 
reviewed.15,17 Generally, monosubstitution can occur on three different positions of the CD skeleton 
(Figure 3), thus allowing  the preparation of mono-2-, mono-3-, mono-6-CD derivatives.   
However, among CD precursors monosubstituted on the primary rim for further use, 6-O-
tosyl-CDs are the most common precursors of several types of C-6 monosubstituted derivatives.17 The 
widely used tosylation method19 is based on the fact that OH-6 atoms on the primary rim are the most 
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nucleophilic and the most accessible. Furthermore, pyridine, both as a solvent and as a base, can be 
included into the CD cavity, therein activating the primary rim hydroxyl groups. Importantly, full 
conversion into monotosylated CDs has not been achieved because the formation of overtosylated 
products could not be avoided due to the presence of hydroxyl groups of similar reactivity.  
Accordingly, the yields20 of this reaction range from 10 to 25%.  Nevertheless, other important 
precursors are usually prepared from 6I-O-tosyl-CDs (I) such as 6I-azido-6I-deoxy-CDs (II) which are 
the most commonly used derivatives in CuAAC click reactions21,22 (Figure 4). 
 
Figure 4. 6I-Monotosyl-CDs (I) and 6I-monoazido-CDs (II)  
Other monosubstituted precursors should be mentioned, such as  6I-bromo-6I-deoxy-CDs, 
which are also used to prepare different kind of CD derivatives by nucleophilic substitution, for 
example the previously mentioned 6I-azido-6I-deoxy-CDs (II).23  
3.2.2.  Disubstituted CD derivatives 
In comparison with the selective monosubstitution of CDs, disubstitution methods are less 
direct, and no general precursor of disubstituted CDs can be easily prepared by direct disubstitution 
because products usually consist of a mixture of regioisomers. Accordingly, disubstitution is not used 
for CD derivatization as much as monosubstitution since these mixtures of regioisomers require 
sophisticated, time-consuming chromatographic separations. Notwithstanding, both direct (A, B) and 
indirect (C) approaches (Scheme 1) for the preparation of selectively disubstituted CDs have been 
already proposed.24,17 This problem of mixtures of regioisomers and pseudoenantiomers will be 
discussed in more detail in the section 3.2.3.  
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Scheme 1. General approaches for CDs disubstituted on the primary rim25  
3.2.2.1. Direct approach for the preparation of disubstituted CDs 
The first – direct – approach consists of using (sterically demanding or capping) agents to 
modify the preferential position on the CD skeleton (Scheme 1).25,26 On the one hand, sterically 
demanding agents, blocked by bulky functional groups already attached on CD (reaction A), can 
modify only an accessible glucose unit; on the other hand, capping agents (usually a single organic 
molecule with two reactive functional groups) are preferentially attached to two glucose units on CD 
skeleton (reaction B).27  
 Tabushi and Fujita pioneered capping methods testing a wide range of capping agents, and 
observed preferentially capped positions in some cases. Their reaction with m-benzenedisulfonyl 
chloride reached 97% selectivity for the AB position (III) on β-CD (Scheme 2).28 A different 
regioisomer ratio was observed with benzophenone-3,3´-disulfonyl chloride (61% selectivity for AC 
regioisomer IV) and with 4,4´-biphenyldisulfonyl chloride (84% selectivity for AD regioisomer V).29 
Although these methods became milestones in the preparation of disubstituted CDs as particular 
regioisomers, they still have some limitations. The main issue is that the selectivity is lower than 
100%; thus, most of these products consist of impurities, which could hinder subsequent 
chromatographic separations. Subsequently, most of the regioisomer ratios were identified via 
enzymatic degradation28, which is no longer the most convenient method due to improvements in 
HPLC and NMR techniques. Lastly, capped-CDs are very easily hydrolyzed which may also 
complicate their further conversion into single isomer CD derivatives. Thus, they could be 
immediately transformed into more stable CD derivatives, such as diazido-CD derivatives. 
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Nevertheless, these one-step methods for the preparation of AB-, AC- and AD-regioisomers on β-CD 
have already been applied to prepare  several CD derivatives.30,31 
 
Scheme 2. Regioisomer ratio of capped-β-CDs28,29 
However, the preparation of regioisomers of α-CD using capping agents (Scheme 3) is less 
thoroughly studied than the synthesis of capped-β-CDs. More specifically, the reaction between native 
α-CD with m-benzenedisulfonyl chloride resulted in the preferential capping of A and B positions, but 
the regioisomer ratio was unclear (VI).32 Moreover, the capped-α-CDs prepared with the capping 
agent m-benzenedisulfonyl chloride hydrolyzed very quickly. Thus, this capping agent was replaced 
with dimethoxy-m-benzenedisulfonyl chloride which resulted in a more stable, but still easily 
hydrolyzed capped-α-CDs. Similarly, the regioisomer ratio of this preferred AB regioisomer was not 
investigated because compound VI with methoxy groups, still easily hydrolyzed, was immediately 
transformed into a more stable diiodo-α-CD.33 Conversely, dibenzofuran-2,8-disulfonyl chloride as a 
special capping agent was used to form AC regioisomer VII, nevertheless the regioisomer ratio was 
not published and the most abundant regioisomer was indirectly confirmed.34 Lastly, the use of 
methyl-4,4´-biphenyldisulfonyl chloride resulted in a mixture of AC and AD isomers (VIII).35 
Similarly to β-CD skeleton, capping of the α-CD skeleton continued in the problem of the selectivity 
which is not 100%. Overall, this α-CD capping results in mixtures of regioisomers, and the products of 
these reactions are much more labile to hydrolysis than capped-β-CD.33   
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Scheme 3. Regioisomer ratio of capped--CDs33–35 
AD regioisomer precursors on α-CD were later developed by Armspach and Matt,36 who used 
the supertrityl group to selectively substitute the AD position on the primary rim of α-CD (Scheme 4). 
The main advantage of this strategy is the separation of regioisomers IX in gram scale, and not only in 
HPLC scale. However, the product required permethylation before the separation of regioisomers. In 
parallel, Armspach also investigated different unsymmetrically capped CDs for their potential use in 
asymmetric synthesis.37 
 
Scheme 4. Direct approach for the preparation of AD-regioisomer on -CD36 
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3.2.2.2. Indirect approach for disubstituted CDs 
A second – indirect – approach for the preparation of disubstituted CDs was extensively 
studied in the group of Sinaÿ,38 and the highly selective deprotection of perbenzylated CDs produced 
deprotected products as 100% for one regioisomer (X, Scheme 5). This method was a milestone in the 
preparation of selectively 1,4-disubstituted α- and β-CDs without any capping agents. However, this 
deprotective method also has limitations – primarily, this is a time-consuming, four-step-synthesis. 
Another disadvantage is that this reaction is very sensitive to the concentration of diisobutylaluminium 
hydride (DIBAL-H) in the reaction mixture and to the reaction temperature.  
 Scheme 5. Preparation of disubstituted CDs via debenzylation38 
Considering the excellent regioselectivity of this DIBAL-H deprotection, Sinaÿ and 
Sollogoub´s group continued using this method for the preparation of various other CD derivatives39–
46, including CDs used in medical treatments47. Starting from total deprotection of benzyl groups of 
dimesyl-perbenzylated α-CD48 (XI), this group also prepared AD-diazido-α-CD XII (a key CD 
derivative for click reactions21,49). Furthermore, this ongoing research culminated with the preparation 
of hetero-hexasubstituted derivative XIII on the primary rim of -CD (Scheme 6).50 
 
 
Scheme 6. α-CD derivatives (XI-XII) prepared via DIBAL-H deprotection50,48 
As mentioned above, the DIBAL-H debenzylation procedure is quite sensitive to experimental 
conditions – concentrations of DIBAL-H and starting material in the reaction mixture and reaction 
temperature and time. Unsurprisingly, other research groups repeated and improved the original 
procedure described by Sinaÿ38. For example, Ling et al.51,52 investigated the reaction for the 
preparation of diol X with DIBAL-H in a hexane solution.   
Furthermore, Kraus et al.23,53–56 developed complementary procedures towards total 
debenzylation by deprotection of the bisbrominated perbenzylated α-CD XIV using a Pd/C catalyst, 
21 
 
thereby producing CD intermediate for the preparation of the dimer XVI connected via disulfide 
bonds (Scheme 7).  
 
Scheme 7. Dimer XVI prepared via debenzylated intermediate XV23  
In turn, Bols and his research team57,58 successfully used Sinaÿ diol  on α-CD (X, Scheme 8) 
for the preparation of heterobifunctionalized CD derivatives, such as amino-hydroxyl-perbenzylated-
α-CD (XVII) towards the total deprotected α-CD with amino and carboxylic functional groups 
(XVIII).  
 
Scheme 8. Heterodisubstituted α-CD derivatives XVII and XVIII prepared by Bols et al.57,58  
3.2.3. Regioisomers of disubstituted CD derivatives 
As explained in the previous chapter, the problem of regioisomers and pseudoenantiomers is 
one of the main obstacles in the preparation of disubstituted CD derivatives. However, our ultimate 
goal was to prepare organocatalysts on a CD skeleton as a pure regioisomer. Therefore, we only 
focused on α- and β-CD skeletons because the number of possibilities for regioisomers and 
pseudoenantiomers on their primary rims is rather limited.17  
The chiral nature of the CD skeleton makes it possible to differentiate the clockwise (CW) 
from the counterclockwise (CC) orientations of the CD skeleton, as viewed from the secondary rim 
(for example α-CD, Figure 5). The alphabetic numbering of α-CD glucose units with A - F letters was 
originally started in the study by Tabushi and Fujita28, and this numbering is easier to understand in di- 
and higher substituted glucose units than the IUPAC numbering using Greek numbers59. 
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Figure 5. Clockwise and counter-clockwise alphabetical numberings of α-CD glucose units  
Accordingly, Tabushi and Fujita used this alphabetical CW numbering (red bonds) for 
schematic representation of the primary rim. Moreover, Sinaÿ and Sollogoub continued using this CW 
numbering.39,60 However, according to IUPAC reccommendations61, the glucose units of 
oligosaccharides should be numbered from the anomeric carbon (C-1) via the longest part of a glucose 
unit first and only then via the 1,4-linkage, subsequently continuing in the following glucose units 
(CC numbering, green bonds in Figure 5). Therefore, the CC numbering, which does not depend on 
the substitution of glucose units,  is used in this thesis (and in Tichá et al., Beilstein J. Org. Chem. 
201862).  
Furthermore, this inherent chirality of CD skeletons results in an existence of 
pseudoenantiomer pairs of di- and more substituted CD derivatives.28 To better illustrate this problem, 
Figure 6 shows possible regioisomers and pseudoenantiomers of the primary-rim disubstituted α- and 
β-CD skeletons. However, the problem of different pseudoenantiomers has been rarely addressed thus 
far, except for Sollogoub et al.63,60, who discussed the equality of AD/DA disubstituted perbenzylated 
α-CDs. 
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Figure 6. Schematic representation of regioisomers and pseudoenantiomers of α- and β-CD 
derivatives viewed from the primary rim28,60 
Several research groups have aimed to differentiate regioisomers and to determine the 
regioisomer ratio of disubstituted CDs. In pioneering studies, Tabushi and Fujita28 were able to 
determine the regioisomer ratio via enzymatic degradation using Taka-amylase64 hydrolysis and 
NaBH4, reduction, thereby opening the CD ring and detecting the products of these degradations by 
MS methods. However, these methods were time-consuming; some of these degradations took 12 
days. Thus, Fujita et al.65,66 started new, more convenient HPLC separations of CD regioisomers. 
Currently, HPLC separation of regioisomers is a powerful tool for determining the regioisomer ratio, 
albeit requiring standards for the unambiguous characterization of regioisomers. Among others, 
Yamamoto et al.67 investigated the regioisomers of di- and trisubstituted α-CD derivatives with trityl 
groups on the primary rim.  
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3.3.  Organocatalysts based on CDs 
As non-toxic and water-soluble molecules, CDs are key compounds for dissolving organic 
molecules in water. More specifically, CDs can serve as “microvessels” to perform organic reactions 
via covalently bonded intermediates or to mediate such a reaction via non-covalent bonding in the CD 
cavity.68 Regardless, both covalent and non-covalent binding approaches play a key role in catalysis.  
CDs have been applied in catalysis, since the initial research on the CD skeleton. CDs have 
been used as catalysts in biomimetic reactions to mimic the activity of enzymes (literally “to describe 
chemistry inspired by biological processes”). Breslow pioneered this research, successfully applying 
bifunctionalized CDs XIX (different regioisomers) for enolization purposes (Figure 7)69 or for 
mimicking enzymes such as cytochrome P-450 (XX)70,71, among other applications. In addition, he 
also summarized the state of the art in this field two decades ago.72,73 
 
Figure 7. Imidazole-derived CDs XIX and porphyrin-derived CDs XX successfully mimic 
enzymes.69,70 
Following Breslow, Levine et al.74 summarized the current applications of CDs in biomimetic 
catalysis. The important part of this research field focuses on the performing organic reaction in water. 
Monflier’s group is interested in the preparation CD catalysts for various purposes, for the preparation 
of pyrrole rings in water using RAMEB.75 Not only organocatalysts but also metal-CD catalytic 
systems were extensively studied. For example, Gao’s group successfully used Pd-β-CD complex for 
Suzuki-Miyaura coupling in water.76 Other research group used native β-CD as catalysts for the 
preparation of pyrazoles in aqueous solution.77  
Concomitantly, Bols conducted key research on CD-based organocatalysts,78 primarily 
focusing on the preparation of disubstituted α-CD catalysts with an acetone bridge (XXI) for 
epoxidation reactions (Scheme 9).79 Moreover, the Bols group prepared other CD catalysts with 
different types of acetone bridges on β-CD (for example XXII) and with similar activity in 
epoxidation,80 in addition to synthesizing CD derivatives (for example XXIII) as artificial enzymes for 
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amine and benzyl alcohol oxidation81,82. Furthermore, the authors investigated the chiral version of 
their epoxidation reactions, albeit with almost no enantiomeric excess. 
 
Scheme 9. CD catalysts (XXI–XXIII) successful in epoxidation and oxidation79,80 
Wong et al.83 were also interested in epoxidation reactions catalyzed by the CD derivative 
monosubstituted with ketoester XXIV with 40% ee (Scheme 10). Despite the low enantiomeric 
excess, CD derivates have been used in enantioselective catalysis based on these preliminary findings 
and have since shown promising results (Section 3.3.1).  
 
Scheme 10. CD derivative substituted with ketoester (XXIV) for asymmetric epoxidation83 
3.3.1. Enantioselective reactions promoted and catalyzed by CD derivatives 
The separation of enantiomers using native CD chiral skeletons has become the crucial area of 
analytical chemistry. Furthermore, CD skeleton derivatization can enhance the separation of the 
previously inseparable mixture of enantiomers of several compounds.84  
CD-based organocatalysts could also be successfully used in enantioselective catalysis as 
outlined in the previous chapter. Macaev et al.85 and Wang et al.86 have previously reviewed this 
application of CD derivatives in enantioselective reactions. More specifically, proline derivatives have 
already been used in combination with CDs to assess the high efficiency of these organocatalysts. For 
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example, a proline derivative immobilized in the β-CD cavity (XXV), successfully catalyzed an aldol 
reaction with 84% ee (Scheme 11).87 
 
Scheme 11. Proline derivative immobilized in the β-CD cavity (XXV) catalyzed an aldol reaction.87 
In addition, proline covalently bonded via urea linker to β-CD derivative (XXVI) has also 
been prepared and applied in a direct aldol reaction in water with excellent enantiomeric excess 
(Scheme 12).88  
 
Scheme 12. Proline attached to β-CD derivative via a urea linker (XXVI) catalyzed a direct aldol 
reaction88 
In a third application of a proline-CD derivative to enantioselective catalysis, the nature of the 
linker between proline and CD affected the enantiomeric excess of the product of a direct aldol 
reaction89. Moreover, the authors of this study also investigated permethylated CD derivatives with a 
proline moiety (XXVII), albeit with only 54% ee (Scheme 13).  
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Scheme 13. Proline-derived CDs (XXVI) catalyzed a direct aldol reaction.89 
Not only aldol reactions, but also enantioselective Henry reactions were performed by 
Pitchumani et al.90 who used per-6-amino-β-CD (XXVII) (Scheme 14) and achieved an excellent 99% 
ee in ACN/H2O.  
 
Scheme 14. Per-amino-β-CD derivative (XXVII) promoted the Henry reaction.90 
Kraus et al.91–93 used β-CD catalysts attached to flavin moieties (XXVIII) in enantioselective 
sulfoxidations with 91% ee (Scheme 15).  
 
Scheme 15. Flavin-derived CDs (XXVIII) used for enantioselective sulfoxidations93    
In addition, native CDs have also been shown to promote transition-metal enantioselective 
catalysis. For example, allylation of benzaldehyde using Zn and native β-CD as chiral promoter 
resulted in 93% ee.94 Moreover, γ-CD was used as a “chiral cage” for the photochemical 
rearrangement of Morita-Baylis-Hillman (MBH) products, albeit with a lower enantiomeric excess 
(Scheme 16). 95  
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Scheme 16. Photochemical rearrangement of MBH products promoted by γ-CD 
Lastly, the diamine-based CD derivative (XXIX) was used in a direct aldol reaction with an 
excellent 99% ee in acetate buffer (Scheme 17).96 
 
Scheme 17. Diamine-β-CD (XXIX) catalyzed a direct aldol reaction.  
3.4.  Cinchona alkaloids and CDs 
Among other groups used in asymmetric organocatalysis, Cinchona alkaloids stand out for 
their efficiency and wide use in various asymmetric reactions with an excellent enantiomeric excess. 
Originally used as anti-malarial drugs, these natural compounds are now also widely used in various 
biology and chemistry areas. Ongoing research on Cinchona alkaloids, including their chemical 
modifications, continues in preparation of new derivatives, particularly used as cytotoxic compounds. 
The four main derivatives of Cinchona alkaloids group, containing quinoline and quinuclidine parts, 
are cinchonine, cinchonidine, quinine and quinidine (Figure 8).97 
   Figure 8. Most common Cinchona alkaloids (cinchonidine, cinchonine, quinine, quinidine) 
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Cinchona alkaloids are a privileged class of chiral catalysts. Several enantioselective reactions 
are catalyzed by these alkaloids and their analogs with excellent enantiomeric excess.98 For example, 
salts of Cinchona alkaloids which are easily removed and reused from the reaction mixture, achieved 
91% ee in Michael addition.99  
Despite the wide use of Cinchona alkaloids in many industry and research fields, the 
combination of CD skeletons with Cinchona alkaloids has been scarcely investigated. Initially, 
inclusion complexes of CDs or a dimer of β-CD and Cinchona alkaloids were prepared (Figure 9).100 
Their binding constants were experimentally measured by fluorometric titrations which was later used 
to develop a pH-responsive system for drug delivery.101  
 
Figure 9. Inclusion complexes of CD and Cinchona alkaloids100 
 This study revealed that the complexes between γ-CD with quinine and between the bridged 
CD dimer (XXX) and cinchonidine are the most stable inclusion complexes, as shown in Figure 9. In 
addition, while investigating the direction of encapsulation of Cinchona alkaloids in the CD cavity, the 
authors of this study revealed that Cinchona alkaloids are most likely included through the narrow 
(secondary) rim; regardless of the part included (quinoline or quinuclidine moieties).  
Other research group has tested CDs as stereodiscriminants for the separation of quinine and 
quinidine potentially used in drug development.102 Furthermore, the inclusion complexes of 
quinuclidine and α-CD were also investigated via NMR measurements confirming the 1:1 inclusion 
complex of α-CD and quinuclidine.103  
A study published earlier this year has further confirmed the importance of research based on 
the combination of Cinchona alkaloids and CDs.104 In this study, the hydroquinine moiety was 
connected to the per-Me-β-CD through thiourea and squaramide linkers (Scheme 18) and these 
Cinchona-CD derivatives (XXXI and XXXII) catalyzed a Michael addition with excellent 
enantiomeric excess, applied in flow reactors.  
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 Scheme 18. Cinchona-β-CD catalysts (XXXI and XXXII) used in flow chemistry104 
As shown above, the importance of Cinchona alkaloids either creating inclusion complexes 
with CDs or attaching via covalent bonds to CD skeletons have been unequivocally confirmed. 
However, this promising research of Cinchona-CD derivatives for enantioselective organocatalysis is 
still in progress and other studies will likely follow. 
3.5.  In silico molecular modeling 
Molecular modeling, theoretical calculations and computer simulations have been increasingly 
attracting considerable research interest in many fields, including synthetic chemistry, because 
theoretical findings greatly complement experimental results. Thanks to the development of 
sophisticated and user-friendly software tools, computer simulations are now often used to study 
experimentally feasible but extremely expensive or even completely unfeasible phenomena.105 
Concurrently, the spatial arrangement of molecules and molecular complexes can be 
visualized, thus enhancing our understanding of various chemical processes. In the most advanced 
studies of large macromolecules (including ribosomes), computers help us understand substrate 
binding to the active sites of enzymes106 and even decipher the mechanisms of chemical reactions 
catalyzed by these enzymes, thereby bringing new insights into protein function.107   
Several in silico methods are used to study molecular host-guest complexes. In the molecular 
docking108, host molecules are usually treated as rather rigid entities. Numerous possible orientations 
and conformations of guest molecules are generated, and their binding affinities are estimated using 
simple empirical scoring functions.108 However, this often leads to many false-positive and false-
negative findings.  
 In contrast, in molecular dynamics109 (MD) simulations of host-guest complexes surrounded 
by various solvents, the time evolution of whole-simulated systems can be studied in atomic detail.110 
Indeed, relative binding free energies determined by MD quantitatively match the experimental 
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values.111 Accordingly, MD simulations are commonly used to study inclusion complex dynamics, 
more specifically to study dynamics of the inclusion complexes between CDs and various guests.112,113 
Moreover, in recent decades, MD simulations have become widely accessible thanks to low-
cost hardware resources such as large Linux clusters and many-core Graphical Processor Units 
(GPUs).105 Furthermore, several software packages with user-friendly tools are now available and can 
be used as black-boxes.105 One of the most commonly used software packages is NAnoscale 
Molecular Dynamics (NAMD)109, which enables MD simulations of large biomolecular systems such 
as ribosomes or viral particles.114 NAMD is deeply connected with the molecular graphics program 
Visual Molecular Dynamics (VMD)115, which creates an user-friendly environment for the preparation 
of simulated systems and in-depth analysis of MD trajectories (conformational preferences and free-
energy changes, among other parameters).116,117 
Molecular dynamics simulations 
In the MD simulations, atoms are supposed to move according to one of the classical Newton 
laws of motion  
?⃗?𝑖   =  ?⃗?/𝑚𝑖                                                                  (eq. 3) 
where ?⃗?𝑖 is the acceleration of an atom, 𝑚𝑖 is the atom mass and ?⃗? is the net force applied.109 This 
force is usually expressed as a partial derivative of the total potential energy 𝑈𝑡𝑜𝑡 of the simulated 
system, which leads to 
                                      𝑚𝑖𝑟𝑖 = − 𝜕𝜕𝑟𝑖  𝑈𝑡𝑜𝑡  (𝑟1, 𝑟2, … 𝑟𝑁)  𝑖 = 1, 2, … 𝑁,                      (eq. 4) 
where  𝑟𝑖  is the position of the atom 𝑖 and N is the number of atoms in the simulated system.109  
Numerical integration – Verlet algoritm 
In MD simulations of molecular systems, Newton equations of motion are usually numerically 
solved by the Verlet algorithm. The positions and velocities at the next step (n+1) are obtained from 
the current step (n), resulting in the force expression as 
𝜐𝑛+1/2 =  𝜐𝑛 + 𝑀
−1 𝐹𝑛  •  Δ𝑡 2 ⁄ ,                                         (eq. 12) 
𝑟𝑛+1 =  𝑟𝑛 +  𝜐𝑛+1/2 Δ𝑡 ,                                                    (eq. 13) 
𝐹𝑛+1 = 𝐹(𝑟𝑛+1) ,                                                                (eq. 14) 
𝜐𝑛+1 =  𝜐𝑛+1/2 +  𝑀
−1 𝐹𝑛+1  •  Δ𝑡 2  ⁄                               (eq. 15) 
where 𝜐𝑛+1 is the velocity at the next step, 𝑟𝑛+1 is the position at the next step, 𝑀−1 is the mass.109 
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MD simulations of large molecular systems usually require at least hundreds of millions of 
time steps (1-5 fs) leading to ns-ms trajectories. The goal of these MD simulations is not to accurately 
determine the trajectories of atoms and molecules but to correctly sample their phase space.109  
Numerically solving equations of motion lead to the preservation of total energy in 
microcanonical NVE ensembles with a constant number of particles, volume and energy. Temperature 
can be controlled in MD, for example, by Langevin dynamics (NVT), whereas pressure can be 
controlled by Hoover dynamics (NPT).109 Nevertheless, many other thermostats and barostats are 
implemented in software packages like NAMD109 and Assisted Model Building with Energy 
Refinement118 (AMBER). In MD simulations, higher temperatures may enhance the ability of 
molecules to overcome energetic barriers, which was also used in this thesis (section Results and 
Discussion).  
Force field  
The total potential energy  𝑈𝑡𝑜𝑡 of simulated system usually consists of the following partial 
energy contributions 
             𝑈𝑡𝑜𝑡  =  𝑈𝑏𝑜𝑛𝑑  + 𝑈𝑎𝑛𝑔𝑙𝑒  +  𝑈𝑑𝑖ℎ𝑒𝑑𝑟𝑎𝑙  +  𝑈𝑣𝑑𝑊  +  𝑈𝐶𝑜𝑢𝑙𝑜𝑚𝑏                             (eq. 5) 
where 𝑈𝑏𝑜𝑛𝑑  is the potential energy of covalent bonds, 𝑈𝑎𝑛𝑔𝑙𝑒  represents the potential energy of 
angles between each pair of the covalently bonded atoms and 𝑈𝑑𝑖ℎ𝑒𝑑𝑟𝑎𝑙  consists of the potential 
energy of the torsion angles of three covalent bonds between four atoms. In addition, 𝑈𝑣𝑑𝑊 and 
𝑈𝐶𝑜𝑢𝑙𝑜𝑚𝑏  expressed the potential energy of interactions between pairs of non-bonded atoms, that are 
van der Waals and electrostatic interactions. These contributions can be calculated using following 
equations (eq. 6-10) 
𝑈𝑏𝑜𝑛𝑑 =  ∑ 𝑘𝑖
𝑏𝑜𝑛𝑑
𝑏𝑜𝑛𝑑 𝑖 (𝑟𝑖 − 𝑟0𝑖)
2,                                                   (eq. 6) 
𝑈𝑎𝑛𝑔𝑙𝑒 = ∑ 𝑘𝑖
𝑎𝑛𝑔𝑙𝑒
𝑎𝑛𝑔𝑙𝑒𝑠 𝑖  (𝜃𝑖 − 𝜃0𝑖)
2,                                                (eq. 7) 
𝑈𝑑𝑖ℎ𝑒𝑑𝑟𝑎𝑙 =  ∑ {
𝑘𝑖
𝑑𝑖ℎ𝑒  [1 + cos(𝑛𝑖𝜙𝑖 − 𝛾𝑖)], 𝑛𝑖 ≠ 0
𝑘𝑖
𝑑𝑖ℎ𝑒(0𝑖 −  𝛾𝑖)
2 ,                      𝑛 = 0   
𝑑𝑖ℎ𝑒𝑑𝑟𝑎𝑙 𝑖                                  (eq. 8) 
𝑈𝑣𝑑𝑊 =  ∑ ∑ 4𝜀𝑖𝑗𝑗>𝑖𝑖 [(
𝜎𝑖𝑗
𝑟𝑖𝑗
)
12
− (
𝜎𝑖𝑗
𝑟𝑖𝑗
)
6
],                                              (eq. 9) 
𝑈𝐶𝑜𝑢𝑙𝑜𝑚𝑏 =  ∑ ∑
𝑞𝑖𝑞𝑗
4𝜋𝜀0𝑟𝑖𝑗
𝑗>𝑖𝑖  .                                                     (eq. 10) 
where 𝑘𝑖𝑏𝑜𝑛𝑑 , 𝑘𝑖𝑎𝑛𝑔𝑙𝑒 , 𝑘𝑖𝑑𝑖ℎ𝑒  are constants for 𝑖-bond, 𝑖-angle and 𝑖-dihedral angle, respectively, 
whereas the 𝑟𝑖 is the position of i-particle, 𝑟𝑖0 and 𝜃0𝑖 is their values in equilibrium. Then, constant 𝑛𝑖 
indicates periodicity, the 𝛾𝑖 is the dihedral angle, 𝜎𝑖𝑗 is the distance for Lennard-Jones potential, 𝑞𝑖 and 
𝑞𝑗  are the charges of 𝑖-particle and 𝑗-particle, 𝑒𝑖𝑗 is the depth of the potential well, 𝑟𝑖𝑗 is the distance 
between atoms i and j, 𝜀0 is the vacuum permittivity, 𝜃𝑖 is the angle between each pair of bonds and 𝜙𝑖 
is torsion angle.109 
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Energy contributions described above can be visualized using solid balls are connected by 
spring. This model represents atoms connected via the covalent bonds and involved in no chemical 
reactions or electron transfer.109 The parameter r represents the bond stretching, σ represents the bond 
angle, θ represents the dihedral angle and α represents the small-out-plane angle (Figure 10).109  
 
 
Figure 10. The interactions between atoms in MD simulations (modified from literature 109) 
Periodic boundary conditions 
Periodic boundary conditions are commonly used in MD simulations to prevent surface effects 
at boundaries. In other words, particles are enclosed in the cell, which is infinitely replicated by 
periodic translations. If a particle leaves the simulated system through one side of the boundary, 
another identical particle immediately replaces it on the opposite side. Importantly, every cell is the 
identical copy of all other cells. Therefore, only one cell suffices to represent a simulated system.109  
Second approximation used in MD algorithm is the truncation of van der Waals interactions of 
non-bonded atoms in the system at the user-specified cutoff distance. These two approximations (i) 
periodic boundary conditions and (ii) the truncation of long-distance Waals interactions also apply in 
calculations of electrostatic interactions using the Ewald summation method.109 
Ewald summation  
The Ewald method is often used for the summation of long-range electrostatic interactions 
between atoms, not only inside the original cell but also with virtual replicas of atoms due to periodic 
boundary conditions. The Ewald sum involves the following terms 
𝐸𝐸𝑤𝑎𝑙𝑑  =  𝐸𝑑𝑖𝑟  + 𝐸𝑟𝑒𝑐  + 𝐸𝑠𝑒𝑙𝑓  + 𝐸𝑠𝑢𝑟𝑓𝑎𝑐𝑒                                   (eq. 11) 
where 𝐸𝐸𝑤𝑎𝑙𝑑  is Ewald sum of energy, 𝐸𝑑𝑖𝑟  is the direct sum, 𝐸𝑟𝑒𝑐  is the reciprocal sum computed via 
fast Fourier transform, 𝐸𝑠𝑒𝑙𝑓  is the self-energy which is constant, and 𝐸𝑠𝑢𝑟𝑓𝑎𝑐𝑒  is the surface energy, 
which is usually neglected due to the high dielectric constant of water as a solvent.109  
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NAMD and AMBER software packages use the particle-mesh Ewald (PME) method119, which 
distributes the charges of atoms to the nodes of a uniform grid. Furthermore, the electrostatic 
potentials of molecules can be computed and visualized in VMD using the “PME Electrostatics” 
plugin.109 
Binding free energy of host-guest complex 
 Differences in binding free energies ∆𝐹 are often computed in MD simulations to predict the 
dynamics of host-guest inclusion complexes, in this case complexes between CDs and numerous guest 
(ligand) molecules.113 These theoretical values can be compared with the experimentally determined 
stability constant Ks, thereby enabling the development of more potent drug carriers (for example, CD 
drug carriers), among others. 
More specifically for CD, a ligand 1 could be very slowly detached from CDs by external 
forces (route A in Figure 11). The needed energy (work) could be used to estimate relative binding 
free energies of ligands (ligand 1). However, this geometrical approach is extremely time-consuming 
because the simulated system would have to remain close to thermodynamic equilibrium.109     
A much more practical way of calculating relative binding free energies is based on “computer 
alchemy”109, represented by thermodynamic cycle in route B in Figure 11. This alchemical approach 
consists of small, gradual, and neither physically nor chemically meaningful, conversions of one 
ligand (ligand 1) into another intermediate (ligand 2), performed outside (Bo) or inside (Bi) the CD 
cavity. Thus, determined free energy differences ∆𝐺 are subtracted.109 
 
 
 Figure 11. Thermodynamic cycle, calculation of the binding free energies ∆𝐹 using either 
geometrical or alchemical transformations 
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More accurately, the difference in free energy between state a and b of the simulated system is 
expressed as 
                                             ∆𝐹𝑎→𝑏 =  − 1𝛽  𝑙𝑛 ∫ 𝑄 (𝑁, 𝑉, 𝑇)𝑒−𝛽𝑝𝑉𝑑𝑉∞0                                        (eq. 16) 
where ∆𝐹𝑎→𝑏 is difference between free energy in basic state a and target state b, β is 1𝑘𝑇 and 
𝑄 (𝑁, 𝑉, 𝑇) is the partition function. The relative binding free energy of ligands (guests) is then 
calculated using equation 
                          ∆𝐺1 − ∆𝐺2  =  ∆𝐺1→2,𝑎𝑞 − ∆𝐺1→2,𝐶𝐷 =  ∆𝐺𝑟𝑒𝑙 =  ∆𝐹𝑎→𝑏                   (eq.17)  
where ∆𝐺1 is the binding free energy of ligand 1, ∆𝐺2 is the binding free energy of ligand 2, ∆𝐺1→2,𝑎𝑞 
is the free energy needed for the alchemist transformation of ligand 1 into ligand 2 in aqueous box, 
∆𝐺1→2,𝐶𝐷 is the free energy needed for the alchemist transformation of ligand 1 into ligand 2 in the 
CD cavity. These alchemist calculations were successfully applied to study CD complexes with 
isoflavones120, fullerenes121 and some drugs122.  
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 4. RESULTS AND DISCUSSION 
4.1.  Preparation of CD starting materials 
4.1.1.   Preparation of monosubstituted CD precursors 
 The ultimate goal of this thesis was to prepare organocatalysts based on a CD skeleton for 
enantioselective reactions. Thus, the first approach consisted of preparing monosubstituted CD 
precursors. Monosubstitution of the CD skeleton is an initial and easier method for the preparation and 
preliminary testing of CD derivatives as organocatalysts than disubstitution. Accordingly, 6A-O-tosyl-
α-CD (1a) and 6A-O-tosyl-β-CD (1b) as common monosubstituted precursors were prepared according 
to previously published procedures (Scheme 19).19,20  
 
Scheme 19. Preparation of 6A-O-tosyl-α-CD (1a) and 6A-O-tosyl-β-CD (1b) 
 Subsequently, 6A-azido-6A-deoxy-α-CD (2a) and 6A-azido-6A-deoxy-β-CD (2b) were prepared 
from these 6A-O-tosyl-CDs (1a and 1b) under classical azidation conditions (Scheme 20).19 In this 
thesis, we followed the commonly used (but less accurate) nomenclature of the CDs with functional 
groups replacing oxygen atoms, for example, 6A-azido- instead of longer 6A-azido-6A-deoxy-, for 
simplification purposes.  
 
Scheme 20. Preparation of 6A-azido-α-CD (2a) and 6A-azido-β-CD (2b) 
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4.1.2.  Preparation of disubstituted α-CD precursors 
 After preparing monosubstituted precursors for α-CD and β-CD, we focused on synthesis of 
disubstituted CD precursors. However, the α-CD skeleton was chosen for the simplicity because 
disubstitution on its primary rim results in fewer possible mixtures of regioisomers and 
pseudoenantiomers than the disubstitution on β-CD, as discussed in section 3.2.3. Furthermore, the 
smaller cavity of α-CD can prevent a high number of conformational changes of substrates during the 
reaction, which could strongly affect the enantioselectivity. For these reasons, the disubstituted 
precursors containing two azido moieties or two bromo moieties on α-CD were chosen for synthesis 
according to previously published procedures (Scheme 21).23,48 
 
Scheme 21. Preparation of 6A,D-diazido-α-CD (7d)   
 This 5-step synthesis (via total perbenzylated α-CD 3, partially debenzylated derivative 4, 
dibromo perbenzylated α-CD 5 and deprotected dibromo-α-CD (6) with 52% overall yield resulted in 
a pure AD regioisomer. Moreover, the CD derivative 7d was prepared in gram scale (from 20 g of 
native α-CD), and no chromatographic purifications are needed after optimizing each step thanks to 
full conversion into all intermediates (3, 4, 5, 6) and final product (7d).  
The most problematic step in this sequence is partial deprotection with DIBAL-H to prepare 
CD derivative 4. The presence of monodebenzylated byproduct 8 complicated the purification and 
resulted in very low yield of diol 4 (Scheme 22).  
 
Scheme 22. Preparation of the partial deprotected CD derivatives (8 and 4) 
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Several conditions were examined to solve this problem of partial debenzylation; different 
equivalents of the DIBAL-H solution (Table 2, Entries 1 and 2), reaction times (Entries 3, 4 and 5) and 
reaction temperatures (Entries 6 and 7) were tested to optimize this deprotection. In addition, the 
DIBAL-H solution (commercially available as 1.0 M in toluene) had to be concentrated twice (to 2.0 
M in toluene), as indicated in Kraus procedure54; otherwise, the concentration of DIBAL-H would not 
be high enough to deprotect both benzyl group. If the DIBAL-H concentration in solution is 
approximately 2.0 M, the reaction takes 16 hours (Entry 7).  
Table 2. Optimization of DIBAL-H deprotection 
Entry DIBAL-H (eq.) Time (h) Temperature (°C) Yields (%) of 8/4 
1 120 2 50 44/0 
2 30 1.5 rt 13/0 
3 30 1.5 60 36/4 
4 30 48 75 10/2 
5 30 144 rt 44/0 
6 50 24 75 30/8 
7[a] 30 16 rt 0/77 
[a] the DIBAL-H solution is concentrated twice. 
 The reaction is also sensitive to temperature variations when adding DIBAL-H; the optimal 
temperature for partial deprotection of benzyl groups, determined during DIBAL-H addition, is 50 °C.  
Furthermore, we benefited from the byproduct of the optimization process monodebenzylated 
derivative 8, which was used to prepare the heterodisubstituted α-CD, as previously published.44 In 
this sequence of reactions (depicted in Scheme 23), the monomesylated per-Bn-α-CD derivative (9) is 
converted into monoazidated per-Bn-α-CD derivative (10), which is then put to the tandem 
reduction/deprotection with DIBAL-H solution towards heterodisubstituted α-CD derivative (11). 
 
Scheme 23. Unsuccessful preparation of the heterodisubstituted perbenzylated α-CD derivative (11)  
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However, the preparation of this precursor 11 was unsuccessful, because the reaction mixture 
contained products with azido group and partly deprotected benzyl groups (azido with one hydroxyl 
group, azido with two hydroxyl groups or azido with three hydroxyl groups, among others). Moreover, 
derivative 11 was not prepared even when optimizing this reaction (under reaction conditions using a 
concentrated DIBAL-H solution, similarly to Scheme 22). Thus, different approach for the preparation 
of heterodisubstituted α-CD derivatives was investigated as discussed in next section.  
4.2.  Regioisomer ratio of CD derivatives  
One of the goals of this thesis was to prepare catalysts as AC regioisomers on the primary rim 
of α-CDs in order to compare their catalytic activity with those catalysts prepared from AD precursors. 
Accordingly, a synthetic/analytical approach in which AC regioisomer can be prepared in a mixture of 
regioisomers (AB, AC and AD) and from which these regioisomers were subsequently separated by 
column chromatography was investigated. First, standards of each regioisomer had to be prepared for 
the unequivocal identification of regioisomers in our mixture. This strategy was previously used in 
another work by Fujita et al.123 
From the special capping agents previously used on α-CD, we selected the most common, 
relatively inexpensive and commercially available m-benzenedisulfonyl chloride (Method 1, Scheme 
24) and biphenyl-4,4´-disulfonyl chloride (Method 2, Scheme 24).  
 
Scheme 24. Regioisomer ratio of the capping reactions on α-CD 
The regioisomer ratio is given as the percentage areas of HPLC peaks (100% corresponds to 
the total area of AB, AC and AD peaks). These capped CDs 12 and 13 (Scheme 24) due to labile 
sulfonyl bridges can be easily hydrolyzed which could not be completely suppressed. Accordingly, the 
yields of these capped CDs were not optimal and thus, these intermediates were immediately 
transformed into more stable 6A,X-diazido-α-CDs (7). Moreover, the presence of either intramolecular 
or intermolecular disulfonyl bridges resulted in an interesting regioisomer ratio with biphenyl-4,4´-
disulfonyl-α-CD (13, 44% for AB regioisomer). However, these bridges cannot be investigated in 
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detail due to their high hydrolysis rates. Furthermore, the formation of these intra- or intermolecular 
disulfonyl bridges of capped CD derivatives is not even discussed in the original papers of Tabushi 
and Fujita.29  
Second, the standard for the AD regioisomer was also synthesized via an indirect, 5-step 
synthesis sequence (Method 4, Scheme 25), as discussed in section 4.1. Moreover, this reaction 
sequence was compared with the direct bromination of α-CD under Vilsmeier/Haack conditions 
(Method 3, Scheme 25). Again, both 6A,X-dibromo-α-CD derivatives (14 and 6) were transformed into 
corresponding 6A,X-diazido-α-CDs (7) to compare the regioisomer ratios. Furthermore, the hydrolysis 
of 6A,X-dibromo-α-CD (14) was slower than that of capped-disulfonyl-α-CDs (12 and 13).  
 
Scheme 25. Regioisomer ratio of direct (7) and indirect bromination (7d) on α-CD  
The regioisomer ratio (0% vs. 0% vs. 100%) of indirect bromination (Method 4, Scheme 25) 
was confirmed, thus supporting the need for this time-consuming synthesis because the regioisomer 
ratio of direct bromination was 39% vs. 33% vs. 29%.  
 Lastly, to fully compare the regioisomer ratios of common disubstituted α-CDs, the most 
common CD intermediate 6A,X-O-ditosyl-α-CD (15) was synthesized and converted into the 6A,X-
diazido-α-CD (Method 5, Scheme 26). However, almost no preference for the substituted position was 
observed (38% vs. 34% vs. 28%) in this ditosylation of α-CD.  
 
Scheme 26. Regioisomer ratio of ditosylation of α-CD  
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The prepared 6A,X-diazido-α-CDs (7) were separated by HPLC into single AB, AC and AD 
regioisomers (Figure 12). Concomitantly, the reaction towards capped-α-CDs (Method 1, Scheme 24) 
confirmed that the preferential position is AB, hence and it was used as standard for further 
elucidation of regioisomer ratios. The reaction of indirect bromination (Method 4, Scheme 25) 
confirmed the exclusive formation of the AD regioisomer, which was also used as a second standard. 
In addition, all other reactions resulted in mixtures of regioisomers.   
 
Figure 12. HPLC chromatograms of 6A,6X-diazido-α-CDs (7) 
Regioisomer ratios from above mentioned reactions (capping, bromination and tosylation) 
provided crucial data for the unambiguous determination of the regioisomer pattern of 6A,6X-diazido-
α-CD, and moreover, this comparative analysis revealed the regioisomer ratios of the most commonly 
used CD intermediates. Furthermore, the observed regioisomer pattern (first AD regioisomer, second 
AC regioisomer and third AB regioisomer) could also be supported by the fact that the mixture of 
6A,6X-ditritylates on the primary rim on α-CD showed the same order of elution of regioisomers in 
HPLC.67  
4.3.  Synthesis of pure regioisomer heterodisubstituted α-CD derivatives 
After determining of the regioisomer ratio of common disubstituted CDs and identifying the 
AB and AD regioisomers as standards, target heterodisubstituted α-CD derivative with azido and 
mesitylene moieties was synthesized. Based on the previous research in which 6A-azido-6C-
mesitylenesulfonyl-β-CD as an AC regioisomer was prepared as the predominant species on β-CD,124 
the mesitylenesulfonyl group was chosen as a good leaving group of the precursor 16 (Scheme 27) 
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because regioisomers of similar CD derivatives (with tosyl moiety, for example) can be separated by 
reversed-phase column chromatography.65,125 More importantly, the mesitylenesulfonyl moiety was 
chosen because this group is hydrolyzed more slowly than the tosyl group.124 Thus, the starting 
material 6A-azido-α-CD was prepared from 6A-bromo-α-CD, prepared as a byproduct of direct 
bromination of α-CD (Scheme 25), and the reaction of 6A-azido-α-CD with mesitylenesulfonyl 
chloride resulted in the target product (16).  Furthermore, after the reaction work-up, the crude mixture 
was partly converted into 6A,6X-diazido-α-CD (7, Scheme 27) for comparison with the standards 
(Figure 12) in order to elucidate the regioisomer pattern of this diazido-α-CD prepared from 
heterodisubstituted α-CD derivatives.  
 
Scheme 27. Preparation of 6A-azido-6X-mesitylenesulfonyl-α-CD (16) and conversion into 6A,6X-
diazido-α-CD (7) 
 The observed regioisomer ratio AB:AC:AD = 37:44:19 (Scheme 27) supported the small 
preferences for AB and AC regioisomers; however, the AD derivative was slightly suppressed. These 
HPLC measurements were performed with a crude reaction mixture consisting of the starting material 
(2a), 6A,6X-diazido-α-CD regioisomers (7) and oversubstituted 6A,6X,6Y-triazido-α-CDs. As shown in 
Figure 13, the HPLC signals of all components were nicely separated; thus, the regioisomer pattern 
could be achieved in a single step with no need to separate the starting material first and 6A,6X-
diazido-α-CD regioisomers afterwards. 
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Figure 13. HPLC chromatograms of reaction mixture (Scheme 27) with separated 6A-azido-α-CD (2a) 
as starting material and regioisomers of 6A,6X-diazido-α-CD (7). 
 After identifying the regioisomer pattern (Figure 13), separation methods for 6A-azido-6X-
mesitylenesulfonyl-α-CD (16b, 16c, 16d) were investigated.  First, an analytical method was 
developed using UV-Vis detection with an ACN/H2O gradient elution (Figure 14a).  Consequently, the 
regioisomer ratio AB:AC:AD = 32:44:24 was observed. As shown in Figure 14a, the starting material 
6A-azido-α-CD (2a), each 6A-azido-6X-mesitylenesulfonyl-α-CD regioisomer (16b, 16c, 16d) and 
more substituted 6A-azido-6X,6Y-dimesitylenesulfonyl-α-CD products were separated in a single and 
reproducible separation step. This method (analytical-scale) also confirmed that the mesitylenesulfonyl 
group is not hydrolyzed during the separation; thus, this functional group could be used to separate CD 
derivatives in gram-scale quantities by reversed-phase column chromatography (Figure 14b). 
However, the formation of more substituted derivatives (6A-azido-6X,6Y-dimesitylenesulfonyl-α-CD) 
cannot be avoided as confirmed in Figures 14a and 14b which show incomplete conversion into the 
corresponding AB, AC and AD heterodisubstituted products. Therefore, the starting material 6A-azido-
α-CD remains the main component of the reaction mixture and can be recovered. Furthermore, the 
peak splitting of the AC regioisomer (Figure 14a) could be caused by the presence of 
pseudoenantiomers (AC/CA). This hypothesis was further investigated (in the section Identification of 
pseudoenantiomers).  
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Figure 14. HPLC chromatograms of 6A-azido-6X-mesitylenesulfonyl-α-CD (16): a) analytical and 
b) preparative scale at 25 °C. 
AB, AC and AD regioisomers were isolated by reversed-phase column chromatography with 
ACN/H2O gradient elution. The AB (16b) and AC (16c) regioisomers were separated in similar yields 
(approximately 4%), whereas AD regioisomer (16d) was isolated in 3% yield. These isolated yields 
matched the HPLC regioisomer ratio observed in Figure 14a.  
NMR characterization of heterodisubstituted α-CD derivatives 
Each regioisomer of 6A-azido-6X-mesitylenesulfonyl-α-CD was dissolved in deuterated water 
(D2O) to simplify NMR peak assignment (assignment in DMSO-d6 included OH groups). Overall, the 
1H NMR spectra of all three regioisomers match the disubstituted α-CD derivative patterns. The 
separated AC regioisomer (16c) was chosen as a representative example (measurements were 
performed with the mixture of pseudoenantiomers). Specifically, three basic sets of signals were 
observed (Figure 15). The first (Mes-1) corresponded to the mesitylene aromatic peak (7.15 ppm), the 
second to the α-CD region (5.24-3.41 ppm) and the third (Mes-2) to methyl groups on the mesitylene 
skeleton (2.60-2.30 ppm). In the CD region, three areas are clearly distinguished – peaks about 5.07 
ppm (CD H-1) belong to H-1 protons of four unsubstituted glucose units, whereas H-1 protons of 
glucoses with the azido moiety and the mesitylenesulfonyl group are shifted upfield (4.98-4.95 ppm). 
The separated part of the CD region is also H-6 protons (CD H-6 Mes) attached to the 
mesitylenesulfonyl group (~ 4.40 ppm).  
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Figure 15. 1H NMR spectrum of the AC regioisomer (16c) as a mixture of pseudoenantiomers (D2O) 
In Figure 16, the 13C NMR spectrum also showed the substituted C-6 carbons at 51 ppm for 
azido and at 68 ppm for mesitylenesulfonyl moieties. Both substituents on the α-CD primary rim were 
also confirmed by separating the anomeric region into three parts in HSQC. However, the crucial 
splitting of six C-1 anomeric doublets for the characterization of each glucose unit was not achieved. 
 
Figure 16. 13C NMR spectrum of the AC regioisomer (16c) as a mixture of pseudoenantiomers (D2O) 
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Overall, two different substituents (mesitylenesulfonyl and azido) were attached to the primary 
rim of α-CD, but the incomplete splitting of anomeric doublets prevented us from fully identifying 
different regioisomer peaks by NMR measurements. 
4.3.1. Identification of pseudoenantiomers of heterodisubstituted α-CDs by 
HPLC-MS 
 As mentioned above, a peak splitting of the AC regioisomer was observed (Figure 14a) at 
25 °C attributing to the possible mixture of pseudoenantiomers AC/CA (or AC/AE). Further HPLC-
MS investigation explained this splitting. Peak splitting was also observed in the case of the AB 
regioisomer (16b) at 10 °C (Figure 17). Conversely, this splitting was not observed in the spectra of 
the AD regioisomer (16d) which supports the hypothesis of possible pseudoenantiomers on the 
primary rim of α-CD, as discussed in the section 3.2.3. This symmetrically heterodisubstituted 
regioisomer does not contain the pair of pseudoenantiomers (AD/DA). These results are also in 
accordance with Sollogoub et al.60, who did not observe this peak-splitting caused by the presence of 
pseudoenantiomers of AD regioisomer of heterodisubstituted perbenzylated α-CDs.  
 
Figure 17. HPLC-MS chromatogram with the separated pseudoenantiomers of 6A-azido-
6B-mesitylenesulfonyl-α-CD (16b) and 6A-azido-6C-mesitylenesulfonyl-α-CD (16c) at 10 °C 
 
 In conclusion, these heterodisubstituted AB-, AC- and AD-regioisomers of CD derivatives 
were not further studied or used in this project to develop new CD-based organocatalysts because the 
AB- and AC-regioisomer consist of the pseudoenantiomer pairs AB/BA and AC/CA, thereby 
preventing their application in enantioselective catalysis, and AD-regioisomer was separated as a 
minor product. Nevertheless, the synthesis of these heterodisubstituted α-CD precursors introduced a 
new approach for the preparation of preferential AC regioisomers on the primary rim of α-CD with 
suitable functional groups for further derivatization. Based on the above, our subsequent studies only 
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focused on the preparation of monosubstituted and AD-disubstituted CD derivatives as pure 
regioisomers, enabling their large-scale preparation, and not only as a mixture of regioisomers 
requiring time-consuming chromatographic separations.  
4.4.   Synthesis of Cinchona-CD derivatives 
After confirming the existence of pseudoenantiomers of heterodisubstituted AB and AC 
regioisomers on the primary rim of α-CD, the method for the preparation of monosubstituted CDs was 
developed in order to apply it for the synthesis of the disubstituted AD regioisomer of α-CD. Four 
Cinchona alkaloids (cinchonine, cinchonidine, quinine and quinidine) were chosen as organocatalytic 
moieties for attachment to the CD skeleton.  
The first method for attaching Cinchona alkaloids to the CD skeleton consisted of nucleophilic 
substitution of 6A-O-tosyl-α-CD (1a) and 9-amino derivatives of Cinchona alkaloids, cinchonidine and 
quinidine (17a, 17b, Scheme 28). 9-Amino-derivatives of cinchonidine (17a) and quinidine (17b) 
were prepared according to previously published procedures126 through mesyl127 and azido128 
intermediates inverting the configuration on C-9. This nucleophilic substitution approach was chosen 
because of our laboratory´s experience in substitution on 6A-O-tosyl-CDs with various 
(alkyl)amines.129 Thus, we performed the reaction with an excess of 9-amino-(9-deoxy)-Cinchona 
alkaloids (17a and 17b) in DMSO under different conditions (140 °C, 2,6-lutidine, 
N-methylmorpholine, among other bases). Unfortunately, all attempts to synthesize these products 
failed.  
 
Scheme 28.  Unsuccessful preparation of Cinchona-CD derivatives via substitution   
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 In addition to the failed nucleophilic substitution of Cinchona alkaloids, the starting material 
(1a) was decomposed into α-CD and 3,6-anhydro-α-CD after a prolonged time. Moreover, several 
aromatic amines were also tested in this substitution e.g. ethyl(naphthyl)amine (similar in sterical 
demand with Cinchona alkaloids), but the results were similarly unsuccessful. Most likely, this 
reaction failed to proceed due to the high sterical demand of the Cinchona alkaloid and of the leaving 
tosyl moiety in nucleophilic substitution.  
 After the first unsuccessful approach, a different synthetic approach via a CuAAC click 
reaction22 was started. Accordingly, 6A-azido-α-CD (2a, Scheme 29) reacted with 9-O-propargylated 
Cinchona alkaloids (18a-18d) resulting in the preparation of α-CD products (19a-19d). Thus, the 
CuAAC click reaction was also applied for 6A-azido-β-CD (2b) with 9-O-propargylated Cinchona 
alkaloids, thereby preparing a series of Cinchona-CD derivatives (19a-19d, 20a-20d) linked by a 
triazole moiety.   
 
Scheme 29. Preparation of Cinchona-CD derivatives via a CuAAC click reaction 
 The preparation of Cinchona-CD derivatives via a CuAAC reaction was optimized (Table 3). 
First, the α-CD product was formed in a THF/H2O mixture with 1.5 eq. of 9-O-propargylated 
cinchonine (18a) and 50 mol % CuI (Entry 1). The same yield of the product (Entry 2) was obtained 
when using fewer equivalents of the propargylated cinchonine (18a, 1.3 eq.), with a lower amount of 
Cu salts (20 mol %). Conversely, conversion into the product was lower (Entry 3) when using less 
amount (1.05 eq.) of propargylated cinchonine (18a). Thus, reactions with other Cinchona alkaloids 
(18b‒8d) were performed in a mixture of THF/H2O with 20 mol% Cu and with 1.3 eq. of Cinchona 
alkaloid. Overall, the α-CD derivatives (19a‒19d) were isolated in high yields (up to 86% yield, 
Entries 2 and 4‒6). However, the solvent mixture THF/H2O was not appropriate for full conversion 
into the product on the β-CD skeleton (2b, Table 3), not even after 48 hours (Entry 7). Conversely, 
when changing the solvent to DMF, full conversion was achieved after 2 hours with excellent yields 
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(up to 95%, 20a‒20d, Entries 8‒11). Moreover, the yield of the product decreased when using DMF 
for a CuAAC reaction on an α-CD skeleton (only 38% of 19a after 48 hours, Entry 12). 
 
Table 3. Optimized conditions for the CuAAC from Scheme 29. 
 [a] Isolated yield. [b] After 48 hours. 
NMR elucidation of Cinchona-non-methylated CD derivatives 
Structures of non-methylated CD derivatives (19a‒19d, 20a‒20d) were unambiguously 
confirmed in NMR measurements (numbering of CD skeletons is depicted in section 6.1). As a 
representative example of these CD derivatives, we chose an α-CD derivative with quinidine (19d). 
The 1H NMR spectrum of this non-methylated CD derivative (in DMSO-d6) is in accordance with 
monosubstituted derivatives at position 6 on the primary rim (Figure 18). Generally, four different 
regions with typical signals were observed: the first, a well-resolved aromatic region belongs to the 
quinoline part of Cinchona alkaloids (9.00‒7.55 ppm) and to the hydrogen signal of triazole (8.21 
ppm), thus confirming the attachment of Cinchona alkaloids to the CD skeleton in CuAAC click 
reactions. The second part of the 1H NMR spectrum is the resolved signal of the double bond on the 
quinuclidine skeleton of the Cinchona alkaloid (5.93 ppm). The third part of the spectrum consisted of 
the CD region (5.50-3.20 ppm) with H-1 atoms of nonsubstituted glucose units (4.80 ppm) and H-1 
(5.03 ppm) of the substituted glucose. Accordingly, signals of H-2, H-3, H-4 and H-6 atoms of 
nonsubstituted units were found around 4.00‒3.00 ppm, whereas the H-6 signal of the substituted 
glucose unit is visible around 4.75 ppm (especially in HSQC and 1H-1H COSY spectra). This part also 
includes primary (4.49-4.34 ppm) and secondary (5.91-5.53 ppm) rim OH groups. The last part of this 
Entry CD Alkaloid R1 x (eq.) y (mol %) Solvent Yield[a] in % 
(Product) 1 2a 18a (8R, 9S) H 1.5 50 THF/H2O (1:1) 78 (19a) 
2 2a 18a (8R, 9S) H 1.3 20 THF/H2O (1:1) 77 (19a) 
3 2a 18a (8R, 9S) H 1.05 20 THF/H2O (1:1) 56 (19a) 
4 2a 18b (8S, 9R) H 1.3 20 THF/H2O (1:1) 86 (19b) 
5 2a 18c (8S, 9R) OCH3 1.3 20 THF/H2O (1:1) 72 (19c) 
6 2a 18d (8R, 9S) OCH3 1.3 20 THF/H2O (1:1) 74 (19d) 
7[b] 2b 18a (8R, 9S) H 1.3 20 THF/H2O (1:1) 20 (20a) 
8 2b 18a (8R, 9S) H 1.3 20 DMF 89 (20a) 
9 2b 18b (8S, 9R) H 1.3 20 DMF 70 (20b) 
10 2b 18c (8S, 9R) OCH3 1.3 20 DMF 80 (20c) 
11 2b 18d (8R, 9S) OCH3 1.3 20 DMF 95 (20d) 
12[b] 2a 18a (8R, 9S) H 1.3 20 DMF 38 (19a) 
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1H NMR spectrum corresponds to the signals of the quinuclidine skeleton of the Cinchona alkaloid, 
which are identified around 2.00‒1.20 ppm.  
 
Figure 18. 1H NMR spectrum of the non-methylated quinidine-α-CD derivative (19d, DMSO-d6) 
Subsequently, 13C NMR, DEPT-edited HSQC and HMBC spectra also confirmed substitution 
on the primary rim of CD skeleton (Figure 19). The C-6 atom from the substituted glucose unit is 
correlated with the hydrogen signal of the triazole (50.41 ppm of C-6I to 8.16 ppm of H-14´of triazole) 
and the peak at 126.13 ppm of C-14  ´triazole is correlated with the signal at 4.57 ppm of the quinidine 
part. 
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Figure 19. 13C NMR spectrum and parts of HMBC spectra of the non-methylated quinidine-α-CD 
derivative (19d, DMSO-d6). 
Moreover, the supramolecular properties of these Cinchona-CD derivatives were also 
investigated in order to study the possible inclusion of the Cinchona alkaloid moiety into CD cavity. 
Thus, cinchonine-β-CD (20a) and quinine-β-CD (20c) were measured in D2O; the additional 2D 
ROESY spectrum showed crosspeaks between substituent (hydrogen atoms of double bond on the 
quinuclidine skeleton) and the inner H-3 atoms of β-CD cavity (Figure 20). Nevertheless, low 
solubility of these non-methylated Cinchona-β-CDs in H2O (approximately 1 mg/1 mL) did not allow 
us to further investigate the nature of the inclusion, e.g., with a concentration dependence. Overall, 
these observed crosspeaks in ROESY can be caused by intermolecular interactions (inclusion of the 
cinchonine moiety to the second CD cavity) or intramolecular interactions (as discussed by Hapiot and 
Monflier130). This phenomenon was further studied by MD and discussed in section 4.9.2. 
 
 
10 20 30 40 50 60 70 80 90 100 110 120 130 140 150 160 170 180 
f1 (ppm) 
C-6 of glucose unit to H-14´of triazole C-14´of triazole to H-12´ of quinidine 
4.2 4.3 4.4 4.5 4.6 4.7 4.8 4.9 
125 
130 
{4.57,126.58} 
8.0 8.1 8.2 8.3 
40 
45 
50 
55 
60 
{8.16,50.41} 
52 
 
 
Figure 20. 2D ROESY spectra of non-methylated  Cinchona-β-CD derivatives 20a (red) and 20c 
(blue) in D2O showing crosspeaks between double bond of the Cinchona alkaloid and inner protons 
(H-3) of β-CD cavity.  
In conclusion, we unambiguously confirmed Cinchona alkaloid attachment to the CD skeleton 
through triazole using 2D NMR measurements. This thorough investigation revealed no triple bond 
and a new triazole hydrogen signal, simultaneously correlating C6 atom on the substituted glucose unit 
with triazole. Therefore, the prepared CD derivatives are substituted on the primary side.  
4.5.  Synthesis of Cinchona-permethylated CD derivatives 
After developing the approach for attaching Cinchona alkaloids to non-methylated CDs, 
permethylated CD derivatives were also prepared for their better solubility in water and in organic 
solvents. First, the starting CD compounds per-Me-N3-α-CD (21) and per-Me-N3-β-CD (22) were 
prepared according to published procedures131,132 and they were used under previously optimized 
conditions for CuAAC click reactions (non-methylated CDs with propargylated Cinchona alkaloids 
18a‒18d as outlined in Table 3). Cinchona-permethylated CD derivatives (23a‒23d, 24a‒24d) were 
isolated in high yields (up to 69%, Scheme 30). 
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Scheme 30. Preparation of Cinchona-permethylated CD derivatives (23a-23d, 24a-24d) 
 As mentioned above, the conditions assessed using non-methylated CDs were applied to 
prepare their analogs on per-Me-α-CD (21); the propargylated Cinchona alkaloid (18a) was added in 
1.3 molar equivalents, with 20 mol% CuI in DMF (Table 4, Entry 1). Thus, a series of permethylated 
Cinchona α-CD derivatives (23a‒23d) was prepared with good yields (59-42% yield, Entries 1‒4). In 
the case of per-Me-β-CD (22), the products (24a‒24d) were also isolated with good to high yields (up 
to 69% yield, Entries 6‒9). Furthermore, the mixture of solvents THF/H2O was investigated (Entry 5), 
but the reaction in DMF showed a higher isolated yield (Entry 3). 
Table 4. Optimized conditions for the CuAAC reaction from the Scheme 30 
 
 
 
 
 
 
 
 
 
 
 
[a] Isolated yield. [b] THF/H2O mixture. 
Entry CD Alkaloid R1 Yield[a] in % (Product) 
1 21  18a (8R, 9S) H 59 (23a) 
2 21 18b (8S, 9R) H 48 (23b) 
3 21 18c (8S, 9R) OCH3 49 (23c) 
4 21 18d (8R, 9S) OCH3 42 (23d) 
5[b] 21 18c (8S, 9R) OCH3 34 (23c) 
6 22 18a (8R, 9S) H 64 (24a) 
7 22 18b (8S, 9R) H 69 (24b) 
8 22 18c (8S, 9R) OCH3 48 (24c) 
9 22 18d (8R, 9S) OCH3 63 (24d) 
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NMR elucidation of permethylated CD derivatives 
NMR spectra of permethylated derivatives were assessed in CD3OD. A representative 
example, per-Me-β-CD derivative with quinidine (24d) was chosen to compare the spectra with those 
of the non-methylated CD derivatives. The 1H NMR spectrum of this derivative 24d is also divided 
into several parts; the aromatic region was similar to the region of non-methylated CD analogs (8.75 ‒ 
7.15 ppm), and the CD region (5.45 ‒ 2.55 ppm) included methyl groups instead of hydroxyl groups 
(Figure 21). The quinuclidine skeleton was also observed around 1.2 ppm. 
 
Figure 21. 1H NMR spectrum of the per-Me-quinidine-β-CD derivative (24d) in CD3OD 
Similarly to non-methylated CD derivatives, 13C NMR, DEPT-edited HSQC and HMBC 
spectra also confirmed substitution on the primary rim of permethylated CD skeleton (Figure 22). The 
C-6 atom from the substituted glucose unit is correlated with the hydrogen signal of the triazole 
moiety (50.93 ppm of C-6I to 7.99 ppm of H-14´of triazole). 
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Figure 22. 13C NMR spectrum and a part of HMBC spectra of the per-Me-quinidine-β-CD derivative 
(24d) in CD3OD 
In conclusion, Cinchona alkaloid attachment to the CD skeleton through triazole linker was 
confirmed by 2D NMR spectra. These results revealed no triple bond and a new triazole hydrogen 
signal. Moreover, C6 atom on the substituted glucose unit correlated with the triazole. Therefore, the 
prepared permethylated CD derivatives are substituted on the primary side.  
4.6.  Solubility of prepared Cinchona-CD derivatives and gram-scale 
preparation 
Before assessing the catalytic activity of Cinchona-CD derivatives, their solubility in water 
was examined. As expected,133 permethylated CD derivatives were more soluble in water than non-
methylated CDs (Figure 23).   
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Figure 23. Solubility of Cinchona-CD derivatives in water 
Moreover, the cinchonidine-β-CD (20b) was prepared in gram-scale for further tests in 
enantioselective reactions. This CuAAC reaction proceeded in 0.95 g of product (53% isolated yield); 
in addition, an excess amount of 9-O-propargyl-cinchonidine (2.5 eq.) and the catalyst CuI (40 mol %) 
were needed for the conversion into the product, which occurred after 16 hours of reaction (Scheme 
31). This derivative is currently being tested in enantioselective hydroformylation reactions in 
collaboration with Professor Éric Monflier’s group, Université de d´Artois, Lens, France. 
 
Scheme 31. Gram-scale preparation of cinchonidine-non-methylated-β-CD (20b) 
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4.7.  Preparation of AD disubstituted α-CD derivatives 
After developing the method for attaching Cinchona alkaloid to CD skeletons, the preparation 
of AD disubstituted α-CD derivatives was investigated. Although nucleophilic substitution failed 
when attempting to attach Cinchona alkaloids to monosubstituted CD skeletons (section 4.4), two 
leaving groups (bromo groups instead of tosyl moiety) of the precursors may differently influence the 
nucleophilic substitution. Thus, 6A,6D-dibromo-α-CD (6) was tested in this reaction with an excess of 
9-amino-(9-deoxy)-cinchonidine (17a) in DMSO under harsh conditions (140 °C, 2,6-lutidine, N-
methylmorpholine, among other bases, Scheme 32). Similarly to the nucleophilic substitution on the 
monosubstituted CD derivatives, the reaction did not proceed at all, similarly due to sterical demand of 
the bulky Cinchona alkaloid. 
 
Scheme 32. Unsuccessful substitution on the 6A,6D-dibromo-α-CD derivative (6). 
However, the approach of nucleophilic substitution on the disubstituted CD skeleton failed as 
expected; subsequently, the CuAAC click reaction, developed for monosubstituted CD derivatives, 
was used in this preparation of disubstituted α-CD derivatives. The starting material 6A,6D-diazido-α-
CD (7) successfully reacted with quinine moiety (18c, Scheme 33), and the AD disubstituted product 
27 was isolated in 76% yield.  
 
Scheme 33. Preparation of the AD disubstituted quinine-α-CD derivative (27). 
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 Considering the possibility of the preparation of heterodisubstituted α-CD derivatives, the 
reaction was investigated in order to isolate first intermediate, quinine-azido-α-CD derivative (Scheme 
34). However, a mixture of starting material 7, monosubstituted Cinchona-azido-α-CD and 
disubstituted α-CD with two quinine moieties (27) was presented from the beginning of the reaction. 
Thus, the time-consuming isolation of this Cinchona-monosubstituted product yielded only traces of 
this product. 
 
Scheme 34. Monosubstituted and disubstituted α-CD skeletons with quinine moieties  
4.8.  Evaluation of Cinchona-CD derivatives as organocatalysts 
The prepared Cinchona-CD derivatives (monosubstituted and disubstituted) were evaluated in 
various asymmetric reactions. Initially, the CD derivatives were designed for reactions of aliphatic 
aldehydes, which were supposed to be included in the CD cavity; thus their inclusion may affect the 
enantioselectivity (Figure 24). In addition, Cinchona-CD derivatives were designed to be soluble in 
water or in mixtures of solvents with water. Hence, a series of permethylated and non-methylated CDs 
were prepared (19a-19d, 20a-20d, 23a-23d, 24a-24d, 27).   
 
Figure 24. Active centers of Cinchona-CD derivatives possible affecting enantioselective reactions. 
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4.8.1. Evaluation of CD derivatives using the MBH reaction  
The catalytic activity of CD derivatives was initially studied using the MBH reaction.134 
Therefore, the prepared CD derivatives were first evaluated using the classical substrates of the MBH 
reaction, benzaldehyde and methyl-acrylate (Scheme 35).  
 
 Scheme 35. MBH reaction for the evaluation of the catalytic activity of Cinchona-CD derivatives 
 Initially, the racemic version of this reaction was performed under standard conditions with 
50% mol of the catalyst 1,4-diazabicyclo[2.2.2]octane (DABCO) in MeOH (Table 5, Entry 1). Then, 
different solvents (DMF, buffer/MeOH or MeOH), suitable for the prepared CD derivatives, were 
tested in this racemic MBH reaction. However, the conversion to the product drastically decreased 
(Entries 2-3); the rate of the reaction rate was much slower in DMF and in a mixture of phosphate 
buffer and with MeOH. The phosphate buffer was chosen to prevent a possible protonation of the 
quinuclidine moiety (as one of the possible centers for catalysis) and, thus, to maintain this moiety 
active for the reaction. Furthermore, the reaction with the prepared CD derivatives (19b, 20b, 23c, 
24b) yielded almost no products after one week at room temperature (Entries 4-8). 
Table 5. Evaluation of prepared CD derivatives using the MBH reaction[a] from Scheme 35. 
Entry Catalyst Time (h) Conversion (%)[b] Solvent Yield[c] (%) 
1 DABCO 72 90 MeOH 66 
2 DABCO 72 < 10 DMF - 
3 DABCO 72 ~30 Buffer[d]/MeOH - 
4 19b 168 < 10 Buffer[d]/MeOH - 
5 19b 168 < 10 DMF - 
6 [e] 19b 168 < 10 DMF - 
7 20b 168 < 10 Buffer[d]/MeOH - 
7 23c 168 < 10 Buffer[d]/MeOH - 
8 24b 168 < 10 MeOH - 
 [a] Standard conditions: 1.3 eq. of methyl-acrylate, 1 eq. of catalysts (or 50 mol % of DABCO), solvent, 
25 °C, 168 hours. [b] Determined via 1H NMR. [c] Isolated yield. [d] Phosphate buffer (pH=7.1, 0.05 M). 
[e] Temperature 40 °C. 
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Aliphatic aldehydes and various esters were also tested in this MBH reaction with prepared 
CD derivatives (19b, 20b, 23c, 24b, Scheme 36). Electron-withdrawing groups on aldehydes (nitro 
group) and electron donating groups on esters (commonly used135 hexafluoroisopropyl-acrylate) were 
also tested. Similarly to the previous tests, all results were negative.  
 
Scheme 36. MBH reaction with aliphatic aldehydes and esters for the evaluation of CD derivatives 
4.8.2. Evaluation of CD derivatives using aldol-type reactions 
Subsequently, Cinchona-CD derivatives were tested in aldol reactions considering the 
excellent results with native CDs (99% ee) in water136 and considering the proline-CD derivatives (the 
section 3.2) were efficiently applied in aldol reactions.89,88 Thus, p-NO2-benzaldehyde and acetone 
were tested with Cinchona-CD derivatives 20c and 23a (Scheme 37). However, the products were 
isolated in low yields as the racemic mixtures. 
 
Scheme 37. Aldol reaction with acetone using the Cinchona-CD derivatives  
Based on the previous results, the prepared CD derivatives unsuccessfully performed as 
catalysts in those reactions in water. Thus, new types of enantioselective reactions were further tested. 
4.8.3. Evaluation of CD derivatives undergoing the Michael addition 
 We continued to screen these CD derivatives in other reactions. Michael addition was chosen 
to screen with our CD derivatives because previous studies have shown that Cinchona alkaloid 
catalyze this reaction with excellent yields and enantiomeric excess of up to 99% ee. Thus, the 
classical substrates for Michael addition (dimethyl-malonate and NO2-styrene) were chosen for this 
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screening. In contrast to the previous reactions (MBH and aldol reactions), the product of Michael 
addition was isolated, albeit with no enantioselectivity (Scheme 38). 
 
Scheme 38. Michael addition catalyzed with Cinchona-CD derivatives 
4.8.4.  Evaluation of permethylated CD derivatives using the AAA reaction 
After unsuccessfully applying the Cinchona-CD derivatives in the MBH and aldol-type 
reactions and also in Michael addition, first, permethylated CD derivatives (23a-23d, 24a-24d) were 
tested in the decarboxylative asymmetric allylic amination137 (AAA) of MBH carbamate (28), as 
shown in Scheme 39. The previously published most efficient organocatalyst is the dimeric Cinchona 
alkaloid hydroquinidine(antraquinone-1,4-diyl)diether (DHQD)2AQN, resulting in 98% isolated yield 
and 97% ee.137 
 
Scheme 39. Permethylated CD derivatives (23a-23d, 24a-24d) tested as catalysts in the 
decarboxylative AAA.  
Fortunately, the first tests showed that the prepared permethylated CD derivatives (23a-23d, 
24a-24d) catalyzed this AAA reaction with high isolated yields and with significantly high ee (Table 
6).  
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Table 6. The catalyst and solvent screening in AAA reaction[a] 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
[a] Standard conditions: 10 mol % catalyst, 0.4 M solution, solvent 40 °C, 168 hours. [b] Isolated yield 
[c] Temperature 25 °C. “n.d.” not detected, “-“ not measured. 
As outlined in Table 6, the racemic reaction of the MBH carbamate (28) was performed with 
DABCO (Entry 1) in toluene at 40 °C in one week. These reaction conditions were chosen based on a 
previous study137 in which authors obtained 98% isolated yields and up to 97% ee with dimeric 
Cinchona alkaloid catalysts in aromatic solvents (Scheme 44). Thus, toluene was chosen as solvent for 
our permethylated Cinchona-CD derivatives.  
Then, the permethylated α- and β-CDs without Cinchona alkaloid moieties were also tested as 
blank catalysts to confirm that the Cinchona alkaloid moiety is a necessary part of the catalyst (Entries 
2 and 3). Subsequently, permethylated Cinchona-CD derivatives showed low to high ee (Entries 3-11). 
Surprisingly, significant differences were observed in pairwise comparisons between Cinchona 
alkaloid moieties, and cinchonidine-per-Me-CDs (23b and 24b) showed the best ee (Entries 4 and 8), 
but other Cinchona alkaloids showed low ee ranging from 13 to 27 % (Entries 5-7 and 9-11). Based on 
Entry Catalyst Solvent Yield[b] (%) ee (%) 
1 DABCO toluene 89 - 
2 per-Me-α-CD toluene n.d. - 
3 per-Me-β-CD toluene n.d. - 
4 23a toluene 42 74 
5 23b toluene 62 13 
6 23c toluene 76 25 
7 23d toluene 47 27 
8 24a toluene 55 69 
9 24b toluene 37 15 
10 24c toluene 12 15 
11 24d toluene 44 25 
12 24a CHCl3 63 69 
13 24a MTBE 63 69 
14 24a MeOH 73 33 
15[c] 24a toluene 15 75 
63 
 
the comparison of CD cavity sizes between α- and β-CDs, it was concluded that the size of the cavity 
has no effect on the reaction because yield and ee results are similar (Entries 4-11). Quinine-per-Me-α-
CD (23c) has the highest isolated yield (76%), but its ee was low (25%).  
The advantage of the permethylated CD derivatives is their good solubility in organic solvents. 
The reactions in methyl(tert-butyl)ether (MTBE), in CHCl3 and in toluene resulted in similar yields 
and ee (Entries 8, 12, 13). Although the yield of the reaction in MeOH was similar to toluene, ee was 
lower (Entry 14). Lastly, the reaction was performed at room temperature with 75% ee but 
unfortunately in 15% yield (Entry 15). Thus, the solvent strongly affects enantioselectivity and this 
problem will be further discussed in the section 4.9.2 in MD studies.  
4.8.5.  Evaluation of non-methylated CD derivatives using the AAA reaction 
Non-methylated Cinchona-CD catalysts were also tested using the conditions found for 
Cinchona-per-Me-CDs. However, the solvent had to be changed because the prepared non-methylated 
CD derivatives (19a-19d, 20a-20d) show low solubility in organic solvents (Scheme 45).  
 
Scheme 45. Decarboxylative AAA reaction used prepared CD derivatives. 
The results from the tests with non-methylated CD derivatives (19a-19d, 20a-20d) and 
disubstituted CD derivative (27) are shown in Table 7. Native α- and β-CDs were also tested as blank 
catalysts (Entries 1-2). Although non-methylated monosubstituted CD derivatives (19a–19d) showed 
lower enantiomer excess (Entries 3–10), they achieved catalytic activity in a solvent mixture 
ACN/H2O, which indicates the potential of these catalysts for future applications in water. DMF was 
also tested, albeit with no conversion into the product (Entries 12 and 13), and cinchonidine-α-CD 
(19b) was inactive (Entry 11). Similarly, cinchonidine-β-CD (20b) in DMF and DMSO showed low ee 
and low isolated yields (Entries 12 and 13). Lastly, the disubstituted CD derivative (27) was tested; 
unfortunately it also failed to show any activity (Entry 14). In addition, this derivative was 
unsuccessfully tested in this reaction with a cocatalyst, (1S)-10-camphorsulfonic acid (CSA) according 
to the original procedure,137 in which this cocatalyst had enhanced the enantiomeric excess of dimeric 
Cinchona alkaloid (DHQD)2AQN, as shown previously in Scheme 44.  
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Table 7. Catalyst and solvent screening[a] for Cinchona-non-methylated CDs 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
[a] Standard conditions: 10 mol % catalyst, 0.4 M solution, solvent 40 °C, 168 hours. [b] Isolated yield. [c] With 
(1S)-CSA (5 mol %). “n.d.” not detected, “-“ not measured. 
In conclusion, the Cinchona-CD derivatives were successfully applied in AAA with up to 76% 
isolated yield and up to 75% ee. Permethylated Cinchona-CD derivatives were more successful than 
non-methylated Cinchona-CD derivatives. Moreover, the size of the CD cavity in the case of 
permethylated derivatives had no effect on the reaction. In the case of non-methylated CDs, the 
enantiomeric excess was low but promising even in ACN/H2O. Overall, these Cinchona-CD derivates 
can be used as catalysts for enantioselective reactions (even in water).  
  
Entry Catalyst Solvent Yield[b] (%) ee (%) 
1 α-CD ACN/H2O n.d. - 
3 β-CD ACN/H2O n.d. - 
3 19a ACN/H2O 5 0 
4 19b ACN/H2O 10 3 
5 19c ACN/H2O 12 0 
6 19d ACN/H2O 18 21 
7 20a ACN/H2O 19 19 
8 20b ACN/H2O 26 5 
9 20c ACN/H2O 5 0 
10 20d ACN/H2O 21 13 
11 19a DMF n.d. - 
12 20a DMF 9 25 
13 20a DMSO 19 23 
14 27 ACN/H2O n.d. - 
15[c] 27 ACN/H2O n.d. - 
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4.9.   Molecular modeling of Cinchona-CD derivatives  
Computational studies of CDs involved a wide range of simulation methods using various 
tools and algoritms.113 Molecular docking and molecular dynamics simulations, most common used 
methods in molecular modeling of host-guest complexes, have been used to study inclusion complexes 
of CDs113,138 and CD derivatives112,113. Researchers are able to specifically measure distances between 
hosts (CDs) and their ligands (guests). In addition, conformational changes of CD derivatives in 
different solvent environments can be also studied.139 The MD studies provide detailed information on 
atomic positions, velocities and forces, thus allowing us to study the physics of the system.117 
Therefore, computer simulations enable description of driving forces responsible for complexation of 
guests-ligands into cavities of hosts-CDs in terms of the binding free energies.  
More specifically, molecular modeling of CDs is mainly focused on the development of CD 
derivatives that could be potentially used as drug carriers. Importantly, drug encapsulation into the CD 
cavity remarkably enhances drug solubility and bioavailability in aqueous solutions.140 In comparison 
to nuclear magnetic resonance (NMR)141 or to differential thermal analysis (DTA)142, in silico 
modeling of CD inclusion complexes provides crucial additional information and can substantially 
accelerate the development of sophisticated drug delivery systems.143–145 For example, comprehensive 
studies on the complexation of steroids and cholesterol into the CD cavity have improved the 
treatment for Niemann-Pick disease.146  
Specifically, Cinchona-CD derivatives are almost unexplored as regards molecular modeling. 
Only study, dealing with X-ray analysis of inclusion complexes, confirmed the encapsulation of 
quinine into the β-CD cavity.147 Furthermore, just a simple QM geometry optimization (using density 
functional theory - DFT) of covalently attached Cinchona-CD derivatives, linked via thiourea and 
squaramide moieties, used as catalysts in Michael addition (discussed in section 3.4, Scheme 18) was 
studied by DFT calculations.104  In contrast to the CD modeling, catalysis using Cinchona alkaloids 
has been mainly examined in (DFT) calculations.148 However, according to our best knowledge, no 
MD study of Cinchona-CD catalysts and substrates has not been performed yet. 
Therefore, in this thesis, spatial arrangements of CD derivatives and substrates were studied in 
silico by extensive MD simulations to shed some light on the catalytic (in)activity of prepared 
Cinchona-CD derivatives.  
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4.9.1. Inclusion of quinine into native β-CD 
First, an MD protocol was developed to assess whether a ligand is able to penetrate 
spontaneously into the β-CD cavity. For this purpose, the simulated system consisting of quinine, 
native β-CD and water molecules was studied through series of 4000 nano-second MD simulations 
performed at different temperatures in the range of 300-400K using the AMBER software package. 
The initial arrangement of β-CD and quinine is shown in Figure 25. The atoms that were 
chosen to track time-evolution of mutual distances between quinine and β-CD are numbered as 
follows: atoms C1 and C0 belong to the quinoline moiety, C19 and C10 to the quinuclidine part. 
Moreover, primary and secondary rims of CD are also indicated. Hydrogen atoms in MD snapshots 
are usually omitted to simplify the representations. 
 
 
 
 
 
 
 
Figure 25. Initial arrangement (A) of native β-CD and quinine in MD studies.  
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Possible mutual orientations of quinine encapsulated into β-CD are schematically drawn in 
Figure 26. In principle, quinine can penetrate either the primary (orientation B or C) or the secondary 
(orientation F or G) rim of β-CD. In addition, either quinuclidine (orientation B or G) or quinoline 
(orientation C or F) can be involved in the encapsulation process. Furthermore, two intermediate 
complexes with fully buried quinine could also be formed in this process (orientation D or E). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 26. Possible orientations (B, C, D, E, F, G) of quinine encapsulation into the β-CD cavity. 
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Importantly, the time-evolution of distances between the centers of mass of quinine and β-CD 
unambiguously confirmed the formation of the inclusion complexes in our MD simulations (see 
Figure 27). The values of distances (y axis) were often lower 5Å in these MD simulations. At lower 
temperatures, the encapsulation times were slightly longer (almost 2000 ns at 300K), but the resulting 
complexes were more stable. In contrast, at higher temperatures, the complexes transiently formed, 
that is, CD repeatedly encapsulated and released quinine many times. 
 Figure 27. Time evolution of distances between the centers of mass of β-CD and quinine at 
300-400 K MD runs. 
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Interestingly, even the whole-quinine inclusion into the β-CD cavity (i.e. the inclusion 
complexes D or E, as proposed in Figure 26) was confirmed by MD simulations (note the nearly zero 
y values shown in Figure 28).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 28.  (Top) Schemes and snapshot from MD trajectories representing the D and E inclusion 
complexes.  
(Bottom) Almost zero values for distances between the centers of mass of β-CD and quinine indicate 
complete inclusion of the whole quinine into the β-CD cavity. 
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 Subsequently, the time evolution of the distances between selected atoms in quinine and in β-
CD within MD runs were depicted to differentiate inclusion complexes B, C, F and G (see charts in 
Figures S1-S4). Accordingly, the results showed that quinine inclusion through the primary rim (i.e. B 
or C inclusion complexes – see Figure 29) was found as minor. The quinuclidine (B) and the quinoline 
moiety (C) were inserted into the β-CD cavity only for short intervals, for example, see the orange line 
in Figure 29 at the interval of 3600-4000 ns for B inclusion and the black line at the interval 3200-
4000 ns interval for C inclusion.  
       
 
 
 
Figure 29. (Top) Schemes and snapshots of MD trajectories representing quinine inclusion into the β-
CD cavity through primary rim leading to inclusion complexes B and C.  
(Middle - Left) Time evolution of distance d3 (purple) between C10 of quinine (quinuclidine moiety) 
and the primary rim of β-CD. Time evolution of distance d4 (orange) between C10 of quinine and the 
secondary rim of β-CD. 
(Middle - Right) Time evolution of distance d5 (black) between C1 of quinine (quinoline moiety) and 
the primary rim of β-CD. Time evolution of distance d6 (yellow) between C1 of quinine and the 
secondary rim of β-CD. 
(Bottom) Atoms selected for tracking distances between Cinchona alkaloid substituents and CDs in 
MD are highlighted as yellow spheres. All hydrogen atoms are omitted to simplify and clarify this 
representation.  
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As suggested above, quinine inclusion through the secondary rim (Figure 30) is more 
favorable than through the primary rim. Shorter distances (10 Å) are observed during most of the 
simulation, more specifically, for 1400-4000 ns in quinoline (F) and for 400-3200 ns in quinuclidine 
(G) inclusion. Thus, quinuclidine inclusion is the most favored of all six possible orientations of 
quinine encapsulation into the β-CD cavity.  
  
 
 
 
 
 
 
 
 
 
 
Figure 30.  (Top) Schemes and snapshots of MD trajectories representing quinine inclusion into the β-
CD cavity through the secondary rim, thereby forming inclusion complexes F and G. 
(Middle - Left) Time evolution of distance d7 (light-blue) between the C0 atom of the methoxy group 
of quinine (quinoline moiety) and the primary rim of β-CD. Time evolution of distance d8 (magenta) 
between the C0 atom of the methoxy group of quinine and the secondary rim of β-CD. 
(Middle - Right) Time evolution of distance d1 (dark-blue) between C19 of quinine (quinuclidine part) 
and the primary rim of β-CD.  Time evolution of distance d2 (green) between C19 of quinine and the 
secondary rim β-CD. 
(Bottom) Atoms selected for tracking of distances between Cinchona alkaloid substituents and CDs in 
MD are highlighted as yellow spheres. All hydrogen atoms are omitted to simplify and clarify this 
representation. 
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 Previously, quinine encapsulation into the β-CD cavity had been confirmed by X-ray 
analysis.147 The authors showed that the quinuclidine moiety is preferably included in the CD cavity 
and that the quinoline moiety is surrounded by other native β-CDs that stabilize this aromatic moiety 
in higher-order crystal structures. The comparison between the inclusion complex experimentally 
solved by X-ray analysis147 (X) and the most populated inclusion complex resulting from our MD 
simulations (G) shows that their structures are identical (Figure 31). 
 
 
Figure 31. Comparison between structures of the inclusion complex solved by X-ray analysis147 (X) 
and obtained by MD in this study (G). 
In conclusion, our MD protocol, developed to study the formation of the inclusion complex 
between quinine and β-CD, enable us to find complexes with all possible mutual orientations of 
quinine encapsulation into the β-CD. The MD data on the most preferred complex, that is, the complex 
with quinuclidine included into the CD cavity, reproduces X-ray data, thus unambiguously confirming 
the appropriateness of our MD approach for further analysis of the spatial arrangements of new CDs 
and substrates in enantioselective reactions as described in detail below.  
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4.9.2. Molecular modeling of non-methylated Cinchona-CD derivatives 
4.9.2.1. Geometry optimization 
Subsequently, all prepared Cinchona-CD derivatives were studied in detail using MD 
simulations. First, non-methylated Cinchona-CD derivatives (19a-19d and 20a-20d, Figure 32) in 
water were geometry optimized to the minimal potential energy and equilibrated in short MD runs 
produced using the NAMD software package.  
 
 
 
 
Figure 32. Schematic representations of non-methylated Cinchona-CD derivatives 19a-19d, 20a-20d 
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The geometry-optimized and equilibrated conformations resulting from the short MD runs 
match a 6-monosubstituted, cone-shaped CD cavity. In contrast to the Cinchona-α-CD derivatives 
(19a-19d), whose triazole moiety is located outside the cavity and whose substituent is not included in 
the CD cavity, the triazole moiety of Cinchona-β-CD derivatives (20a-20d) is partly included in the 
cavity (Figure 33).  
    
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 33.  Optimized and equilibrated structures of non-methylated Cinchona-CD derivatives (19a-
19d and 20a-20d) 
Water molecules and hydrogen atoms are omitted for the simplicity and clarity.  
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4.9.2.2. Substituent self-inclusion 
The problem of self-inclusion of Cinchona-β-CD derivatives has already been discussed in 
section 4.4 (NMR elucidation of non-methylated Cinchona-CD derivatives). This NMR analysis 
revealed crosspeaks in 2D ROESY, thus confirming non-covalent interactions between H-3 protons 
inside the CD cavity and quinuclidine and quinoline hydrogen atoms of the Cinchona-alkaloid 
substituent. 
Hence, the MD protocol developed for quinine-CD inclusion complexes, presented in previous 
section, was also applied here to non-methylated Cinchona-CD derivatives. The conformational 
preferences of solvated CD derivatives 20a, 20b and 20c were investigated by 500 ns MD runs at 
different temperatures, more specifically, in the range of 300-400K. These MD simulations were 
produced using the AMBER software package.  
Time evolution of distances between chosen atoms (i.e. hydrogen atom H76 of the vinyl group 
on the quinuclidine moiety, hydrogen atom H64 of the quinoline moiety and hydrogen atoms (H-3) of 
the CD cavity - see Figure 33) were tracked to confirm potential inclusion events of Cinchona alkaloid 
substituents into the CD cavity (see Figures S5-S7).  
 
 
 
 
 
 
 
 
 
 
Figure 33. Atoms selected for tracking distances between Cinchona alkaloid substituents and CDs in 
MD simulations are highlighted as violet spheres (i.e., all H-3 atoms of β-CD derivatives, hydrogen 
atom H76 of the vinyl group on quinuclidine moiety and hydrogen atom H64 on the quinoline 
moiety). All other hydrogen atoms are omitted to simplify and clarify this representation. 
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Quinuclidine inclusion into the CD moiety of the first studied catalyst 20a is represented in 
Figure 34. Importantly, the distances between H76 of the vinyl group of quinine and H-3 atoms of CD 
unambiguously confirmed quinuclidine inclusion as shown by the sharp and persistent decrease of y-
values (blue line) at 340 K in the 320-500 ns interval. Similarly, the inclusion of the quinoline segment 
was also confirmed - note the decreasing y-values in the second chart (green line). The entire set of 
graphs for MD runs produced at 300-400 K are shown in Supplemental Information (Figure S5). 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 34. (Top) Schematic representations, (middle) MD snapshots and (bottom) time evolution of 
the inclusion of quinuclidine (blue line) or quinoline moieties (green line) into the non-methylated 
cinchonine-β-CD (20a).  
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MD study of the second catalyst 20b showed Cinchona-alkaloid (in this case cinchonidine) 
moiety is not included into the β-CD cavity (Figure 35), in contrast to the previously investigated 
catalyst 20a. In addition, the distances between H76 of the vinyl group (A) of quinine and H-3 atoms 
and between the quinoline moiety (B) and H-3 atoms were not constant during the whole simulation. 
The entire set of graphs of MD runs, produced at 300-400 K, is shown in Supplemental Information 
(Figure S6). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 35. (Top) Schematic representations, (middle) MD snapshots and (bottom) time evolution of 
the inclusion of quinuclidine (blue line) or quinoline moieties (green line) into the non-methylated 
cinchonine-β-CD (20b).  
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Third MD studied catalyst 20c confirmed the inclusion of both quinuclidine and quinoline 
moieties into the β-CD cavity (Figure 36). The distances between H76 of the vinyl group of quinine 
(blue line) and H-3 atoms of CDs and between the quinoline moiety (green line) and H-3 atoms 
decreased to low y-values after the inclusion. Moreover, quinuclidine inclusion is more pronounced 
than quinoline inclusion, most likely due to the methoxy functional group of this aromatic part. The 
entire set of graphs for MD runs produced at 300-400 K is shown in Supplemental Information (Figure 
S7). 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 36. (Top) Schematic representations, (middle) MD snapshots and (bottom) time evolution of 
the inclusion of quinuclidine (blue line) or quinoline moieties (green line) into the non-methylated 
cinchonine-β-CD (20c). 
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4.9.3.  Molecular modeling of permethylated Cinchona-CD derivatives 
4.9.3.1. Geometry optimization 
The structures of Cinchona alkaloid-permethylated CD derivatives (23a-23d, 24a-24d, Figure 
38) were optimized and equilibrated in MeOH.  
 
 
Figure 37. Schematic representations of permethylated Cinchona-CD derivatives 23a-23d, 24a-24d 
The resulting conformers showed that the spatial arrangement of these permethylated 
Cinchona CD derivatives is completely different from that of non-methylated CD derivatives. The CD 
cavity lacks the typical cone shape, and the Cinchona alkaloid moieties are completely outside the CD 
skeleton (Figure 38). No inclusion was observed in either α- or β-CD derivatives. 
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Figure 38. Optimized structures of permethylated Cinchona-CD derivatives (23a-23d and 24a-24d)  
MeOH molecules and hydrogen atoms are omitted for the simplicity and clarity.
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4.9.3.2. Substituent self-inclusion 
To further investigate a potential self-inclusion of these permethylated Cinchona-CD 
derivatives, the most successful catalyst in enantioselective reactions – i.e., cinchonidine-per-Me-β-
CD (24b) – was studied in 500 ns MD runs produced using the AMBER software package (Figure 39). 
Again, the atoms chosen to track this self-inclusion process were similar to those selected in non-
methylated CD derivatives. The entire set of graphs of MD runs produced at 300 – 400 K is shown in 
Supplemental Information (Figure S8). The time evolution of distances between Cinchona H76 and 
inner H-3 atoms of the CD skeleton confirmed that no substituent inclusion into the CD cavity occurs 
in these complexes.  
Based on these results, we concluded that neither self-inclusion of Cinchona moieties nor 
potential inclusion of substrates into the CD cavity are likely to occur because cone shape of the cavity 
collapses in permethylated catalysts. Accordingly, the enantioselective reaction catalyzed by the 
Cinchona alkaloid moiety should preferentially occur outside this permethylated CD cavity.  
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 39. (Top) Schematic representations, (middle) MD snapshots and (bottom) time evolution of 
the inclusion of quinuclidine (blue line) or quinoline moieties (green line). The substituent clearly 
resides outside the CD cavity of the catalyst 24b. 
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4.9.4. Complexes of permethylated Cinchona-CD catalysts and substrates  
To further investigate the previously mentioned hypothesis about the occurrence of an 
enantioselective reaction outside our permethylated Cinchona-CD catalysts, the spatial arrangement of 
the most successful catalyst 24b with MBH carbamate (32) as a substrate in AAA reaction was studied 
by MD simulations. The corresponding MD simulation revealed that the substrate 32 is positioned in a 
“outside pocket”, as it was predicted (Figure 40). 
 
 
 
 
 
 
 
Figure 40. Representation and MD snapshots of cinchonidine-per-Me-β-CD (24b) in AAA reaction in 
toluene 
Our spatial arrangement of CD catalyst and substrate were subsequently compared to the 
spatial arrangements of two previously mentioned, very recently published104 CD catalysts, used in 
enantioselective Michael addition. First arrangement of Cinchona-CD catalysts with a thiourea linker 
(XXXII), β-nitrostyrene and 1,3-diketone compound (Figure 41) were visualized using VMD 
software. Hydrogen atoms are omitted for simplicity and clarity.  
 
 
 
 
 
 
 
 
Figure 41. Representation and MD snapshots of previously published Cinchona alkaloid-per-Me-β-
CD attached through a thiourea moiety in Michael addition.104 
83 
 
 Spatial arrangement of the second previously published Cinchona-CD catalyst with a 
squaramide linker (XXXI), β-nitrostyrene and 1,3-diketone compound is shown in Figure 42.   
 
 
 
 
 
 
 
 
Figure 42. Representation and MD snapshots of previously published Cinchona alkaloid-per-Me-β-
CD attached through a squaramide in Michael addition. 
Both these published spatial arrangements (Figures 41 and 42) showed that the cone shape of 
the β-CD cavity collapsed, Cinchona-alkaloid moiety is positioned outside the cavity, resulting in the 
formation of “outer pocket”, similarly to our findings by MD. Moreover, the hydrogen bonds between 
the substrates and the linkers fix the positions of these substrates and thus, affect the enantioselective 
formation of the products.   
In conclusion, the collapsed cone-shape of the permethylated β-CD cavity and the Cinchona-
alkaloid moiety positioned outside this CD cavity most likely created the “outer pocket” where the 
AAA reaction most likely occurs. Nevertheless, no hydrogen bonds can support the fixing of the 
substrate in this pocket resulting in lower enantiomeric excess (75% ee), compared to the previously 
published Cinchona-CD catalysts with squaramide and thiourea linkers (99% ee). 
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5. CONCLUSION 
The research discussed in this thesis was divided into the following stages: (i) preparation of 
heterodisubstituted AC regioisomers on α-CD, (ii) synthesis of Cinchona-CD derivatives for 
enantioselective reactions and (iii) molecular modeling of the catalytic activity of Cinchona-CD 
derivatives.  
In the first stage of this research, a method for the preparation of the heterodisubstituted α-CD 
derivatives was developed to prepare CD derivatives with two different moieties as pure regioisomer 
for enantioselective catalysis. The precursor for these catalysts, a CD derivative with azido and 
mesitylene sulfonyl group, was prepared and isolated as a pure AC regioisomer in gram scale from the 
mixture of AB, AC and AD regioisomers. In addition, the pseudoenantiomers of these 
heterodisubstituted AB and AC regioisomers were confirmed via HPLC-MS method at 10 °C. 
Furthermore, the regioisomer pattern of the most common disubstituted CD derivatives was 
investigated and used to investigate a regioisomer ratio of the mixture with this AC disubstituted 
regioisomer. Unfortunately, these heterodisubstituted regioisomers were not further studied to develop 
new CD-based organocatalysts because they have pseudoenantiomer pairs AB/BA and AC/CA, 
thereby preventing their application in enantioselective catalysis. 
In the second stage, a method for attaching Cinchona alkaloids to CD skeletons was developed 
to prepare new CD-based organocatalysts for enantioselective reactions. First, four common Cinchona 
alkaloids (cinchonine, cinchonidine, quinine and quinidine) were attached to CD skeletons via a 
CuAAC reaction, subsequently preparing a series of new Cinchona-CD derivatives. Second, their 
permethylated analogs were synthesized to enhance their solubility in different organic solventsand in 
water. Third, their catalytic activity was evaluated in asymmetric reactions, specifically in the AAA 
reaction with high enantiomeric excess (up to 75% ee) and high isolated yields (up to 74%). Fourth, a 
disubstituted α-CD with two quinine moieties was prepared as a pure AD regioisomer and tested in 
this AAA reaction, albeit with no isolated product. Fifth, the supramolecular properties of Cinchona-β-
CD derivatives were confirmed via 2D ROESY NMR interactions between protons of the substituent 
and inner protons of the β-CD cavity which showed the partial inclusion into the cavity. 
In the third and final stage, the experimental findings about Cinchona-CD catalysts were 
further supported with computational studies based on MD calculations. Initially, the MD protocol, 
developed for this study, confirmed the quinine encapsulation into the native β-CD cavity in water. 
Subsequently, the spatial arrangements of non-methylated Cinchona-CD derivatives were studied, 
confirming the self-inclusion of the Cinchona alkaloid moiety into the non-methylated β-CD cavity. 
Moreover, permethylated Cinchona-CD derivatives were also tested for self-inclusion; however, this 
phenomenon was not observed. Conversely, permethylated CD derivatives create an “outer pocket” 
where substrates likely interact with the catalytic center of these catalysts, as confirmed in the AAA 
reaction by MD simulations.  
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6. EXPERIMENTAL SECTION 
6.1. Synthesis - general information, instruments and materials 
Organic solvents were distilled before use. Native CDs (α- and β-CDs) were purchased from 
Wacker Chemie (Germany). Other reagents were purchased from common commercial sources 
(Sigma, Penta Chemicals) and used without further purification. Concentrated (25%) aqueous solution 
of NH3 was used. 
Silica gel 60 (0.040–0.063 mm) was used for column chromatography, and TLC was 
performed on aluminium sheets with a layer of silica gel 60 F254, both purchased from Merck, 
Germany. The solvent ratio in elution mixtures is given as volume/volume. Argon was used as an inert 
gas. Spots on TLC plates were detected by using an UV lamp (λ = 254 nm for cinchonine and 
cinchonidine derivatives and λ = 365 nm for quinine and quinidine derivatives) and by dipping the 
TLC plates in sulfuric acid (50% aqueous solution) for CD derivatives or in basic KMnO4 solution and 
by subsequent heating with a heat gun. Plates were developed in a saturated chamber; the mobile 
phases are given at each procedure in volume/volume ratio. CD starting materials and derivatives were 
dried to constant weight at oil bath at appropriate temperature using an oil pump or in a vacuum drying 
box in the presence of P2O5 and KOH. Quantitative analysis of TLC plates was performed with the 
software JustQuantify Free.  
Preparative chromatographic separations of heterodisubtiuted AB-, AC- and AD-regioisomers 
were performed on a Büchi preparative chromatography system using SiliCycle SiliaCartridger – 40 
mm Cartridge packed with Lichroprep RP-18 Phase (40-63 µm) reversed-phase silica gel as a 
stationary phase, ACN/water gradient elution and Büchi UV Photometer C-635 as a detector 
(detection wavelengths: 280 nm for mesitylene derivatives and 214 nm for azido derivatives). HPLC 
regiochemical measurements were carried out on an Agilent 1100 HPLC system equipped with UV-
Vis and evaporative light scattering (ELS) detector. Reversed-phase separations were carried out on an 
Inertsil ODS-3 (4.6 × 150 mm, particle size 5 m) analytical column using ACN/water as the mobile 
phase with gradient elution at a flow rate of 1.0 mL/min with UV (280 nm for mesitylene derivatives 
and 214 nm for azido derivatives). Inclusion assisted HPLC separations were obtained on a CD-Screen 
stationary phase (Bio-Sol-Dex Ltd, Hungary, 4.6 × 250 mm, particle size 5 m) with the mobile phase 
of ACN/water with gradient elution at a flow rate of 0.5 mL/min with UV (280 nm for mesitylene and 
214 nm for azido derivatives) detection.  
The pseudoenantiomers HPLC-MS measurements were carried out on a Poroshell C-18 (4.6 × 
150 mm, particle size 2.7 m) analytical column using acetonitrile (+ 0.05% formic acid)/water (+ 
0.05 % formic acid) as the mobile phase. Linear gradient elution was used as: 20% acetonitrile in 0 
min, 30% acetonitrile at 15 min, 70% acetonitrile at 17.5 min and stop time was 25 min. Flow rate was 
0.7 mL/min under the temperature 10 °C. UV detection was done at 280nm.  
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For IR measurements, samples were mixed with KBr powder and measured on a Thermo 
Nicolet AVATAR 370 FT-IR spectrometer using DRIFT method. Specific optical rotation was 
performed on Rudolph Research AUTOPOL III polarimeter at 589 nm (sodium D line) and the values 
of [α]25D are reported together with the concentration (c, g/100 mL) and solvent. Mass spectra (HRMS) 
were measured on an Agilent 6530Q-TOF MS spectrometer. Samples were dissolved in a mixture of 
ACN/H2O. 
 1H NMR spectra were acquired on Bruker AVANCE III spectrometer at 600 MHz, 13C NMR 
spectra at 125 MHz, with DEPT and 2D NMR measurements (1H, 1H-COSY, HSQC, and HMBC). 
Samples were dissolved in DMSO-d6, CD3OD or D2O with a drop of tert-butanol. Signals of 
tetramethylsilane (for 1H NMR) and CDCl3 (for 13C NMR) served as internal standards. Chemical 
shifts are given in ppm; coupling constants J are given in Hz. For NMR, the atoms were numbered 
according to numbering system used in the literature on CD chemistry and on Cinchona alkaloids, thus 
alphabetical numbering was replaced with Greek numbering for the clarity (Figure 40). 
 
 
Figure 40. Numbering of CD skeletons in NMR spectra 
 
6.2.  Computational study – general information 
The initial structures of α-CD, β-CD and quinine were retrieved from the Protein data bank 
(PDB identification: 5E6Y for α-CD149, protein 5AB1 for β-CD150 and protein 4UIN for quinine151). 
The initial structures for quinidine, cinchonine and cinchonidine were built from quinine using the 
Molefacture plugin115 in the VMD 1.9.3 Their geometries were optimized at the semiempirical 
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quantum mechanics (SQM). The initial structures of Cinchona-CD derivatives were constructed using 
structures of CDs and Cinchona alkaloids, also in Molefacture plugin. Simple organic molecules such 
as MeOH, toluene and MBH carbamate were also obtained in Molefacture plugin. Non-methylated 
Cinchona α- and β-CD derivatives were surrounded by octahedral periodic boxes of 4875 water 
molecules represented by TIP3 potential152. Permethylated Cinchona-CD derivatives were surrounded 
by MeOH or by 1734 toluene molecules parameterized by CGenFF.153   
The atom numbering in VMD simulations is presented in Figure 41. Labeled atoms C61, C62, 
C63, C64, C65, C66, C67 (violet) are the primary-rim (C-6) atoms, whereas C21, C22, C23, C24, 
C25, C26, C27 (black) are the secondary-rim (C-3) atoms. 
 
 
Figure 41. Atom numbering of Cinchona alkaloid-CD complexes and Cinchona-CD 
derivatives used in MD simulations 
Preliminary MD trajectories were produced by NAMD software package.109 Simulations were 
performed at 310 K. Langevin thermostat and Langevin-Hoover barostat were applied for the 
temperature and pressure control.109 VdW interactions were computed using non-bonded cutoff 12 Å. 
The smooth-PME method was used for summation of long-range electrostatic interactions.119 Long 
MD runs were obtained by AMBER software package.118  
Analysis of MD trajectories 
MD trajectories were analyzed by CPPTRAJ program.154 Graphs were produced by Gnuplot 4.6 and 
figures were retrieved by ICM Molsoft and ChemBioOffice software packages.   
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6.3. Synthesis of starting materials – cyclodextrins 
6A-O-Toluenesulfonyl-α-CD (1a)  
Compound 1a was prepared according to a previously published procedure19, 
with some modifications20. 1H NMR and MS spectra are in accordance with this 
literature.   
1H NMR (400 MHz, DMSO-d6): δ (ppm): 7.76 (d, J = 8.8 Hz, 2H, H-2’), 7.45 
(d, J = 8.2 Hz, 2H, H-3’), 5.60-5.35  (m, 12H, 6 × OH-2, 6 × OH-3), 4.80 – 4.63 
(6 × H-1), 4.54-4.42 (m, 5H, 5 × OH-6), 4.28 (m, 2H, 2 × H-6I), 3.86-3.12 (m, 
34H, 6 × H-2, 6 × H-3, 6 × H-4, 6 × H-5, 10 × H-6), 2.39 (s, 3H, H-5’).  
MS (ESI): found 1149.3. For [M + Na]+ calculated 1149.3.  
6A-O-Toluenesulfonyl-β-CD (1b)  
Compound 1b was prepared according to a previously published procedure19, with 
some modifications20. 1H NMR and MS spectra are in accordance with these 
references.   
1H NMR (400 MHz, DMSO-d6): δ (ppm): 7.75 (d, J = 8.1 Hz, 1H, H-2’), 7.43 (d, J 
= 8.1 Hz, 1H, H-3’), 5.81-5.63 (m, 14H, 7 × OH-2, 7 × OH-3), 4.84-4.76 (m, 7H, 7 
× H-1), 4.49-4.34 (m, 6H, 6 × OH-6), 4.43-3.20 (m, 42H, 7 × H-2, 7 × H-3, 7 × H-
4, 7 × H-5, 14 × H-6), 2.43 (s, 3H, 3 × H-5’).  
MS (ESI): found 1311.3. For [M + Na]+ calculated 1311.3.  
6A-Azido-6A-deoxy-α-CD (2a)  
Compound 2a was prepared according to a previously published procedure19, with 
some modifications of the purification process adapted from a different procedure48. 
1H NMR and MS spectra are in accordance with these references.   
1H NMR (400 MHz, D2O): δ (ppm): 5.13–5.04 (m, 6H, 6 × H-1), 4.06-3.80 (m, 24H, 
12 × H-6, 6 × H-5, 6 × H-3), 3.74-3.51 (m, 12H, 6 × H-2, 6 × H-4). 
MS (ESI): found 1020.8 For [M + Na]+ calculated 1020.8. 
6A-Azido-6A-deoxy-β-CD (2b) 
Compound 2b was prepared according to the a previously published procedure19, with 
some modifications of the purification process, which was adapted from the 
literature155. 1H NMR and MS spectra are in accordance with this literature.156 
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1H NMR (400 MHz, D2O): δ (ppm): 5.13–5.04 (m, 7H, 7 × H-1), 4.25-3.80 (m, 28H, 14 × H-6, 7 × H-
5, 7 × H-3), 3.74-3.44 (m, 14H, 7 × H-2, 7 × H-4). 
MS (ESI): found 1182.9. For [M + Na]+ calculated 1182.9 
2A-F,3A-F,6A-F-Octadeca-O-benzyl-α-CD (3)  
Compound 3 was prepared according to a previously published procedure.157 1H NMR and MS spectra 
are in accordance with the literature.39   
1H NMR (400 MHz, CDCl3): δ (ppm): 7.25-7.09 (m, 90H, Harom), 5.20-5.15 (m, 
6H, CH2Ph), 5.10-5.06 (m, 6H, 6 × H-1), 4.88-4.84 (m, 6H, CH2Ph), 4.51-4.36 
(m, 18H, CH2Ph), 4.34-4.28 (m, 6H, CH2Ph), 4.16-4.09 (m, 6H, H-4), 4.06-4.96 
(m, 12H, 6 × H-6, 6 × H-3), 3.92-3.86 (m, 6H, 6 × H-5), 3.50-3.42 (m, 12H, 6 × 
H-2, 6 × H-6).  
MS (MALDI-TOF): found 2618.2. For [M + Na]+ calculated 2618.1. 
2A-F,3A-F,6B-C,6E-F-Hexadeca-O-benzyl-α-CD (4) 
Compound 4 was prepared according to a previously published procedure38, 
which was subsequently modified.54 1H NMR and MS spectra are in accordance 
with these references.39   
1H NMR (400 MHz, CDCl3): δ (ppm): 7.31-7.11 (m, 80H, Harom), 5.73-5.70 (m, 
2H, 2 × H-1), 5.47-5.40 (m, 2H, 1 × CH2Ph), 5.20-5.14 (m, 2H, 1 × CH2Ph), 
4.92-3.53 (m, 64H, 4 × H-1, 2 × H-2, 6 × H-3, 6 × H-4, 6 × H-5, 12 × H-6, 14 × CH2Ph), 3.45 – 3.37 
(m, 4H, 4 × H-2), 3.25 (br s, 2H, 2 × OH-6). 
MS (MALDI-TOF): found 2437.1. For [M + Na]+ calculated 2437.8. 
2A-F,3A-F,6B-C,6E-F-Hexadeca-O-benzyl-6A,D-dibromo-6A,D-dideoxy-α-CD (5) 
Compound 5 was prepared according to a previously published procedure.23 1H NMR and MS spectra 
are in accordance with this literature.    
1H NMR (400 MHz, CDCl3): δ (ppm): 7.31-7.11 (m, 80H, Harom), 5.25-3.35 (m, 
74H, 6 × H-1, 6 × H-2, 6 × H-3, 6 × H-4, 6 × H-5, 12 × H-6, 16 × CH2Ph). 
MS (MALDI-TOF): found 2536.6. For [M + H]+ calculated 2536.9.  
6A,D-Dibromo-6A,D-dideoxy-α-CD (6) 
Compound 6 was prepared according to a previously published procedure.23 1H 
NMR and MS spectra are in accordance with this literature.   
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1H NMR (400 MHz, DMSO-d6): δ (ppm): 5.72-5.38 (m, 12H, 6 × OH-2, 6 × OH-3), 4.89-4.79 (m, 
6H, 6 × H-1), 4.61-4.54 (m, 4H, 4 × OH-6), 4.02-3.25 (m, 36H, 6 × H-2, 6 × H-3, 6 × H-4, 6 × H-5, 12 
× H-6). 
MS (ESI): found 1121.1, For [M + Na]+ calculated 1121.6. 
6A,D-Diazido-6A,D-dideoxy-α-CD (7d) 
Compound 7d was prepared according to a previously published procedure.158 
1H NMR and MS spectra are in accordance with the literature.48   
1H NMR (400 MHz, D2O): δ (ppm): 5.07-4.98 (m, 6H, 6 × H-1), 4.02-3.82 (m, 
24H, 6 × H-3, 6 × H-5, 12 × H-6), 3.71-3.57 (m, 12H, 6 × H-2, 6 × H-4).  
MS (ESI): found 1045.3. For [M + Na]+ calculated 1045.3. 
2A-F,3A-F,6B-F-Heptadeca-O-benzyl-α-CD (8) 
Compound 8 was prepared as a byproduct of the preparation of compound 9 
according to the original procedure.38 1H NMR and MS spectra are in 
accordance with the literature.43   
1H NMR (400 MHz, CDCl3): δ (ppm): 7.29-7.11 (m, 85H, Harom), 5.73-5.70 
(m, 2H, 2 × H-1), 5.47-5.40 (m, 2H, 1 × CH2Ph), 5.20-5.14 (m, 2H, 1 × 
CH2Ph), 4.92-3.53 (m, 64H, 4 × H-1, 2 × H-2, 6 × H-3, 6 × H-4, 6 × H-5, 12 × H-6, 15 × CH2Ph), 
3.45-3.36 (m, 4H, 4 × H-2), 2.50 (br s, 1H, 1 × OH-6). 
MS (MALDI-TOF): found 2526.5. For [M + Na]+ calculated 2526.1. 
6A-O-Methanesulfonyl-2A-F,3A-F,6B-F-Heptadeca-O-benzyl-α-CD (9) 
Compound 9 was prepared according to a previously published procedure.159 1H 
NMR and MS spectra are in accordance with this literature.  
1H NMR (400 MHz, CDCl3): δ (ppm): 7.29-7.13 (m, 85H, Harom), 5.31-4.83 (m, 
12H, 6 × H-1, 3 × CH2Ph), 4.63-3.40 (m, 64H, 14 × CH2Ph, 6 × H-2, 6 × H-3, 6 × 
H-4, 6 × H-5, 12 × H-6), 2.61 (s, 3H, SO2CH3). 
MS (MALDI-TOF): found 2604.3. For [M + Na]+ calculated 2604.1. 
6A-Azido-6A-deoxy-2A-F,3A-F,6B-F-Heptadeca-O-benzyl-α-CD (10) 
Compound 10 was prepared according to a previously published procedure.159 1H 
NMR and MS spectra are in accordance with this literature.  
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1H NMR (400 MHz, CDCl3): δ (ppm): 7.31-7.07 (m, 85H, Harom), 5.24-4.77 (m, 12H, 6 × H-1, 3 × 
CH2Ph), 4.59-3.36 (m, 64H, 14 × CH2Ph, 6 × H-2, 6 × H-3, 6 × H-4, 6 × H-5, 12 × H-6). 
MS (MALDI-TOF): found 2527.6. For [M + H]+ calculated 2528.1.  
6A-Azido-6A-deoxy-2A-F,3A-F,6B-F-Heptadeca-O-methyl-α-CD (21)  
Compound 21 was prepared according a previously published procedure.131 1H 
NMR and MS spectra are in accordance with this literature.   
1H NMR (400 MHz, CDCl3): δ (ppm): 5.01-4.95 (m, 6H, 6 × H-1), 3.77-3.36 (m, 
81H, 6 × H-3, 6 × H-4, 6 × H-5, 12 × H-6, 17 × OCH3), 3.22-3.15 (m, 6H, 6 × H-
2). 
MS (ESI): found 1259.1. For [M + Na]+ calculated 1259.3. 
6A-Azido-6A-deoxy-2A-G,3A-G,6B-G-Heptadeca-O-methyl-β-CD (22)  
Compound 22 was prepared according to a previously published procedure.155 1H 
NMR and MS spectra are in accordance with this literature.   
1H NMR (400 MHz, CDCl3): δ (ppm): 5.14-5.05 (m, 7H, 7 × H-1), 4.00– 3.40 
(m, 95H, 7 × H-3, 7 × H-4, 7 × H-5, 14 × H-6, 20 × OCH3), 3.19-3.10 (m, 7H, 7 
× H-2).  
MS (ESI): found 1463.2. For [M + Na]+ calculated 1463.5. 
6.4.  Synthesis of starting materials – Cinchona alkaloid derivatives 
(8S, 9S)-9-Amino-9-deoxy-epi-cinchonidine (17a) 
Compound 17a was prepared from (8S,9R)-cinchonidine via mesyl127 and 
azido160 functional groups. 1H NMR and MS spectra correspond with this 
literature.126  
1H NMR (400 MHz, CDCl3): δ (ppm): 8.89 (d, J = 4.4 Hz, 1H, H-2´), 8.35 (br 
s, 1H, H-5´), 8.14 (dd, J = 8.3 Hz, J = 1.2 Hz, 1H, H-8´), 7.70-7.65 (m, 1H, H-
6´), 7.58-7.55 (m, 1H, H-7´), 7.53 (d, J = 4.4 Hz, 1H, H-3´), 5.78-5.75 (m, 1H, H-10), 5.02-4.94 (m, 
2H, H-11), 4.70 (d, J = 9.6 Hz, 1H, H-9), 3.29-3.14 (m, 2H, H-2, H-6), 3.11-3.02 (m, 1H, H-8), 2.84-
2.73 (m, 2H, H-2, H-6), 2.28 (br s, 3H, H-3, NH2), 1.60-1.50 (m, 3H, H-4, H-5), 1.44-1.37 (m, 2H, H-
7), 0.75-0.72 (m, 1H, H-7). 
MS (ESI): found 294.1. For [M + H]+ calculated 294.2 
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(8R,9R)-9-Amino-9-deoxy-epi-quinidine (17b)  
Compound 17b was prepared from (8R,9S)-quinidine in a sequence via 
mesyl127 and azido128 functional groups. 1H NMR and MS spectra correspond 
with the literature.161  
 1H NMR (400 MHz, CDCl3): δ (ppm): 8.74 (d, J = 4.4. Hz, 1H, H-2´), 8.03 (d, 
J = 9.2 Hz, 1H, H-5´), 7.65 (br s, 1H, H-5´), 7.46 (d, J = 4.4 Hz, 1H, H-3´), 
7.38-7.35 (m, 1H, H-7´), 5.80-5.76 (m, 1H, H-10), 5.03-4.95 (m, 2H, H-11), 
4.60 (d, J = 9.9 Hz, 1H, H-9), 3.95 (s, 3H, CH3), 3.31-3.16 (m, 2H, H-2, H-6), 3.12-3.04 (m, 1H, H-8), 
2.84-2.74 (m, 2H, H-2, H-6), 2.27 (br s, 1H, H-3), 2.18 (br s, 2H, NH2), 1.63-1.52 (m, 3H, H-4, H-5), 
1.46-1.38 (m, 1H, H-7), 0.75-0.72 (m, 1H, H-7).  
MS (ESI): found 324.2. For [M + H]+ calculated 324.4. 
(8R, 9S)-9-O-Propargyl-cinchonine (18a) 
Compound 18a was prepared according to a previously published procedure.162 
1H NMR and MS spectra are in accordance with this literature.   
1H NMR (400 MHz, CDCl3): δ (ppm): 8.91 (d, 1H, J = 4.3 Hz), 8.18-8.14 (m, 
2H) 7.73-7.65 (m, 1H), 7.59-7.64 (m, 1H), 7.48 (d, 1H, J = 4.3 Hz), 6.10-6.02 
(m, 1H), 5.14 (d, 1H, J = 11.1 Hz), 5.01 (d, 1H, J = 3.7 Hz), 4.25 (d, 1H, J = 
2.4 Hz), 4.21 (d, 1H, J = 2.4 Hz), 3.95 (d, 1H, J = 1.8 Hz), 3.92 (d, 1H, J = 8.0 
Hz), 3.11-3.06 (m, 1H), 2.72-2.97 (m, 3H), 2.46 (t, 1H, J = 2.3 Hz), 2.28 (q, 1H, J = 8.0 Hz), 2.11-2.02 
(m, 2H), 1.52-1.40 (m, 2H), 1.24-1.21 (m, 1H).  
MS (ESI): found 333.1. For [M + H]+ calculated 333.2. 
(8S, 9R)-9-O-Propargyl-cinchonidine (18b) 
Compound 18b was prepared according to a previously published procedure.162,163 1H NMR and MS 
spectra are in accordance with this literature.   
1H NMR (400 MHz, CDCl3): δ (ppm): 8.89 (d, J = 4.5Hz, 1H), 8.20 – 8.10 (m, 
2H), 7.78-7.65 (m, 1H), 7.62-7.53 (m, 1H), 7.46 (d, J = 4.5 Hz, 1H), 5.76-5.62 
(m, 1H), 5.01-4.86 (m, 2H), 4.22 (dd, J = 15.8 Hz, J = 2.5Hz, 1H), 3.90 (dd, J = 
15.8Hz, J = 2.5Hz, 1H), 3.17-3.04 (m, 2H), 2.69-2.54 (m, 2H), 2.44 (t, J = 
2.5Hz, 1H), 2.28-2.18 (m, 1H), 1.88-1.45 (m, 6H). 
MS (ESI): found 333.1. For [M + H]+ calculated 333.2. 
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(8S, 9R)-9-O-Propargyl-quinine (18c) 
Compound 18c was prepared according to a previously published procedure.164  1H NMR and MS 
spectra are in accordance with this literature.   
1H NMR (400 MHz, CDCl3): δ (ppm): 8.77 (d, J = 4.5 Hz, 1H), 8.03 (d, J = 9.8 
Hz, 1H), 7.33-7.45 (m, 3H), 6.02-6.17 (m, 1H), 5.36 (d, J = 4.0 Hz, 1H), 5.05- 
5.16 (m, 2H), 4.24 (dd, J = 16.0, J = 2.3 Hz, 1H), 3.93 (s, 3H), 3.95-3.87 (m, 
1H), 3.21-3.35 (m, 1H), 3.16-3.04 (m, 1H), 2.97-2.70 (m, 3H), 2.46 (t, J = 2.4 
Hz, 1H), 2.34-2.18 (m, 1H), 2.00 – 1.20 (m, 5H). 
MS (ESI): found 263.2. For [M + H]+ calculated 263.4. 
(8R, 9S)-9-O-Propargyl-quinidine (18d) 
Compound 18d was prepared according to a previously published procedure.164 
1H NMR and MS spectra are in accordance with this literature.   
1H NMR (400 MHz, CDCl3): δ (ppm): 8.77 (d, J = 4.5 Hz, 1H), 8.03 (d, J = 9.8 
Hz, 1H), 7.33-7.45 (m, 3H), 6.02-6.17 (m, 1H), 5.36 (d, J = 4.0 Hz, 1H), 5.05-
5.16 (m, 2H), 4.24 (dd, J = 16.0, J = 2.3 Hz, 1H), 3.93 (s, 3H), 3.95-3.87 (m, 1H), 3.21 – 3.35 (m, 1H), 
3.16-3.04 (m, 1H), 2.97-2.70 (m, 3H), 2.46 (t, J = 2.4 Hz, 1H), 2.34-2.18 (m, 1H), 2.00-1.20 (m, 5H).  
MS (ESI): found 263.2. For [M + H]+ calculated 263.4. 
6.5.  Synthesis of new CD derivatives 
6A,6B-Diazido-6A,6B-dideoxy-α-CD (7b) via 6A, 6B-capped-α-CD (12) 
6A,6B-Capped α-CD (2) was prepared according by combining procedures first 
described for α-CD32 and β-CD28. Dried α-CD (1, 5 g, 5.1 mmol) was dissolved 
in freshly distilled pyridine (115 mL). m-Benzene-1,3-disulfonyl chloride (1.41 
g, 5.1 mmol) was dissolved in freshly distilled pyridine (40 mL), and the 
resulting pale, yellow solution was added dropwise to the α-CD solution under 
vigorous stirring at 8 °C within 1 hour. The mixture was stirred at 25 °C for another 4 hours. The 
white precipitate (part of unreacted α-CD), observed after fishing of stirring, was filtered off, and the 
mother liquid was evaporated under reduced pressure at 30 °C. The remaining gel-like, pale yellow 
residue was subsequently poured into 200 mL of MeOH resulting in the formation of a white 
precipitate. The solid was recovered by filtration, washed with MeOH (3 × 50 mL) and dried.  
This solid (0.87 g), containing unreacted α-CD (~90% based on TLC, RF = 0.35, eluent: 
1,4-dioxane/conc.aq.NH3 10/7) and 6A,6B-capped α-CD (7b, ~10% based on TLC, RF = 0.5, eluent: 
1,4-dioxane/conc.aq.NH3 10/7), was dissolved in DMF (20 mL). Then, sodium azide (0.14 g, 2.2 
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mmol) was added to the mixture, which was subsequently heated to 80 °C for 5 hours. DMF was 
removed under reduced pressure at 60 °C; the yellowish residue was poured into acetone (200 mL) 
under vigorous stirring. The white precipitate was recovered by filtration, washed with acetone (3 x 50 
mL) and dried to constant weight (0.84 g). Direct-phase TLC (1,4-dioxane/conc.aq.NH3 10/7) and 
reversed-phase HPLC (ACN/H2O gradient elution) analysis revealed that the precipitate contained 
unreacted α-CD (RF = 0.35), monoazido-α-CD (2a, RF = 0.5) and diazido-α-CD (7a, RF = 0.65). The 
diazido-α-CD fraction was isolated by direct column chromatography. The precipitate was dissolved 
in ACN/water/conc.aq.NH3 10/7/1 (8.7 mL) and injected into the chromatographic column (44 g). The 
mobile phase was ACN/water/conc.aq.NH3 10/5/1. After the chromatographic separation, the 6A,6B-
diazido-α-CD (7b, 0.09 g, 2% yield) was obtained as a white solid. 6A-Azido-α-CD (2a) was also 
obtained as a white solid (0.19 g, 4% yield) as the second eluted compound. 
6A,6X-Diazido-6A,6X-dideoxy-α-CD (7) via 6A,6X-capped-α-CD (13)  
6A,6X-Capped α-CD (13) was prepared 
by modifying a procedure previously 
described for β-CD29. Dried α-CD (5 g, 
5.1 mmol) was dissolved in freshly 
distilled pyridine (77 mL). The mixture 
was heated up to 50 °C and biphenyl-4,4´-disulfonyl chloride (1.4 g, 3.8 mmol) was added during one 
hour in four portions, every 15 minutes. The resulting yellow solution was stirred at 50 °C for another 
1.5 h and then evaporated under reduced pressure at 25 °C. The remaining gel-like, pale yellow 
residue was subsequently poured into MeOH (200 mL) resulting in the formation of a white 
precipitate. The solid was recovered by filtration, washed with methanol (3 × 50 mL) and dried.  
This white solid (3.27 g), containing unreacted α-CD (~85% based on TLC, RF = 0.35, eluent: 
1,4-dioxane/conc.aq.NH3 10/7) and 6A,6X-capped α-CD (13, ~15% based on TLC, RF = 0.55, eluent: 
1,4-dioxane/conc.aq.NH3 10/7), was dissolved in DMF (30 mL). Sodium azide (0.34 g, 5.2 mmol) was 
added, and the reaction mixture was heated to 80 °C for 5 h. Unreacted NaN3 was filtered off, and the 
reaction mixture was concentrated under reduced pressure at 50 °C; the yellowish residue was poured 
into acetone (220 mL) under vigorous stirring. The white precipitate was recovered by filtration, 
washed with acetone (3 × 50 mL) and dried to constant weight (2.45 g) in a vacuum drying box in the 
presence of P2O5 and KOH. Direct-phase TLC (1,4-dioxane/conc.aq.NH3 10/7) and reversed-phase 
HPLC (ACN/H2O gradient elution) analysis revealed that the precipitate contained unreacted α-CD 
(RF = 0.35), monoazido-α-CD (7, RF = 0.5) and diazido-α-CD (7, RF = 0.65). The diazido-α-CD 
fraction was isolated by direct column chromatography. The precipitate was dissolved in 
ACN/water/conc.aq.NH3 10/7/1 (24 mL) and injected into the chromatographic column (134 g). The 
mobile phase was ACN/water/conc.aq.NH3 10/5/1. After the chromatographic separation, the 
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6A,6X-diazido-α-CD (7, 0.25 g, 5% yield) was obtained as a white solid material. 6A-Azido-α-CD (2a) 
was also obtained as a white solid (0.34 g, 7% yield) as the second eluted compound.  
6A,6X-Diazido-6A,6X-dideoxy-α-CD (7) via 6A,6X-dibromo-α-CD (14)  
6A,6X-Brominated α-CD (14) was 
prepared following a modified procedure 
previously described for 6A,6X,6Y-
tribromo-α-CD.165 Triphenylphosphine 
(36.4 g, 138 mmol) was dissolved in 125 mL of freshly distilled DMF under Ar atmosphere. The 
solution was cooled down to 8 °C, and NBS was slowly added to the solution which became dark 
violet. Dried α-CD (1, 25 g, 25.7 mmol) was dissolved in 100 mL of DMF and added to the dark violet 
reaction mixture in one portion for 20 minutes. The mixture was heated up to 50 °C, and the 
conversion to dibromo-α-CD was monitored by direct phase TLC (1,4-dioxane/conc.aq.NH3/ 
1-propanol 10/7/3). After 7.5 h the reaction was stopped by adding 100 mL of MeOH. After 10 
minutes of vigorous stirring, the red-violet reaction mixture was cooled down and poured into 1.3 L of 
MeOH (pH = 3). The addition of a sodium methoxide solution (100 mL) resulted in slow precipitation 
(pH = 12). The yellowish precipitate was recovered by filtration, washed with MeOH (3 × 300 mL) 
and dried.  
The white solid (15.27 g), containing unreacted α-CD (~35% based on TLC, RF = 0.15, eluent: 1,4-
dioxane/conc.aq.NH3/1-propanol 10/7/3), monobromo α-CD (~35 % based on TLC, RF = 0.25, eluent: 
1,4-dioxane/conc.aq.NH3/1-propanol 10/7/3), dibromo-α-CD (14, ~20% based on TLC, RF = 0.35, 
eluent: 1,4-dioxane/conc.aq.NH3/1-propanol 10/7/3) and oversubstituted products (less than 10% 
based on TLC, RF = 0.5, eluent: 1,4-dioxane/conc.aq.NH3/1-propanol 10/7/3)  was dissolved in DMF 
(300 mL), sodium azide (2.72 g, 42.0 mmol) was added, and the mixture was heated to 80 °C for 5 h. 
DMF was removed under reduced pressure at 60 °C; the yellowish residue was poured into acetone 
(1.3 L) under vigorous stirring. The white precipitate was recovered by filtration, washed with acetone 
(3 × 100 mL) and dried to constant weight (17.9 g). Direct-phase TLC (eluent: 1,4-
dioxane/conc.aq.NH3/1-propanol 10/7/3) and reversed-phase HPLC (ACN/H2O gradient elution) 
analysis revealed that the precipitate contained unreacted α-CD (RF = 0.15), monoazido-α-CD (7, RF = 
0.35) and diazido-α-CD (7, RF = 0.45). The diazido-α-CD fraction was isolated by direct column 
chromatography. The one-third of precipitate was dissolved in ACN/water/conc.aq.NH3 10/7/1 (40 
mL) and injected to the chromatographic column (310 g). After chromatographic separation of all 
three parts of crude mixture using mobile phase ACN/water/conc.aq.NH3 10/5/1, the 6A,6X-diazido-α-
CD (7, 1.26 g, 5% yield) was obtained as a white solid material. 6A-Azido-α-CD (2a) was also 
obtained as a white solid (3.69 g, 15% yield) as the second eluted compound. 
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6A,6X-Diazido-6A,6X-dideoxy-α-CD (7) via 6A,6X-O-ditosyl-α-CD (15)  
6A,6X-Ditosyl-α-CD (15) was prepared 
according a modified procedure previously 
published for monotosyl-α-CD.19 Dried α-
CD (1, 5 g, 5 mmol) was dissolved in 
freshly distilled pyridine (150 mL), cooled down to 0 °C, and p-toluenesulfonyl chloride (3.49 g, 18 
mmol) was added gradually spoon by spoon. After adding of p-toluenesulfonyl chloride, the reaction 
mixture was stirred at room temperature for 6 h, and then pyridine was evaporated under reduced 
pressure at 30 °C. After solvent evaporation, the remaining gel-like, light yellow residue was then 
dissolved in MeOH (30 mL) and subsequently poured into acetone (350 mL), resulting in the 
immediate formation of a white precipitate. The solid was recovered by filtration, washed with acetone 
(3 × 50 mL) and dried.  
The white material (6.3 g), containing unreacted  α-CD (~35% based on TLC, RF = 0.15, eluent: 1,4-
dioxane/conc.aq.NH3/1-propanol 10/7/3), 6A-tosyl-α-CD (~30% based on TLC, RF = 0.3, eluent: 1,4-
dioxane/conc.aq.NH3/1-propanol 10/7/3), 6A,6X-ditosyl-α-CD (15, ~30% based on TLC, RF = 0.45, 
eluent: 1,4-dioxane/conc.aq.NH3/1-propanol 10/7/3) and the overtosylated 6A,6X,6Y-tritosyl-α-CD 
(~20% based on TLC, RF = 0.55, eluent: 1,4-dioxane/conc.aq.NH3/1-propanol 10/7/3) was dissolved in 
DMF (120 mL), sodium azide (0.76 g, 17 mmol) was added and the reaction mixture was heated to 
80 °C for 5 hours. DMF was removed under reduced pressure at 60 °C; the yellowish residue was 
poured into acetone (300 mL) under vigorous stirring. The white precipitate was recovered by 
filtration, washed with acetone (3 × 50 mL) and dried to constant weight (5.74 g). Direct-phase TLC 
(1,4-dioxane/conc.aq.NH3/1-propanol 10/7/3) and reversed-phase HPLC (ACN/H2O gradient elution) 
analysis revealed that the precipitate contained unreacted α-CD (RF = 0.15), monoazido-α-CD (2a, RF 
= 0.35) and diazido-α-CD (7, RF = 0.45) and triazido-α-CD (RF = 0.5). The diazido-α-CD fraction was 
isolated by direct column chromatography (394 g). The precipitate was dissolved in 
ACN/water/conc.aq.NH3 10/7/1 (50 mL) and injected to the chromatographic column. After 
chromatographic separation in the mobile phase ACN/water/conc.aq.NH3 10/5/1, the 6A,6X-diazido-α-
CD (7, 0.69 g, 16% yield) was obtained as a white solid material. 6A-Azido-α-CD (2a) was also 
obtained as a white solid (7, 0.46 g, 11% yield) as the second eluted compound. 
6A,6X-Diazido-6A,6X-dideoxy-α-CD (7) via 6A-azido-6X-O-mesitylenesulfonyl-
α-CD (16)  
6A-Azido-6X-mesitylenesulfonyl-α-CD (16, 0.3 g, 0.2 mmol) was dissolved in freshly distilled DMF (5 
mL), sodium azide (0.044 g, 1.9 mmol) was added, and the reaction mixture was heated to 80 °C for 5 
h. DMF was removed under reduced pressure at 60 °C; the yellowish residue was poured into acetone 
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(300 mL) under vigorous stirring. The 
white precipitate was recovered by 
filtration, washed with acetone (3 x 50 
mL) and dried to constant weight (0.2 
g). Direct-phase TLC (eluent: 1,4-dioxane/conc.aq.NH3/1-propanol 10/7/3) and reversed-phase HPLC 
(ACN/H2O gradient elution) analysis revealed that the precipitate contained 6A-azido-α-CD (2a, ~60% 
based on TLC, RF = 0.35) and 6A,6X-diazido-α-CD (7, ~35% based on TLC, RF = 0.45) and more 
substituted 6A,6X,6Y-triazido-α-CD (~5% based on TLC, RF = 0.5). The 6A,6X-diazido-α-CD fraction 
was not isolated by direct column chromatography but instead used directly as a mixture of the starting 
material, diazido-α-CD and triazido-α-CD in HPLC separations. 
1H NMR, 13C NMR spectra for diazido-α-CDs (7) were measured (i) as a mixture of three 
regioisomers (ii) as a single AD isomer and are in accordance with literature.48 
1H NMR (600 MHz, D2O): δ (ppm): 5.07 (m, H-1, 6H), 4.02 –3.82 (m, 24H, H-3, H-5, H-6), 3.71 –
3.57 (m, 12H, H-2, H-4).  
13C NMR (150 MHz, D2O): δ (ppm): 103.99, 103.81, 84.73, 83.90, 75.87, 75.65, 74.71, 74.51, 74.17, 
74.10, 73.29, 63.00, 53.80.  
HRMS data are identical for all homobifunctionalized 6A,6X-diazido-α-CDs (7).  
HRMS: [M + Na]+ found 1045.3094. For C36H58N6O28 [M + Na]+ calculated 1045.3191. 
IR (KBr) ν = 3354, 3321, 2104, 1416, 1332, 1293, 1655, 1207, 1033 cm-1. 
(i) [α]D25 = + 90.3⁰ (c = 0.30, H2O)  (ii) [α]D25 = + 133.3⁰ (c = 0.31, H2O) 
6A-Azido-6A-deoxy-6X-O-mesitylenesulfonyl-α-CD (16)  
Dried 6A-azido-α-CD (7, 1.23 g, 1.2 mmol) was dissolved in pyridine (12 mL) and cool down to 0 °C. 
2-Mesitylenesulfonyl chloride (0.52 g, 2.4 mmol) was gradually added spoon by spoon. The reaction 
mixture was stirred at room temperature for 2 hours; the yellowish residue was poured into acetone 
(300 mL) under vigorous stirring. The white precipitate was recovered by filtration, washed with 
acetone (3 x 50 mL) and dried to constant weight (1.60 g). Direct-phase TLC (eluent: 1,4-
dioxane/conc.aq.NH3/1-propanol 10/7/3) and reversed-phase HPLC (H2O/ACN gradient elution) 
analysis revealed that the precipitate contained unreacted 6A-azido-α-CD (2a, ~60% based on TLC, RF 
= 0.35, eluent: 1,4-dioxane/conc.aq.NH3/1-propanol 10/7/3), 6A-azido-6X-mesitylenesulfonyl-α-CD 
(16, ~35% based on TLC, RF = 0.5, eluent: 1,4-dioxane/conc.aq.NH3/1-propanol 10/7/3) and 6A-azido-
6X,6Y-dimesitylenesulfonyl-α-CD (~5% based on TLC, RF = 0.6, eluent: 1,4-
dioxane/conc.aq.NH3/1-propanol 10/7/3). The 6A-azido-6X-mesitylenesulfonyl-α-CD fraction was 
isolated by reversed-phased column chromatography (H2O/ACN gradient elution). The first eluted 
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(95:5), starting material, 6A-azido-α-CD (520 mg) was recovered. Then, 6A-azido-
6X-mesitylenesulfonyl-α-CD was eluted (70:30): AD regioisomer in 10.0 min, AC regioisomer 
(mixture of AC/CA pseudoenantiomers) in 13.5 min and AB regioisomer (mixture of AB/BA 
pseudoenantiomers) in 19.5 min. The isolated yield of regioisomers was 26.4 mg (3%) for AD (16d), 
37.5 mg (4%) for AC (16c) and 38.2 mg (4%) for AB (16b), obtained from 960 mg precipitate of 
reaction mixture.  
6A-Azido-6A-deoxy-6D-O-mesitylenesulfonyl-α-CD (16d) 
Compound 16d was prepared according to above described procedure.  
From the mixture of 6A-azido-6X-mesitylenesulfonyl-α-CD, 26 mg of 
product was obtained in the form of a white solid (3% yield calculated from 
the starting 6A-azido-α-CD).   
1H NMR (600 MHz, D2O): δ (ppm): 7.19 (2H, s, C-2´), 5.24 (1H, m, H-1-I), 
5.08 (4H, m, H-1), 4.95 (1H, m, H-1-IV), 4.39 (2H, s, H-6-IV), 4.04 (1H, m, H-5-IV), 3.95-3.41 (34H, 
m, H-5, H-6, H-3, H-4, H-2), 2.60 (6H, s, CH3-6´), 2.34 (3H, s, CH3-5´).  
13C NMR (150 MHz, D2O): δ (ppm): 144.74 (C-1´), 140.07 (2 × C-3´), 131.67 (2 × C-2´), 128.73 (C-
4´), 101.51 (5 × C-1), 99.36 (1× C-1-I), 81.11 (6 × C-4), 73.14 (6 × C-3), 72.10 (4 × C-5, 5 × C-2), 
70.50 (1 × C-2I), 69.97 (1 × C-5IV), 68.82 (1 × C-6IV), 60.18 (4 × C-6), 58.37 (1 × C-5-I), 51.36 (1 × 
C-6-I), 21.93 (2 × CH3-6´), 20.32 (CH3-5´).  
HRMS: [M+Na]+, found: 1202.3444. For C45H69N3O31S [M+Na]+ calculated 1202.3528.  
IR (KBr) ν = 3294, 2929, 2101, 1461, 1347, 1287, 1156, 1018 cm-1.  
[α]D25 = + 124.6 ⁰ (c = 0.25, DMSO). 
6A-Azido-6A-deoxy-6C-O-mesitylenesulfonyl-α-CD (16c)  
Compound 16c was prepared according to above described procedure.  From 
the mixture of 6A-azido-6X-mesitylenesulfonyl-α-CD, 38 mg of product the 
(mixture of AC/CA pseudoenantiomers) was obtained in the form of a white 
solid (4% yield calculated from the starting 6A-azido-α-CD).   
1H NMR (600 MHz, D2O): δ (ppm): 7.19 (2H, s, C-2´), 5.08 (4H, m, H-1), 
4.98 (1H, m, H-1I), 4.95 (1H, m, H-1III), 4.40 (2H, m, H-6III), 4.03-3.72 (20H, m, H-2, H-5, H-6, H-3), 
3.73-3.44 (14H, m, H-6I, H-4), 2.59 (6H, s, CH3-6´), 2.30 (3H, s, CH3-5´).  
13C NMR (150 MHz, D2O): δ (ppm): 144.74 (C-1´), 140.07 (2 × C-3´), 131.67 (2 × C-2´), 128.73 (C-
4´), 101.51 (5 × C-1), 100.08 (1 × C-1I), 81.59 (6 × C-4), 73.34 (6 × C-3), 71.90 (4 × C-5, 5 × C-2), 
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70.83 (1 × C-2I), 69.59 (1 × C-5III), 68.60 (1 × C-6III), 60.23 (4 × C-6), 51.33 (1 × C-6I), 21.93 (2 × 
CH3-6´), 20.32 (CH3-5´).  
HRMS: [M + Na]+ found: 1202.3435. For C45H69N3O31S [M + Na]+ calculated 1202.3528.  
IR (KBr) ν = 3294, 2929, 2101, 1721, 1335, 1237, 1153, 1078 cm-1.  
[α]D25 = + 107.9⁰ (c = 0.26, DMSO). 
6A-Azido-6A-deoxy-6B-O-mesitylenesulfonyl-α-CD (16b) 
Compound 16b was prepared according to above described procedure.  From 
the mixture of 6A-azido-6X-mesitylenesulfonyl-α-CD, 38 mg of product (the 
mixture of AB/BA pseudoenantiomers) was obtained in the form of a white 
solid (4% yield calculated from the starting 6A-azido-α-CD).   
1H NMR (600 MHz, D2O): δ (ppm): 7.19 (2H, s, H-2´), 5.07 (4H, m, H-1), 4.98 
(1H, m, H-1I), 4.95 (1H, s, H-1II), 4.40 (2H, m, H-6II), 4.03-3.72 (20H, m, H-2, H-5, H-6, H-3), 3.66-
3.45 (14H, m, H-6I, H-4), 2.60-2.59 (6H, s, CH3-6´), 2.34 (3H, s, CH3-5´).  
13C NMR (150 MHz, D2O): δ (ppm): 144.74 (C-1´), 140.07 (2 × C-3´), 131.67 (2 × C-2´), 128.73 (C-
4´) 101.51 (6 × C-1), 81.05 (6 × C-4), 73.14 (6 × C-3), 72.10 (4 × C-2, 5 × C-2), 70.65 (1 × C-2I), 
68.60 (1 × C-5II), 60.18 (4 × C-6), 51.10 (1 × C-6I), 21.95-21.89 (2 × CH3-6´), 20.32 (CH3-5´).  
HRMS: [M + Na]+, found: 1202.3432. For C45H69N3O31S [M + Na]+ calculated 1202.3528.  
IR (KBr) ν = 3294, 2929, 2104, 1419, 1350, 1242, 1150, 1030 cm-1.  
[α]D25 = + 95.0⁰ (c = 0.25, DMSO). 
  
100 
 
General procedure for the preparation of monosubstituted non-methylated 
Cinchona-CD derivatives (GP1) 
For α-CD derivatives: The first starting material, 9-O-propargyl Cinchona alkaloids (18a‒18d, 
0.13 mmol) was dissolved in 0.5 mL of distilled THF (sonicated for 10 minutes under Ar atmosphere). 
Then, 6I-azido-6I-deoxy-α-CD19 (2a, 0.10 mmol) was dissolved in 0.4 mL of distilled H2O (sonicated 
for 10 minutes under Ar atmosphere) and added to the stirring solution of the Cinchona alkaloid. 
Lastly, copper iodide (0.02 mmol), suspended in H2O (0.1 mL), was added to the reaction mixture and 
stirred at 50 °C for 2-3 hours.  
For β-CD derivatives: The first starting material, 9-O-propargyl Cinchona alkaloid (18a‒18d, 
0.11 mmol) was dissolved in 0.5 mL of distilled DMF (sonicated for 10 minutes under Ar 
atmosphere). The second starting material, 6I-azido-6I-deoxy-β-CD19 (2b, 0.09 mmol), was dissolved 
in 0.5 mL of distilled DMF (sonicated for 10 minutes under Ar atmosphere) and added to the solution 
of the Cinchona alkaloid under stirring. Copper iodide (0.02 mmol), suspended in 0.1 mL of distilled 
DMF (sonicated for 10 minutes under Ar atmosphere), was added to the reaction mixture and stirred at 
60 °C for 2-3 hours. 
 Conversion into the product was monitored by TLC in eluent ACN/H2O/conc.aq.NH3 (10/5/1). 
After full conversion into the product, the reaction mixture was slowly added to acetone (75 mL) 
under stirring, resulting in a white-yellow precipitate. This solid was recovered by filtration, washed 
with acetone (3 × 20 mL) and dried to constant weight. Crude product was purified on column 
chromatography (50 g of silica gel) with mobile phase ACN/H2O/conc.aq.NH3 12/5/1. When full 
conversion into the product was not achieved, the CD starting material was regenerated (eluted as the 
second compound). A blue precipitate formed at the top of the column creates as copper cations 
interacted with ammonia. The purified product was dried at 50 °C under reduced pressure. 
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6I-Deoxy-6I-(4-(((S)-quinolin-4-yl(5-vinylquinuclidin-2-yl)methoxy) methyl)-
1H-1,2,3-triazol-1-yl)-α-CD (19a)  
Compound 19a was prepared according to the general procedure (GP1).  
From 6I-azido-6I-deoxy-α-CD 2a (164 mg, 0.16 mmol), 9-O-propargyl-
cinchonine 18a (71 mg, 0.2 mmol) and copper-iodide (6 mg, 0.03 mmol), 
168 mg of product was obtained in the form of a white-yellow solid (77% 
yield). TLC (ACN/H2O/conc.aq.NH3 10/5/1): RF = 0.45.  
1H NMR (600 MHz, DMSO-d6): δ (ppm): 8.96-8.94 (m, 1H, H-2´´), 8.39-
8.37 (m, 1H, H-8´´), 8.14-8.13 (s, 1H, H-14´), 8.10-8.08 (m, 1H, H-5´´), 
7.82-7.80 (m, 1H, H-6´´), 7.70-7.68 (m, 1H, H-7´´), 7.64-7.63 (m, 1H, H-
3´´), 5.89-5.87 (m, 1H, H-10´), 5.65-5.35 (m, 12H, OH-2, OH-3), 5.06-
5.04 (m, 1H, H-1I), 5.05-5.03 (m, 2H, H-11´), 4.86-4.72 (m, 5H, H-1), 4.84-4.83 (m, 2H, H-6I), 4.58-
4.50 (m, 5H, OH-6), 4.52-4.50 (m, 2H, H-12´), 4.02-4.00 (m, 1H, H-5I), 3.84-3.18 (m, 33H, H-2, H-3, 
H-4, H-5, H-6), 3.40-3.38 (m, 1H, H-8´), 3.14-3.12 (m, 2H, H-2´), 3.08-3.06 (m, 1H, H-6a´), 2.95-2.94 
(m, 1H, H-6b´), 2.48-2.45 (m, 1H, H-3´), 1.81-1.79 (m, 1H, H-4´), 1.65-1.63 (m, 2H, H-5´), 1.29-1.27 
(m, 2H, H-7´).  
 H-9´and C-9´signals are not seen. 
13C NMR (150 MHz, DMSO-d6): δ (ppm): 150.24 (C-2´´), 147.97 (C-10´´*), 143.71 (C-4´´*), 142.67 
(C-13´), 138.56 (C-10´), 129.81 (C-5´´), 129.34 (C-6´´), 126.98 (C-7´´), 126.14 (C-14´), 125.80 (C-
9´´), 123.75 (C-8´´), 119.07 (C-3´´), 115.79 (C-11´), 101.59 (6 × C-1), 82.42 (6 × C-4), 72.62 (5 × C-
5, 6 × C-3, 6 × C-2), 69.58 (C-5I), 61.93 (C-12´), 60.02 (5 × C-6), 59.36 (C-8´), 49.96 (C-6I), 48.62 
(C-6´), 47.48 (C-2´), 37.25 (C-3´), 26.98 (C-4´), 23.80 (C-7´), 23.57 (C-5´).  
Signals tagged with * can be mutually interchanged. 
HRMS (ESI): found 1330.5064. For C58H83N5O30 [M+H]+ calculated 1330.5196. 
IR (KBr) 3291, 3105, 2938, 1640, 1413, 1240, 1150, 1076, 1039 cm-1. 
[α]D25 = +61.7° (c = 0.30, DMSO). 
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6I-Deoxy-6I-(4-(((R)-quinolin-4-yl(5-vinylquinuclidin-2-yl)methoxy) 
methyl)-1H-1,2,3-triazol-1-yl)-α-CD (19b)  
Compound 19b was prepared according to the general procedure 
(GP1). From 6I-azido-6I-deoxy-α-CD 2a (100 mg, 0.10 mmol), 9-O-
propargyl-cinchonidine 18b (43 mg, 0.13 mmol) and copper-iodide (4 
mg, 0.02 mmol), 115 mg od product 19b was obtained in the form of a 
white-yellow solid (86% yield). TLC (ACN/H2O/conc.aq.NH3 10/5/1): 
RF = 0.45.   
1H NMR (600 MHz, DMSO-d6): δ (ppm): 8.96-8.94 (m, 1H, H-2´´), 
8.43-8.40 (m, 1H, H-8´´), 8.27-8.24 (s, 2H, H-14´), 8.12-8.09 (m, 1H, 
H-5´´), 7.85-7.81 (m, 1H, H-6´´), 7.73-7.69 (m, 1H, H-7´´), 7.69 -7.64 
(m, 1H, H-3´´), 5.80-5.76 (m, 1H, H-10´), 5.67-5.34 (m, 12H, OH-2, 
OH-3), 5.04-5.00 (m, 1H, H-11a´), 5.01-4.99 (m, 1H, H-1I), 4.95-4.93 
(m, 1H, H-1b´), 4.84-4.73 (m, 5H, H-1), 4.81-4.79 (m, 1H, H-6aI), 
4.61-4.59 (m, 1H, H-6bI), 4.58-4.50 (m, 5H, OH-6), 4.55-4.52 (m, 1H, 
H-12a´), 4.50-4.47 (m, 1H, H-12b´), 4.10-4.08 (m, 1H, H-5I), 3.88-3.16 (m, 33H, H-2, H-3, H-4, H-5, 
H-6), 3.59-3.56 (m, 2H, H-6´), 3.51-3.48 (m, 1H, H-8´), 3.32-3.29 (m, 1H, H-2a´), 2.92-2.89 (m, 1H, 
H-2b´), 2.51-2.49 (m, 1H, H-3´), 1.89-1.85 (m, 1H, H-4´), 1.27-1.23 (m, 2H, H-5´), 1.24-1.21 (m, 2H, 
H-7´).  
 H-9´and C-9´signals are not seen.  
13C NMR (150 MHz, DMSO-d6): δ (ppm): 150.19 (C-2´´), 147.99 (C-10´´*), 143.56 (C-4´´*), 142.85 
(C-13´), 139.69 (C-10´), 129.77 (C-5´´), 129.39 (C-6´´), 127.14 (C-7´´), 125.94 (C-14´), 125.75 (C-
9´´), 123.87 (C-8´´), 119.11 (C-3´´), 115.70 (C-11´), 101.30 (6  C-1), 82.57 (6  C-4), 72.35 (6  C-2, 
6  C-3, 5  C-5), 69.41 (C-5I), 62.03 (C-12´), 60.14 (5  C-6), 59.32 (C-8´), 53.92 (C-2´), 50.25 (C-
6I), 42.69 (C-6´), 37.45 (C-3´), 30.64 (C-7´), 26.62 (C-4´), 22.59 (C-5´).  
Signals tagged with * can be mutually interchanged. 
HRMS (ESI): found 1330.5151. For C58H83N5O30 [M+H]+ calculated 1330.5196.  
IR (KBr) 3288, 3166, 3105, 2926, 2361, 1156, 1120, 1075, 1036 cm-1. 
[α]D25 = +25.8° (c = 0.33, DMSO). 
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6I-Deoxy-6I-((4-(((S)-(6-methoxyquinolin-4-yl)(5-vinylquinuclidin-2-
yl)methoxy)methyl)-1H-1,2,3-triazol-1-yl)-α-CD (19c)  
Compound 19c was prepared according to the general procedure (GP1). 
From 6I-azido-6I-deoxy-α-CD 2a (316 mg, 0.3 mmol), 9-O-propargyl-
quinine 18c (149 mg, 0.4 mmol) and copper-iodide (12 mg, 0.06 mmol), 
306 mg of product 19c was obtained in the form of a white-yellow solid 
(72% yield). TLC (ACN/H2O/conc.aq.NH3 10/5/1): RF = 0.45.  
1H NMR (600 MHz, DMSO-d6): δ (ppm): 8.76-8.75 (m, 1H, H-2´´), 8.21 
(s, 1H, H-14´), 7.98-7.96 (m, 1H, H-8´´), 7.87-7.86 (m, 1H, H-3´´), 7.56-
7.55 (m, 1H, H-5´´), 7.44-7.42 (m, 1H, H-7´´), 5.82-5.76 (m, 1H, H-10´), 
5.65-5.36 (m, 12H, OH-2, OH-3), 5.01-4.99 (m, 1H, H-11a´), 4.94-4.92 
(m, 1H, H-11b´), 4.82-4.73 (m, 5H, H-1), 4.80-4.79 (m, 2H, H-6I), 4.58-
4.44 (m, 5H, OH-6), 4.52-4.50 (m, 1H, H-12a´), 4.47-4.45 (m, 1H, H-
12b´), 4.05-4.04 (m, 1H, H-5I), 3.95 (s, 3H, OCH3-6´´), 3.84-3.13 (m, 33H, 
H-2, H-3, H-4, H-5, H-6), 3.33-3.31 (m, 1H, 8´´), 3.24-3.22 (m, 1H, H-5I), 3.13-3.12 (m, 2H, H-2´), 
2.75-2.73 (m, 2H, H-6´), 2.38-2.36 (m, 1H, H-3´), 1.80-1.78 (m, 1H, H-4´), 1.69-1.65 (m, 1H, H-5a´), 
1.55-1.52 (m, 1H, H-5b´), 1.53-1.51 (m, 2H, H-7´). 
 H-9´and C-9´signals are not seen. 
13C NMR (152 MHz, DMSO-d6): δ (ppm): 157.41 (C-6´´), 147.50 (C-2´´), 147.20 (C-4´´*), 144.01 (C-
10´´*), 143.12 (C-13´), 140.79 (C-10´), 131.26 (C-8´´), 127.09 (C-9´´), 126.07 (C-14´), 121.53 (C-
7´´), 119.07 (C-3´´), 114.96 (C-11´), 102.33 (C-5´´), 101.90 (6 × C-1), 83.16 (C-4I), 82.66 (5 × C-4), 
72.22 (6 × C-2, 6 × C-3, 5 × C-5), 69.52 (C-5I), 61.93 (C-12´), 60.18 (5 × C-6), 59.38 (C-8´), 55.97 
(OCH3-6´´), 54.59 (C-2´), 50.12 (C-6I), 42.39 (C-6´), 38.18 (C-3´), 26.79 (C-4´), 25.74 (C-5´), 23.18 
(C-7´).  
Signals tagged with * can be mutually interchanged. 
HRMS (ESI): found 1360.5155. For C59H85N5O31 calculated [M+H]+ 1360.5301. 
IR (KBr) 3282, 2920, 1625, 1512, 1431, 1242, 1153, 1078, 1039 cm-1. 
[α]D25 = +57.4° (c = 0.31, DMSO). 
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6I-Deoxy-6I-((4-(((R)-(6-methoxyquinolin-4-yl)(5-vinylquinuclidin-2-
yl)methoxy)methyl)-1H-1,2,3-triazol-1-yl)-α-CD (19d)  
Compound 19d was prepared according to the general procedure (GP1). 
From 6I-azido-6I-deoxy-α-CD 2a (174 mg, 0.17 mmol), 9-O-propargyl-
quinidine 18d (82 mg, 0.23 mmol) and copper-iodide (6 mg, 0.03 mmol), 
176 mg of product 19d was obtained in the form of a white-yellow solid 
(74% yield). TLC (ACN/H2O/conc.aq.NH3 10/5/1): RF = 0.45. 
1H NMR (600 MHz, DMSO-d6): δ (ppm): 8.80-8.79 (m, 1H, H-2´´), 
8.16-8.14 (m, 1H, H-14´), 8.00-7.99 (m, 1H, H-8´´), 7.60-7.56 (m, 1H, 
H-3´´), 7.57-7.55 (m, 1H, H-5´´), 7.48-7.45 (m, 1H, H-7´´), 5.88-5.81 (m, 
1H, H-10´), 5.67-5.42 (m, 12H, OH-2, OH-3), 5.07-5.01 (m, 1H, H-1I), 
5.05-5.03 (m, 1H, H-11a´), 5.02-5.00 (m, 1H, H-11b´), 4.97-4.74 (m, 5H, 
H-1), 4.82-4.80 (m, 1H, H-6aI), 4.76-4.74 (m, 1H, H-6bI), 4.64-4.50 (m, 
5H, OH-6), 4.55-4.53 (m, 2H, H-12´), 3.99 (s, 3H, OCH3-6´´), 3.98-3.95 (m, 1H, H-5I), 3.86-3.18 (m, 
33H, H-2, H-3, H-4, H-5, H-6), 3.69-3.67 (m, 1H, H-2a´), 3.49-3.47 (m, 1H, H-8´), 3.44-3.42 (m, 1H, 
H-9´), 3.28-3.26 (m, 1H, H-2b´), 3.23-3.21 (m, 1H, H-6a´), 3.07-3.05 (m, 1H, H-6b´), 2.53-2.51 (m, 
1H, H-3´), 1.85-1.82 (m, 1H, H-4´), 1.71-1.69 (m, 2H, H-7´), 1.23-1.21 (m, 2H, H-5´).  
13C NMR (150 MHz, DMSO-d6): δ (ppm): 157.73 (C-6´´), 147.57 (C-2´´), 144.05 (C-10´´*), 142.69 
(C-13´), 141.43 (C-4´´*), 138.06 (C-10´), 131.34 (C-8´´), 126.64 (C-9´´), 126.13 (C-14´), 121.88 (C-
7´´), 118.80 (C-3´´), 116.02 (C-11´), 101.89 (6 × C-1), 101.20 (C-5´´), 82.21 (6 × C-4), 73.10 (C-9´), 
72.06 (6 × C-2, 6 × C-3, 5 × C-5), 69.66 (C-5I), 62.02 (C-12´), 60.20 (5 × C-6), 58.81 (C-8´), 56.28 
(OCH3-6´´), 49.98 (C-6I), 48.43 (C-6´), 47.25 (C-2´), 36.75 (C-3´), 28.98 (C-5´), 26.87 (C-4´), 23.12 
(C-7´). 
Signals tagged with * can be mutually interchanged. 
HRMS (ESI): found 1360.5182. For C59H85N5O31 calculated [M+H]+ 1360.5301. 
IR (KBr) 3381, 3330, 2995, 1625, 1515, 1365, 1245, 1156, 1054 cm-1. 
[α]D25 = +60.0° (c = 0.30, DMSO).  
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6I-Deoxy-6I-((4-(((S)-quinolin-4-yl(5-vinylquinuclidin-2-
yl)methoxy)methyl)-1H-1,2,3-triazol-1-yl)-β-CD (20a)  
Compound 20a was prepared according to the general procedure (GP1). 
From 6I-azido-6I-deoxy-β-CD 2b (100 mg, 0.09 mmol) and 9-O-
propargyl-cinchonine 18a (37 mg, 0.11 mmol) and copper-iodide (3 mg, 
0.02 mmol), 114 mg of product 20a was obtained in the form of a white-
yellow solid (89% yield). TLC (ACN/H2O/conc.aq.NH3 10/5/1): RF = 
0.39. 
1H NMR (600 MHz, DMSO-d6): δ (ppm): 8.93-8.90 (m, 1H, H-2´´), 
8.34-8.31 (m, 1H, H-8´´), 8.08-8.07 (m, 1H, H-5´´), 8.03-8.01 (m, 1H, 
H-14´), 7.82-7.76 (m, 1H, H-6´´), 7. 67-7.65 (m, 1H, H-7´´), 7.60-7.58 
(m, 1H, H-3´´), 5.96-5.93 (m, 1H, H-10´), 5.85-5.64 (m, 14H, OH-2, 
OH-3), 5.05-4.91 (m, 7H, H-1), 5.03-5.01 (m, 2H, H-11´), 4.85-4.83 (m, 
1H, H-6aI), 4.64-4.62 (m, 1H, H-6bI), 4.63-4.51 (m,  6H, OH-6), 4.46-4.44 (m, 1H, H-12a´), 4.38-4.36 
(m, 1H, H-12b´), 3.98-3.96 (m, 1H, H-5I), 3.79-3.24 (m, 39H, H-2, H-3, H-4, H-5, H-6), 3.17-3.15 (m, 
1H, H-8´), 3.10-3.08 (m, 1H, H-2a´), 2.74-2.72 (m, 1H, H-2b´), 2.60-2.58 (m, 1H, H-6a´), 2.24-2.22 
(m, 1H, H-3´), 1.83-1.81 (m, 1H, H-7a´), 1.69-1.67 (m, 1H, H-4´), 1.49-1.47 (m, 2H, H-5´), 1.48-1.46 
(m, 1H, H-6b´), 1.43-1.41 (m, 1H, H-7b´).  
 H-9´signal is not seen.  
13C NMR (DMSO-d6): δ (ppm): 150.13 (C-2´´), 147.93 (C-10´´*), 146.21 (C-4´´*), 143.20 (C-13´), 
140.29 (C-10´), 129.75 (C-5´´), 129.50 (C-9´´), 129.06 (C-6´´), 126.54 (C-7´´), 125.40 (C-14´), 123.94 
(C-8´´), 119.70 (C-3´´), 114.84 (C-11´), 101.94 (7 × C-1), 81.60 (7 × C-4), 80.60 (C-9´), 72.22 (7 × C-
2, 7 × C-3, 6 × C-5), 69.83 (C-5I), 61.71 (C-12´), 60.10 (6 × C-6), 60.05 (C-8´), 50.11 (C-6I), 47.85 
(C-2´), 39.50 (C-3´), 27.39 (C-4´), 25.41 (C-5´), 48.89 (C-6´), 25.41 (C-7´).  
Signals tagged with * can be mutually interchanged. 
HRMS (ESI): found 1492.5610. For C64H93N5O35 calculated [M+H]+ 1492.5724. 
IR (KBr) 3348, 3105, 2929, 1646, 1422, 1156, 1105, 1081, 1033 cm-1. 
[α]D25 = + 75.0° (c = 0.30, DMSO). 
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6I-Deoxy-6I-((4-(((R)-quinolin-4-yl(5-vinylquinuclidin-2-
yl)methoxy)methyl)-1H-1,2,3-triazol-1-yl)-β-CD (20b)  
Compound 20b was prepared according to the general procedure (GP1). From 6I-azido-6I-deoxy-β-
CD 2b (100 mg, 0.09 mmol), 9-O-propargyl-cinchonidine 18b (37 mg, 
0.11 mmol) and copper-iodide (3 mg, 0.02 mmol), 90 mg of product 
was obtained in the form of a white-yellow solid (70% yield). TLC 
(ACN/H2O/conc.aq.NH3 10/5/1): RF = 0.39. 
1H NMR (600 MHz, DMSO-d6): δ (ppm): 8.93-8.91 (m, 1H, H-2´´), 
8.39-8.37 (m, 1H, H-8´´), 8.09-8.07 (m, 1H, H-5´´), 8.08-8.07 (m, 1H, 
H-14´), 7.80-7.78 (m, 1H, H-6´´), 7.66-7.64 (m, 1H, H-7´´), 7.61-7.59 
(m, 1H, H-3´´), 5.81-5.79 (m, 1H, H-10´), 5.79-5.64 (m, 14H, OH-2, 
OH-3), 5.08-5.07 (m, 1H, H-1I), 5.00-4.98 (m, 1H, H-11a´), 4.93-4.91 
(m, 1H, H-11b´), 4.87-4.85 (m, 1H, H-6aI), 4.85-4.81 (m, 6H, H-1), 
4.63-4.49 (m, 6H, OH-6), 4.61-4.58 (m, 1H, H-6bI), 4.45-4.43 (m, 2H, 
H-12´), 3.99-3.97 (m, 1H, H-5I), 3.78-3.26 (m, 39H, H-2, H-3, H-4, H-5, H-6), 3.31-3.29 (m, 1H, H-
6a´), 3.27-3.25 (m, 1H, H-8´), 3.00-2.98 (m, 1H, H-2a´), 2.61-2.59 (m, 1H, H-6b´), 2.60-2.58 (m, 1H, 
H-2b´), 2.32-2.30 (m, 1H, H-3´), 1.77-1.75 (m, 1H, H-4´), 1.69-1.67 (m, 1H, H-5a´), 1.51-1.49 (m, 
1H, H-5b´), 1.64-1.61 (m, 2H, H-7´).  
H-9´and C-9  ´signals are not seen.  
13C NMR (150 MHz, DMSO-d6): δ (ppm): 150.13 (C-2´´), 147.97 (C-10´´), 145.50 (C-4´´), 143.14 (C-
13´), 141.24 (C-10´), 129.75 (C-5´´), 129.17 (C-6´), 126.73 (C-7´´), 126.24 (C-9´´), 125.40 (C-14´), 
123.94 (C-8´´), 119.46 (C-3´´), 114.76 (C-11´), 101.83 (7 × C-1), 81.75 (7 × C-4), 72.46 (7 × C-2, 7 × 
C-3, 6 × C-5), 69.81 (C-5I), 61.86 (C-12´), 60.10 (6 × C-6), 59.05 (C-8´), 55.14 (C-2´), 50.20 (C-6I), 
42.13 (C-6´), 38.61 (C-3´), 26.20 (C-5´), 26.97 (C-4´), 22.96 (C-7´).  
Signals tagged with * can be mutually interchanged. 
HRMS (ESI): found 1492.5604. For C64H93N5O35 calculated [M+H]+ 1492.5724. 
IR (KBr) 3297, 2932, 1661, 1637, 1509, 1461, 1362, 1335, 1030 cm-1. 
[α]D25 = +48.3° (c = 0.30, DMSO). 
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6I-Deoxy-6I-((4-(((S)-(6-methoxyquinolin-4-yl)(5-vinylquinuclidin-2-
yl)methoxy)methyl)-1H-1,2,3-triazol-1-yl)-β-CD (20c)  
Compound 20c was prepared according to the general procedure (GP1). From 
6I-azido-6I-deoxy-β-CD 2b (100 mg, 0.09 mmol), 9-O-propargyl-quinine 18c 
(41 mg, 0.11 mmol) and copper-iodide (3 mg, 0.02 mmol), 105 mg of product 
was obtained in the form of a white-yellow solid (80% yield). TLC 
(ACN/H2O/conc.aq.NH3 10/5/1): RF = 0.43.  
1H NMR (600 MHz, DMSO-d6): δ (ppm):  8.78-8.76 (m, 1H, H-2´´), 8.21-
8.19 (m, 1H, H-14´), 7.99-7.97 (m, 1H, H-8´´), 7.66-7.64 (m, 1H, H-5´´), 
7.59-7.57 (m, 1H, H-3´´), 7.46-7.44 (m, 1H, H-7´´), 5.84-5.71 (m, 14H, OH-
2, OH-3), 5.82-5.80 (m, 1H, H-10´), 5.07-5.05 (m, 1H, H-11a´), 5.04-4.95 (m, 
7H, H-1), 4.94-4.92 (m, 1H, H-11b´), 4.95-4.93 (m, 1H, H-6aI), 4.64-4.50 (m, 
6H, OH-6), 4.59-4.57 (m, 1H, H-6bI), 4.50-4.48 (m, 2H, H-12´), 4.10-4.08 (m, 1H, H-5I), 3.97 (s, 3H, 
OCH3-6´´), 3.78-3.16 (m, 39H, H-2, H-3, H-4, H-5, H-6), 3.07-3.05 (m, 1H, H-8´), 3.75-3.73 (m, 2H, 
H-2´), 2.54-2.52 (m, 2H, H-6´), 2.42-2.40 (m, 1H, H-3´), 1.85-1.83 (m, 1H, H-4´), 1.77-1.75 (m, 1H, 
H-5a´), 1.59-1.57 (m, 1H, H-5b´), 1.30-1.28 (m, 2H, H-7´). 
 H-9´and C-9  ´signals are not seen. 
13C NMR (150 MHz, DMSO-d6): δ (ppm):  157.58 (C-6´´), 147.44 (C-2´´), 144.01 (C-10´´*), 144.01 
(C-4´´*), 143.11 (C-13´), 140.31 (C-10´), 131.17 (C-8´´), 127.09 (C-9´´), 125.34 (C-14´), 121.67 (C-
7´´), 118.93 (C-3´´), 115.17 (C-11´), 102.16 (C-5´´), 101.50 (7  C-1), 83.56 (C-4I), 81.70 (6  C-4), 
73.12 (7  C-2, 7  C-3, 6  C-5), 61.95 (C-12´), 69.76 (C-5I), 60.05 (6  C-6), 59.30 (C-8´), 56.07 
(OCH3-6´´), 54.39 (C-2´), 50.38 (C-6I), 42.53 (C-6´), 38.15 (C-3´), 26.85 (C-4´), 25.52 (C-5´), 25.15 
(C-7´). 
Signals tagged with * can be mutually interchanged. 
HRMS (ESI): found 1522.5741. For C65H95N5O36 calculated [M+H]+ 1522.5831. 
IR (KBr) 3396, 3330, 3073, 2935, 1655, 1622, 1419, 1237, 1030 cm-1. 
[α]D25 = + 46.7° (c = 0.30, DMSO). 
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6I-Deoxy-6I-((4-(((R)-(6-methoxyquinolin-4-yl)(5-vinylquinuclidin-2-
yl)methoxy)methyl)-1H-1,2,3-triazol-1-yl)-β-CD (20d)  
Compound 20d was prepared according to the general procedure (GP1). 
From 6I-azido-6I-deoxy-β-CD 2b (100 mg, 0.09 mmol), 9-O-propargyl-
quinidine 18d (41 mg, 0.11 mmol) and copper-iodide (3 mg, 0.02 mmol), 
124 mg of product was obtained in the form of a white-yellow solid 
(95% yield). TLC (ACN/H2O/conc.aq.NH3 10/5/1): RF = 0.43. 
1H NMR (600 MHz, DMSO-d6): δ (ppm): 8.78-8.76 (m, 1H, H-2´´), 
8.09-8.05 (m, 1H, H-14´), 8.00-7.98 (m, 1H, H-8´´), 7.58-7.56 (m, 1H, 
H-5´´), 7.59-7.57 (m, 1H, H-3´´), 7.46-7.44 (m, 1H, H-7´´), 5.93-5.88 
(m, 1H, H-10´), 5.86-5.70 (m, 14H, OH-2, OH-3), 5.05-4.75 (m, 7H, H-
1), 5.02-5.00 (m, 2H, H-11´), 4.85-4.83 (m, 1H, H-6aI), 4.64-4.50 (m, 
6H, OH-6), 4.63-4.60 (m, 1H, H-6bI), 4.49-4.46 (m, 1H, H-12a´), 4.40-
4.38 (m, 1H, H-12b´), 3.98-3.95 (m, 1H, H-5I), 3.96 (s, 3H, OCH3-6´´), 3.78-3.16 (m, 39H, H-2, H-3, 
H-4, H-5, H-6), 3.07-3.05 (m, 1H, H-8´), 3.75-3.73 (m, 2H, H-2´), 2.54-2.52 (m, 2H, H-6´), 2.30-2.28 
(m, 1H, H-3´), 1.73-1.71 (m, 1H, H-4´), 1.65-1.62 (m, 2H, H-5´), 1.30-1.28 (m, 2H, H-7´). 
 H-9´and C-9´signals are not seen. 
13C NMR (150 MHz, DMSO-d6): δ (ppm): 157.20 (C-6´´), 147.58 (C-2´´), 144.0 (C-10´´*), 144.00 (C-
4´´*), 143.17 (C-13´), 140.29 (C-10´), 131.24 (C-8´´), 127.31 (C-9´´), 125.41 (C-14´), 121.46 (C-7´´), 
119.31 (C-3´´), 115.10 (C-11´), 101.50 (7  C-1), 100.16 (C-5´´), 83.26 (C-4I), 81.70 (6  C-4), 73.12 
(7  C-2, 7  C-3, 6  C-5), 69.77 (C-5I), 61.66 (C-12´), 60.05 (6  C-6), 59.30 (C-8´), 55.75 (OCH3-
6´´), 50.17 (C-6I), 48.76 (C-6´), 47.74 (C-2´), 38.15 (C-3´), 27.25 (C-4´), 25.52 (C-5´), 25.15 (C-7´). 
Signals tagged with * can be mutually interchanged. 
HRMS (ESI): found 1522.5646. For C65H95N5O36 calculated [M+H]+ 1522.5831. 
IR (KBr) 3321, 2923, 2881, 1658, 1622, 1350, 1299, 1156, 1030 cm-1. 
[α]D25 = +76.7° (c = 0.30, DMSO). 
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General procedure for the preparation of monosubstituted permethylated 
CD derivatives (GP2)  
The first starting material, 9-O-propargyl Cinchona alkaloids (18a‒18d, 0.10 mmol), was 
dissolved in 0.5 mL of distilled DMF (sonicated for 10 minutes under Ar atmosphere). Second starting 
material, 6I-azido-6I-deoxy-permethyl-α-CD131 (21, 0.08 mmol) or 6I-azido-6I-deoxy-permethyl-β-
CD132 (22, 0.06 mmol), was dissolved in 0.4 mL distilled DMF (sonicated for 10 minutes under Ar 
atmosphere) and added to the Cinchona alkaloid solution. Copper iodide (0.02 mmol), suspended in 
0.1 mL of distilled DMF (sonicated for 10 minutes under Ar atmosphere), was added to the reaction 
mixture and stirred at 50 °C for 16 hours. The conversion into product was monitored by TLC in 
eluent CHCl3/MeOH/conc.aq.NH3 20/1/0.1. After the spot of the starting material 21 or 22 
disappeared on TLC, DMF was evaporated on a rotary evaporator at 50 °C and the crude product was 
purified by column chromatography (50 g of silica gel) with the mobile phase 
CHCl3/MeOH/conc.aq.NH3 (25/1/0.1 → 20/1/0.1). When full conversion to the product was not 
achieved, the starting material was regenerated (eluted as the first compound). A blue precipitate 
formed at the top of the column as copper cations interacted with ammonia. The purified product was 
dried at 50 °C under reduced pressure. 
6I-Deoxy-6I-(4-(((S)-quinolin-4-yl(5-vinylquinuclidin-2-yl)methoxy) methyl)-
1H-1,2,3-triazol-1-yl)-permethyl-α-CD (23a)  
Compound 23a was prepared according to the general procedure (GP2). 
From 6I-azido-6I-deoxy-permethyl-α-CD 21 (100 mg, 0.08 mmol), 9-O-
propargyl-cinchonine 18a (35 mg, 0.10 mmol) and copper-iodide (3 mg, 
0.02 mmol), 75 mg of product was obtained in the form of a white-yellow 
solid (59% yield). TLC (CHCl3/MeOH/conc.aq.NH3 20/1/0.1): RF = 0.40. 
1H NMR (600 MHz, CD3OD): δ (ppm):  8.88-8.87 (m, 1H, H-2´´), 8.29-
8.27 (m, 1H, H-8´´), 8.11-8.09 (m, 1H, H-5´´), 7.94 (s, 1H, H-14´), 7.83-
7.80 (m, 1H, H-6´´), 7.72-7.69 (m, 1H, H-3´´), 7.71-7.68 (m, 1H, H-7´´), 
6.03-5.97 (m, 1H, H-10´), 5.33-5.32 (m, 1H, H-1I), 5.07-5.01 (m, 5H, H-1), 
5.04-5.00 (m, 2H, H-11´), 4.93-4.90 (m, 2H, H-6I), 4.58 (bs, 2H, H-12´), 
4.21-4.18 (m, 1H, H-5I), 4.12-3.89 (m, 5H, H-5), 3.91-3.79 (m, 10H, H-6), 
3.66-3.62 (m, 18H, OCH3-3), 3.57-3.55 (m, 1H, H-9´), 3.55-3.49 (m, 18H, OCH3-2), 3.61-3.49 (m, 
12H, H-3, H-4), 3.37-3.35 (m, 1H, H-2a´), 3.32-3.25 (m, 15H, OCH3-6), 3.21-3.23 (m, 1H, H-8´), 
3.19-3.10 (m, 6H, H-2), 2.89-2.86 (m, 1H, H-6a´), 2.88-2.82 (m, 1H, H-2b´), 2.77-2.73 (m, 1H, H-
6b´), 2.32-2.29 (m, 1H, H-3´), 2.09-2.06 (m, 1H, H-7a´), 1.73-1.72 (m, 1H, H-4´), 1.60-1.51 (m, 2H, 
H-5´), 1.32-1.28 (m, 1H, H-7b´).  
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13C NMR (150 MHz, CD3OD): δ (ppm): 150.98 (C-2´´), 149.19 (C-10´´*), 147.89 (C-4´´*), 144.95 
(C-13´), 141.46 (C-10´), 130.98 (C-6´´), 130.31 (C-5´´), 128.43 (C-7´´), 127.89 (C-9´´), 127.48 (C-
14´), 124.59 (C-8´´), 120.73 (C-3´´), 115.52 (C-11´), 100.19 (6 × C-1), 83.07 (6 × C-2, 6 × C-3, 6 × C-
4), 81.03 (C-9´), 72.83 (5 × C-5, 5 × C-6), 71.66 (C-5I), 63.50 (C-12´), 62.05 (6 × OCH3-3), 61.35 (C-
8´), 59.39 (5 × OCH3-6), 58.64 (6 × OCH3-2), 52.41 (C-6I), 50.81 (C-6´), 50.09 (C-2´), 40.94 (C-3´), 
29.43 (C-4´), 26.95 (C-5´), 23.11 (C-7´). 
Signals tagged with * can be mutually interchanged. 
HRMS (ESI): found 1568.7713. For C75H117N5O30 [M+H]+ calculated 1568.7856.  
IR (KBr) 2926, 2830, 1715, 1512, 1461, 1365, 1196, 1168, 1036 cm-1. 
[α]D25 = +139.0° (c = 0.30, MeOH).  
6I-Deoxy-6I-(4-(((R)-quinolin-4-yl(5-vinylquinuclidin-2-yl)methoxy) 
methyl)-1H-1,2,3-triazol-1-yl)-permethyl-α-CD (23b)  
Compound 23b was prepared according to the general procedure (GP2). 
From 6I-azido-6I-deoxy-permethyl-α-CD 21 (100 mg, 0.08 mmol), 9-O-
propargyl-cinchonidine 18b (35 mg, 0.10 mmol) and copper-iodide (3 mg, 
0.02 mmol), 61 mg of product was obtained in the form of a white-yellow 
solid (48% yield). TLC (CHCl3/MeOH/conc.aq.NH3 20/1/0.1): RF = 0.40. 
1H NMR (600 MHz, CD3OD): δ (ppm): 8.87-8.85 (m, 1H, H-2´´), 8.33-
8.29 (m, 1H, H-8´´), 8.11-8.08 (m, 1H, H-5´´), 7.97 (s, 1H, H-14´), 7.82-
7.80 (m, 1H, H-6´´), 7.73-7.70 (m, 1H, H-3´´), 7.70-7.68 (m, 1H, H-7´´), 
5.80-5.75 (m, 1H, H-10´), 5.32-5.31 (m, 1H, H-1I), 5.07-4.97 (m, 5H, H-
1), 4.97-4.95 (m, 1H, H-6aI), 4.93-4.90 (m, 2H, H-11´), 4.89-4.86 (m, 1H, 
H-6bI), 4.58 (bs, 2H, H-12´), 4.18-4.16 (m, 1H, H-5I), 4.02-3.96 (m, 5H, 
H-5), 3.98-3.85 (m, 10H, H-6), 3.65-3.59 (m, 18H, OCH3-3), 3.60-3.56 (m, 
12H, H-3, H-4), 3.58-3.47 (m, 18H, OCH3-2), 3.41-3.40 (m, 1H, H-6a´), 3.36-3.27 (m, 15H, OCH3-6), 
3.22-3.19 (m, 1H, H-8´), 3.07-3.05 (m, 1H, H-2a´), 3.10-2.99 (m, 6H, H-2), 2.66-2.64 (m, 1H, H-6b´), 
2.59-2.56 (m, 1H, H-2b´), 2.35-2.33 (m, 1H, H-3´), 1.79-1.76 (m, 1H, H-4´), 1.67-1.62 (m, 1H, H-
5a´), 1.60-1.54 (m, 1H, H-5b´), 1.37-1.33 (m, 1H, H-7a´), 1.28-1.24 (m, 1H, H-7b´).  
 H-9´signal is not seen. 
13C NMR (150 MHz, CD3OD): δ (ppm): 151.00 (C-2´´), 149.21 (C-10´´*), 148.07 (C-4´´*), 145.07 
(C-13´), 142.53 (C-10´), 131.00 (C-6´´), 130.33 (C-5´´), 128.46 (C-7´´), 127.93 (C-9´´), 127.43 (C-
14´), 124.65 (C-8´´), 120.54 (C-3´´), 115.11 (C-11´), 100.27 (6 × C-1), 83.04 (6 × C-4, 6 × C-3, 6 × C-
2), 81.30 (C-9´), 72.50 (5 × C-5, 5 × C-6), 71.69 (C-5I), 63.50 (C-12´), 62.03 (6 × OCH3-3), 59.57 (5 × 
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OCH3-6), 58.90(6 × OCH3-2), 61.73 (C-8´), 57.46 (C-2´), 52.45 (C-6I), 43.88 (C-6´), 40.81 (C-3´), 
29.02 (C-4´), 28.25 (C-5´), 23.48 (C-7´). 
Signals tagged with * can be mutually interchanged. 
HRMS (ESI): found 1568.7708. For C75H117N5O30 calculated [M+H]+ 1568.7856.  
IR (KBr) 2920, 2839, 1595, 1455, 1359, 1165, 1111, 1069, 1039 cm-1. 
[α]D25 = +75.0° (c = 0.30, MeOH). 
6I-Deoxy-6I-(4-(((R)-1-(6-methoxyquinolin-4-yl(5-vinylquinuclidin-
2-yl)methoxy) methyl)-1H-1,2,3-triazol-1-yl)-permethyl-α-CD (23c)  
Compound 23c was prepared according to the general procedure (GP2). 
From 6I-azido-6I-deoxy-permethyl-α-CD 21 (100 mg, 0.08 mmol), 9-O-
propargyl-quinine 18c (38 mg, 0.10 mmol) and copper-iodide (4 mg, 0.02 
mmol), 63 mg of product was obtained in the form of a white-yellow solid 
(49% yield). TLC (CHCl3/MeOH/conc.aq.NH3 20/1/0.1): RF = 0.40. 
1H NMR (600 MHz, CD3OD): δ (ppm): 8.71-8.70 (m, 1H, H-2´´), 7.99-
7.98 (m, 1H, H-8´´), 7.98 (s, 1H, H-14´), 7.69-7.67 (m, 1H, H-3´´), 7.53-
7.50 (m, 1H, H-5´´), 7.48-7.45 (m, 1H, H-7´´), 5.81-5.74 (m, 1H, H-10´), 
5.34-5.28 (m, 1H, H-1I), 5.00-4.88 (m, 5H, H-1), 4.97-4.92 (m, 2H, H-
11´), 4.93-4.91 (m, 2H, H-6I), 4.59 (s, 2H, H-12´), 4.19-4.16 (m, 1H, H-
5I), 3.99 (s, 3H, OCH3-6´´), 3.92-3.81 (m, 5H, H-5) 3.82-3.25 (m, 10H, H-
6), 3.67-3.60 (m, 18H, OCH3-3), 3.63-3.61 (m, 1H, H-8´), 3.55-3.53 (m, 1H, H-9´), 3.52-3.45 (m, 
18H, OCH3-2), 3.61-3.41 (m, 12H, H-3, H-4), 3.37-3.25 (m, 15H, OCH3-6), 3.21-3.12 (m, 6H, H-2), 
3.08-3.05 (m, 1H, H-2a´), 2.69-2.66 (m, 2H, H-6´), 2.61-2.59 (m, 1H, H-2b´), 2.38-2.33 (m, 1H, H-
3´), 1.80-1.79 (m, 1H, H-4´), 1.77-1.75 (m, 1H, H-5a´), 1.58-1.56 (m, 1H, H-5b´), 1.33-1.28 (m, 2H, 
H-7´). 
13C NMR (150 MHz, CD3OD): δ (ppm):  159.90 (C-6´´), 148.22 (C-2´´), 146.39 (C-10´´*), 145.18 (C-
4´´*), 145.12 (C-13´), 142.60 (C-10´), 131.65 (C-8´´), 128.98 (C-9´´), 127.42 (C-14´), 123.63 (C-7´´), 
120.40 (C-3´´), 102.55 (C-5´´), 100.26 (6 × C-1), 83.10 (6 × C-2, 6 × C-3, 6 × C-4), 79.47 (C-9´), 
72.42 (6 × C-5, 6 × C-6), 63.40 (C-12´), 62.07 (6 × OCH3-3), 61.16 (C-8´), 59.29 (6 × OCH3-2), 58.99 
(5 × OCH3-6), 57.50 (C-2´), 56.56 (OCH3-6´´), 52.44 (C-6I), 44.08 (C-6´), 40.84 (C-3´), 29.07 (C-4´), 
28.32 (C-5´), 22.51 (C-7´). 
Signals tagged with * can be mutually interchanged. 
HRMS (ESI): found 1568.7849. For C76H119N5O31 [M+H]+ calculated 1598.7962.  
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IR (KBr) 2926, 2836, 1622, 1506, 1476, 1365, 1228, 1141, 1036 cm-1. 
[α]D25 = +92.4° (c = 0.21, MeOH).  
6I-Deoxy-6I-(4-(((S)-1-(6-methoxyquinolin-4-yl(5-vinylquinuclidin-
2-yl)methoxy) methyl)-1H-1,2,3-triazol-1-yl)-permethyl-α-CD (23d)  
Compound 23d was prepared according to the general procedure (GP2). 
From 6I-azido-6I-deoxy-permethyl-α-CD 21 (100 mg, 0.08 mmol), 9-O-
propargyl-quinidine 18d (38 mg, 0.10 mmol) and copper-iodide (4 mg, 
0.02 mmol), 54 mg of product was obtained in the form of a white-yellow 
solid (42% yield). TLC (CHCl3/MeOH/conc.aq.NH3 20/1/0.1): RF = 0.40. 
1H NMR (600 MHz, CD3OD): δ (ppm):  8.71-8.70 (m, 1H, H-2´´), 7.99-
7.98 (m, 1H, H-8´´), 7.96 (s, 1H, H-14´), 7.66-7.65 (m, 1H, H-3´´), 7.51-
7.50 (m, 1H, H-5´´), 7.46-7.44 (m, 1H, H-7´´), 6.00-5.97 (m, 1H, H-10´), 
5.33-5.32 (m, 1H, H-1I), 5.08-5.00  (m, 5H, H-1), 5.05-5.03  (m, 2H, H-
11´), 4.92-4.91 (m, 2H, H-6I), 4.60-4.58 (m, 1H, H-9´), 4.55 (s, 2H, H-12´), 
4.20-4.16 (m, 1H, H-5I), 3.99 (s, 3H, OCH3-6´´), 3.91-3.81 (m, 4H, H-5), 
3.91-3.61 (m, 10H, H-6), 3.69-3.63 (m, 18H, OCH3-3), 3.65-3.21 (m, 12H, 
H-3, H-4), 3.49-3.41 (m, 18H, OCH3-2), 3.34-3.32 (m, 1H, H-2a´), 3.25-3.31 (m, 15H, OCH3-6), 3.12-
3.10 (m, 1H, H-8´), 3.21-3.05 (m, 6H, H-2), 2.88-2.85 (m, 1H, H-2b´), 2.87-2.85 (m, 1H, H-6a´), 2.79-
2.74 (m, 1H, H-6b´), 2.31-2.28 (m, 1H, H-3´), 2.11-2.08 (m, 1H, H-7a´), 1.72-1.70 (m, 1H, H-4´), 
1.60-1.53 (m, 2H, H-5´), 1.32-1.24 (m, 1H, H-7b´). 
13C NMR (150 MHz, CD3OD): δ (ppm): 159.82 (C-6´´), 148.22 (C-2´´), 146.37 (C-10´´*), 145.15 (C-
4´´*), 145.05 (C-13´), 141.64 (C-10´), 131.60 (C-8´´), 128.92 (C-9´´), 127.46 (C-14´), 123.59 (C-7´´), 
120.54 (C-3´´), 115.42 (C-11´), 102.59 (C-5´´), 100.27 (6 × C-1), 83.08 (6 × C-2, 6 × C-3, 6 × C-4), 
81.33 (C-9´), 72.33 (5 × C-5, 5 × C-6), 71.67 (C-5I), 63.44 (C-12´), 61.11 (6 × OCH3-3), 60.88 (C-8´), 
59.80 (6 × OCH3-2), 58.52 (5 × OCH3-6), 56.45 (OCH3-6´´), 52.41 (C-6I), 50.85 (C-6´), 50.24 (C-2´), 
41.06 (C-3´), 29.50 (C-4´), 27.07 (C-5´), 22.66 (C-7´). 
Signals tagged with * can be mutually interchanged. 
HRMS (ESI): found 1598.7962. For C76H119N5O31 [M+H]+ calculated 1598.7859.  
IR (KBr) 2929, 2839, 1622, 1512, 1456, 1368, 1257, 1144, 1039 cm-1. 
[α]D25 = +154.8° (c = 0.20, MeOH).  
  
113 
 
6I-Deoxy-6I-(4-(((S)-quinolin-4-yl(5-vinylquinuclidin-2-yl)methoxy) methyl)-
1H-1,2,3-triazol-1-yl)-permethyl-β-CD (24a)  
Compound 24a was prepared according to the general procedure (GP2). 
From 6I-azido-6I-deoxy-permethyl-β-CD 22 (100 mg, 0.07 mmol), 9-O-
propargylcinchonine 18a (29 mg, 0.09 mmol) and copper-iodide (3 mg, 
0.01 mmol), 38 mg of product was obtained in the form of a white-yellow 
solid (64% yield). TLC (CHCl3/MeOH/conc.aq.NH3 20/1/0.1): RF = 0.38. 
1H NMR (600 MHz, CD3OD): δ (ppm): 8.90-8.89 (m, 1H, H-2´´), 8.32-
8.29 (m, 1H, H-8´´), 8.12-8.10 (m, 1H, H-5´´), 7.94 (s, 1H, H-14´), 7.84-
7.81 (m, 1H, H-6´´), 7.72-7.69 (m, 1H, H-3´´), 7.71-7.68 (m, 1H, H-7´´), 
6.05-5.99 (m, 1H, H-10´), 5.55-5.21 (m, 7H, H-1), 5.04-5.01 (m, 1H, H-
6aI), 5.04-5.03 (m, 2H, H-11´), 4.80-4.79 (m, 1H, H-6bI), 4.57 (s, 2H, H-
12´), 4.09-4.07 (m, 1H, H-5I), 3.88-3.50 (m, 18H, H-5, H-6), 3.65-3.41 (m, 
14H, H-3, H-4), 3.65-3.59 (m, 21H, OCH3-3), 3.52-3.43 (m, 21H, OCH3-2), 3.36-3.25 (m, 18H, 
OCH3-6), 3.28-3.26 (m, 1H, H-2a´), 3.18-3.16 (m, 1H, H-8´), 3.19-3.10 (m, 7H, H-2), 2.86-2.84 (m, 
1H, H-2b´), 2.84-2.81 (m, 1H, H-6a´), 2.74-2.73 (m, 1H, H-6b´), 2.33-2.29 (m, 1H, H-3´), 2.10-2.07 
(m, 1H, H-7a´), 1.73-1.72 (m, 1H, H-4´), 1.58-1.54 (m, 2H, H-5´), 1.31-1.28 (m, 1H, H-7b´).  
 H-9´signal is not seen. 
13C NMR (150 MHz, CD3OD): δ (ppm): 150.99 (C-2´´), 149.18 (C-10´´*), 148.04 (C-4´´*), 144.98 
(C-13´), 141.59 (C-10´), 130.96 (C-6´´), 130.29 (C-5´´), 128.41 (C-7´´), 127.91 (C-9´´), 127.46 (C-
14´), 124.62 (C-8´´), 120.81 (C-3´´), 115.45 (C-11´), 99.67 (7 × C-1), 83.65 (7 × C-4, 7 × C-2), 81.67 
(C-9´), 81.03 (7 × C-3), 72.87 (6 × C-5, 6 × C-6), 71.81 (C-5I), 63.45 (C-12´), 62.14 (7  OCH3-3), 
61.38 (C-8´), 59.72 (6  OCH3-6, 7  OCH3-2), 52.33 (C-6I), 50.81 (C-6´), 50.10 (C-2´), 41.07 (C-3´), 
29.45 (C-4´), 27.07 (C-5´), 23.34 (C-7´). 
Signals tagged with * can be mutually interchanged. 
HRMS (ESI): found 1772.8706. For C84H133N5O35 [M+H]+ calculated 1772.8716.  
IR (KBr)  2923, 2833, 1679, 1458, 1368, 1195, 1162, 1108, 1033 cm-1. 
[α]D25= +152.9° (c = 0.43, MeOH). 
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6I-Deoxy-6I-(4-(((R)-quinolin-4-yl(5-vinylquinuclidin-2-yl)methoxy) 
methyl)-1H-1,2,3-triazol-1-yl)-permethyl-β-CD (24b)  
Compound 24b was prepared according to the general procedure (GP2). 
From 6I-azido-6I-deoxy-permethyl-β-CD 22 (100 mg, 0.07 mmol), 9-O-
propargylcinchonidine 18b (29 mg, 0.09 mmol) and copper-iodide (3 
mg, 0.01 mmol), 85 mg of product was obtained in the form of a white-
yellow solid (69% yield). TLC (CHCl3/MeOH/conc.aq.NH3 20/1/0.1): RF 
= 0.38. 
1H NMR (600 MHz, CD3OD): δ (ppm): 8.88-8.86 (m, 1H, H-2´´), 8.33-
8.31 (m, 1H, H-8´´), 8.12-8.10 (m, 1H, H-5´´), 7.97 (s, 1H, H-14´), 7.83-
7.80 (m, 1H, H-6´´), 7.73-7.71 (m, 1H, H-3´´), 7.71-7.69 (m, 1H, H-7´´), 
5.80-5.75 (m, 1H, H-10´), 5.37-5.36 (m, 1H, H-1I), 5.27-5.13 (m, 6H, H-
1), 5.12-5.10 (m, 1H, H-6aI), 4.98-4.96 (m, 1H, H-11a´), 4.93-4.91 (m, 
1H, H-11b´), 4.78-4.74 (m, 1H, H-6bI), 4.58 (s, 2H, H-12´), 4.09-4.06 (m, 1H, H-5I), 3.90-3.72 (m, 
18H, H-5, H-6), 3.68-3.60 (m, 21H, OCH3-3), 3.59-3.40 (m, 13H, H-3, H-4), 3.52-3.45 (m, 21H, 
OCH3-2), 3.44-3.42 (m, 1H, H-6b´), 3.39-3.36 (m, 1H, H-4I), 3.39-3.24 (m, 18H, OCH3-6), 3.22-3.20 
(m, 1H, H-8´), 3.20-3.07 (m, 7H, H-2), 3.07-3.05 (m, 1H, H-2a´), 2.71-2.67 (m, 1H, H-6a´), 2.61-2.58 
(m, 1H, H-2b´), 2.36-2.33 (m, 1H, H-3´), 1.82-1.77 (m, 1H, H-4´), 1.80-1.77 (m, 1H, H-5a´), 1.60-
1.59 (m, 1H, H-5b´), 1.32-1.29 (m, 2H, H-7´).  
 H-9  ´and C-9  ´signals are not seen. 
13C NMR (150 MHz, CD3OD): δ (ppm): 151.00 (C-2´´), 149.22 (C-10´´*), 147.92 (C-4´´*), 145.08 
(C-13´), 142.43 (C-10´), 131.00 (C-6´´), 130.35 (C-5´´), 128.48 (C-7´´), 127.90 (C-9´´), 127.38 (C-
14´), 124.63 (C-8´´), 120.67 (C-3´´), 115.19 (C-11´), 99.38 (7  C-1), 83.21 (7  C-2, 7  C-4), 80.37 
(7  C-3), 72.57 (6  C-5, 6  C-6), 71.85 (C-5I), 63.52 (C-12´), 61.88 (7  OCH3-3), 61.71 (C-8´), 
59.25 (6  OCH3-6, 7  OCH3-2), 57.43 (C-2´), 52.38 (C-6I), 43.91 (C-6´), 40.81 (C-3´), 29.02 (C-4´), 
28.22 (C-5´), 23.46 (C-7´). 
Signals tagged with * can be mutually interchanged. 
HRMS (ESI): found 1772.8671. For C84H133N5O35 [M+H]+ calculated 1772.8716.  
IR (KBr)  2944, 2836, 1679, 1455, 1329, 1201, 1159, 1105, 1033 cm-1. 
[α]D25= +96.9° (c = 0.18, MeOH). 
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6I-Deoxy-6I-(4-(((R)-1-(6-methoxyquinolin-4-yl(5-vinylquinuclidin-
2-yl)methoxy) methyl)-1H-1,2,3-triazol-1-yl)-permethyl-β-CD (24c)  
Compound 24c was prepared according to the general procedure (GP2). From 6I-azido-6I-deoxy-
permethyl-β-CD 22 (100 mg, 0.07 mmol), 9-O-propargyl-quinine 18c (32 mg, 0.09 mmol) and copper-
iodide (3 mg, 0.01 mmol), 60 mg of product was obtained in the form of a white-yellow solid (48% 
yield). TLC (CHCl3/MeOH/conc.aq.NH3 20/1/0.1): RF = 0.38. 
1H NMR (600 MHz, CD3OD):  δ (ppm): 8.72-8.71 (m, 1H, H-2´´), 8.01 (s, 
1H, H-14´), 8.00-7.99 (m, 1H, H-8´´), 7.70-7.68 (m, 1H, H-3´´), 7.56-7.54 
(m, 1H, H-5´´), 7.48-7.46 (m, 1H, H-7´´), 5.82-5.78 (m, 1H, H-10´), 5.38-
5.36 (m, 1H, H-1I), 5.28-5.10 (m, 6H, H-1), 5.12-5.10 (m, 1H, H-6aI), 5.00-
4.99 (m, 1H, H-11a´), 4.97-4.94 (m, 1H, H-11b´), 4.84-4.80 (m, 1H, H-6bI), 
4.65-4.60 (m, 2H, H-12´), 4.10-4.07 (m, 1H, H-5I), 4.02 (s, 3H, OCH3-6´´), 
4.01-3.21 (m, 18H, H-5, H-6), 3.65-3.58 (m, 21H, OCH3-3), 3.55-3.45 (m, 
21H, OCH3-2), 3.35-3.25 (m, 18H, OCH3-6), 3.64-3.62 (m, 1H, H-8´), 3.18-
3.16 (m, 1H, H-2a´), 3.65-3.25 (m, 14H, H-3, H-4), 3.25-3.07 (m, 7H, H-2), 
2.82-2.80 (m, 2H, H-6´), 2.73-2.70 (m, 1H, H-2b´), 2.43-2.40 (m, 1H, H-3´), 
1.86-1.85 (m, 1H, H-4´), 1.83-1.80 (m, 1H, H-5a´), 1.67-1.60 (m, 1H, H-
5b´), 1.39-1.24 (m, 2H, H-7´). 
H-9´signal is not seen. 
13C NMR (150 MHz, CD3OD): δ (ppm): 160.00 (C-6´´), 148.23 (C-2´´), 145.86 (C-10´´*), 145.20 (C-
4´´*), 144.98 (C-13´), 142.08 (C-10´), 131.66 (C-8´´), 128.89 (C-9´´), 127.45 (C-14´), 123.75 (C-7´´), 
120.30 (C-3´´), 115.40 (C-11´), 102.52 (C-5´´), 99.38 (7 × C-1), 83.69 (7 × C-2, 7 × C-3, 7 × C-4), 
80.05 (C-9´), 72.62 (6 × C-5, 6 × C-6), 71.89 (C-5I), 63.37 (C-12´), 61.84 (7 × OCH3-3), 61.14 (C-8´), 
59.10 (7 × OCH3-2, 7 × OCH3-6), 57.20 (C-2´), 56.77 (OCH3-6´´), 52.38 (C-6I), 44.31 (C-6´), 40.49 
(C-3´), 28.97 (C-4´), 27.90 (C-5´), 23.11 (C-7´). 
Signals tagged with * can be mutually interchanged. 
HRMS (ESI): found 1802.8819. For C85H135N5O36 calculated [M+H]+ 1802.8960.  
IR (KBr) 2932, 2830, 1715, 1626, 1512, 1467, 1365, 1144, 1036 cm-1. 
[α]D= +105.9° (c = 0.25, MeOH). 
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6I-Deoxy-6I-(4-(((S)-1-(6-methoxyquinolin-4-yl(5-vinylquinuclidin-
2-yl)methoxy) methyl)-1H-1,2,3-triazol-1-yl)-permethyl-β-CD (24d)  
Compound 24d was prepared according to the general procedure (GP2). 
From 6I-azido-6I-deoxy-permethyl-β-CD 22 (100 mg, 0.07 mmol), 9-O-
propargylquinidine 18d (32 mg, 0.09 mmol) and copper-iodide (3 mg, 0.01 
mmol), 78 mg of product was obtained in the form of a white-yellow solid 
(63% yield). TLC CHCl3/MeOH/conc.aq.NH3 20/1/0.1): RF = 0.38. 
1H NMR (600 MHz, CD3OD): δ (ppm): 8.74-8.72 (m, 1H, H-2´´), 8.00-7.99 
(m, 1H, H-8´´), 7.97 (s, 1H, H-14´), 7.69-7.66 (m, 1H, H-3´´), 7.54-7.50 (m, 
1H, H-5´´), 7.49-7.46 (m, 1H, H-7´´), 6.03-5.97 (m, 1H, H-10´), 5.39-5.37 
(m, 1H, H-1I), 5.25-5.10 (m, 6H, H-1), 5.06-5.04 (m, 1H, H-6aI), 5.03-5.01 
(m, 2H, H-11´), 4.85-4.83 (m, 1H, H-6bI), 4.59 (s, 2H, H-12´), 4.15-4.11 
(m, 1H, H-5I), 3.99 (s, 3H, OCH3-6´´), 3.90-3.35 (m, 18H, H-5, H-6), 3.67-
3.53 (m, 21H, OCH3-3), 3.58-3.48 (m, 21H, OCH3-2), 3.62-3.45 (m, 14H, 
H-3, H-4), 3.45-3.27 (m, 18H, OCH3-6), 3.23-3.05 (m, 7H, H-2), 3.13-3.11 (m, 1H, H-8´), 2.89-2.87 
(m, 2H, H-6´), 2.86-2.84 (m, 1H, H-2a´), 2.77-2.75 (m, 1H, H-2b´), 2.34-2.31 (m, 1H, H-3´), 2.16-
2.12 (m, 1H, H-7a´), 1.74-1.72 (m, 1H, H-4´), 1.62-1.54 (m, 2H, H-5´), 1.35-1.27 (m, 1H, H-7b´).  
 H-9´signal is not seen. 
13C NMR (150 MHz, CD3OD):  δ (ppm): 159.82 (C-6´´), 148.44 (C-2´´), 146.45 (C-10´´*), 145.14 (C-
4´´*), 145.06 (C-13´), 141.69 (C-10´), 131.59 (C-8´´),  128.94 (C-9´´), 127.42 (C-14´), 123.61 (C-7´´), 
120.66 (C-3´´), 115.39 (C-11´), 102.56 (C-5´´), 99.39 (7 × C-1), 81.52 (C-9´), 83. 47 (7 × C-2, 7 × C-
3, 7 × C-4), 72.51 (6 × C-5, 6 × C-6), 71.80 (C-5I), 63.41 (C-12´), 61.91 (7 × OCH3-3), 60.89 (C-8´), 
59.25 (7 × OCH3-2, 6 × OCH3-6), 56.46 (OCH3-6´´), 52.33 (C-6I), 50.85 (C-2´), 50.26 (C-6´), 41.12 
(C-3´), 29.50 (C-4´), 27.12 (C-5´), 23.67 (C-7´). 
Signals tagged with * can be mutually interchanged. 
HRMS (ESI): found 1802.8839. For C85H135N5O36 [M+H]+ calculated 1802.8960.  
IR (KBr)  2929, 2836, 1619, 1461, 1365, 1228, 1135, 1072, 1042 cm-1. 
[α]D25= +146.9° (c = 0.48, MeOH). 
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6A,6D-Dideoxy-6A,6D-Bis((4-(((S)-(6-methoxyquinolin-4-yl)(5-
vinylquinuclidin-2-yl)methoxy)methyl)-1H-1,2,3-triazol-1-yl)-α-CD (27)  
The starting material 6A,D-diazido-6A,D-dideoxy-α-CD (25 mg, 
0.025 mmol, 7), prepared according to a combination of 
previously published procedures38,43,23, was dissolved in 0.2 mL 
of distilled H2O (sonicated for 10 minutes under Ar atmosphere). 
9-O-propargyl-quinine 18c (12 mg, 0.03 mmol) was dissolved in 
0.2 mL of distilled THF (sonicated for 10 minutes under Ar 
atmosphere) and added to the CD derivative. Copper iodide 
(0.013 mmol), suspended in 0.1 mL of distilled H2O (sonicated 
for 10 minutes under Ar atmosphere), was added to the reaction mixture and stirred at 50 °C for 16 
hours. Conversion into the product was monitored by TLC in ACN/H2O/conc.aq.NH3 (10/5/1). After 
full conversion into the product, the reaction mixture was slowly added to acetone (75 mL) under 
stirring, resulting in a white-yellow precipitate. This solid was recovered by filtration, washed with 
acetone (3 × 20 mL) and dried to constant weight in a vacuum drying box in the presence of P2O5 and 
KOH. The crude product was purified by column chromatography (50 g of silica gel) with the mobile 
phase ACN/H2O/NH3 12/5/1. A blue precipitate formed at the top of the column as copper cations 
interacted with ammonia ions. The purified product was dried at 50 °C under reduced pressure. It was 
isolated 33 mg of a white-yellow product 27 (76% yield). TLC (ACN/H2O/conc.aq.NH3 (10/5/1): RF = 
0.60. 
1H NMR (600 MHz, DMSO-d6): δ (ppm): 8.75-8.73 (m, 2H, H-2´´), 8.22 (s, 2H, H-14´), 7.94-7.95 (m, 
2H, H-8´´), 7.83-7.81 (m, 2H, H-3´´), 7.65-7.63 (m, 2H, H-5´´), 7.43-7.41 (m, 2H, H-7´´), 5.78-5.76 
(m, 2H, H-10´), 5.62-5.36 (m, 12H, OH-2, OH-3), 5.01-4.99 (m, 2H, H-11a´), 4.94-4.92 (m, 2H, H-
11b´), 4.87-4.85 (m, 2H, H-6aI,IV), 4.80-4.72 (m, 6H, H-1), 4.78-4.76 (m, 2H, H-6bI,IV), 4.58-4.44 (m, 
4H, OH-6), 4.52-4.50 (m, 2H, H-12a´), 4.40-4.38 (m, 2H, H-12b´), 4.00-3.98 (m, 2H, H-5I,IV), 3.95 (s, 
6H, OCH3-6´´), 3.88-3.21 (m, 33H, H-2, H-3, H-4, H-5, H-6), 3.38-3.39 (m, 2H, 8´´), 2.44-2.42 (m, 
2H, H-3´), 1.80-1.78 (m, 2H, H-4´). 
 H-2 ,´ H-6 ,´ H-5 ,´ H-7 ,´ H-9 ,´ C-5 ,´ C-7´, C-9´signals are not fully seen. 
13C NMR (150 MHz, DMSO-d6): δ (ppm): 157.56 (2 × C-6´´), 147.44 (2 × C-2´´), 144.20 (2 × C-
4´´*), 144.02 (2 × C-10´´*), 142.94 (2 × C-13´), 140.35 (2 × C-10´), 131.21 (2 × C-8´´), 126.95 (2 × 
C-9´´), 125.50 (2 × C-14´), 121.76 (2 × C-7´´), 118.77 (2 × C-3´´), 115.22 (2 × C-11´), 102.18 (2 × C-
5´´), 101.90 (6 × C-1), 83.06 (6 × C-4), 71.52 (6 × C-2, 6 × C-3, 4 × C-5), 69.07 (2 × C-5I,IV), 61.93 (2 
× C-12´), 61.58 (4 × C-6), 59.02 (2 × C-8´), 56.18 (2 × OCH3-6´´), 54.10 (2 × C-2´), 50.46 (2 × C-
6I,IV), 42.65 (2 × C-6´), 37.79 (2 × C-3´), 26.73 (2 × C-4´). 
Signals tagged with * can be mutually interchanged. 
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HRMS (ESI): found 874.3652. For C82H110N10O32 calculated [M+2H]2+ 874.3717. 
IR (KBr) 3183, 3120, 2935, 1710, 1650, 1401, 1258, 1111, 1048 cm-1. 
[α]D25= +40.7° (c = 0.17, DMSO). 
6.6.  Synthesis of substrates for the organocatalytic reactions 
Methyl 2-(hydroxy(phenyl)methyl)acrylate (28) 
Compound 28 was prepared according to a previously published procedure.166 1H 
NMR and MS spectra are in accordance with the literature. 
1H NMR (400 MHz, CDCl3): δ (ppm): 7.40-7.30 (m, 5H), 6.35 (t, J = 1.6 Hz, 1H), 
5.88 (t, J = 2.4 Hz, 1H), 5.56 (s, 1H), 3.71 (s, 3H), 3.36 (bs, 1H). 
MS (ESI): found 192.1. For C11H12O3 calculated [M+Na]+ 192.1. 
Methyl 2-(hydroxy(4-nitrophenyl)methyl)acrylate (29) 
Compound 29 was prepared according to a previously published procedure.166 1H 
NMR and MS spectra are in accordance with the literature. 
1H NMR (400 MHz, CDCl3): δ (ppm): 8.18-8.16 (m, 2H), 7.56-7.54 (m, 2H), 
6.38 (s, 1H), 5.88 (d, J = 0.8 Hz, 1H), 5.62 (s, 1H), 3.73 (s, 3H), 3.33 (bs, 1H). 
MS (ESI): found 237.1. For C11H11NO5 calculated [M+Na]+ 237.1. 
 
4-Hydroxy-4-(4-nitrophenyl)butan-2-one (30) 
Compound 30 was prepared according to a previously published procedure.167 1H 
NMR and MS spectra are in accordance with the literature.168,169 
1H NMR (400 MHz, CDCl3): δ (ppm): 8.17-8.15 (m, 2H), 7.53-7.51 (m, 2H), 5.27 
(t, J = 6.0 Hz, 1H), 3.69 (bs, 1H), 2.87 (d, J = 6.0 Hz, 1H), 2.23 (s, 3H). 
MS (ESI): found 209.1. For C10H11NO4 calculated [M+Na]+ 209.1. 
 
Dimethyl 2-(2-nitro-1-phenylethyl)malonate (31) 
Compound 31 was prepared according to a previously published procedure.170 1H 
NMR and MS spectra are in accordance with this literature.  
1H NMR (400 MHz, CDCl3): δ (ppm): 7.30-7.25 (m, 5H), 4.90-4.87 (m, 2H), 4.23-
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4.21 (m, H), 3.86 (d, J = 6.9 Hz, 1H), 3.73 (s, 3H), 3.53 (s, 3H).  
MS (ESI): found 281.2. For C13H15NO6 calculated [M+Na]+ 281.2. 
Methyl 2-(phenyl((phenylcarbamoyl)oxy)methyl)acrylate (32)  
Compound 32 was prepared according to a previously published procedure.137  
1H NMR and MS spectra are in accordance with this literature.  
1H NMR (400 MHz, CDCl3): δ (ppm): 7.46 – 7.24 (m, 9H), 7.06 (t, J = 7.4 Hz, 
1H), 6.80 (s, 1H), 6.71 (s, 1H), 6.44 (s, 1H), 5.91 (s, 1H), 3.72 (s, 3H). 
MS (ESI): found: 334.1. For C18H17NO4 calculated [M+Na]+ 334.1.  
Methyl (R)-2-(phenyl(phenylamino)methyl)acrylate (33) 
Compound 32 was prepared according to a previously published procedure 
from MBH carbamate 32.137 1H NMR and MS spectra are in accordance with 
this reference.171 
1H NMR (400 MHz, CDCl3): δ (ppm): 7.41 – 7.27 (m, 5H), 7.22 – 7.10 (m, 2H), 
6.77 (t, J = 7.3 Hz, H), 6.64 (d, J = 7.8 Hz, 2H), 6.41 (s, 1H), 6.03 (s, 1H), 5.43 (s, 
1H), 4.17 (bs, 1H) 3.71 (s, 3H).  
MS (ESI): found 290.1. For C17H17NO2 calculated [M+Na]+ 290.1.   6.7.  General procedures for organocatalytic reactions 
General procedure for the MBH reaction  
The starting material, aromatic or aliphatic aldehydes were dissolved in DMF, MeOH or buffer/MeOH 
(phosphate buffer (pH=7.1, 0.05M or pH=8.0, 0.05M). Corresponding acrylates (methyl-acrylate or 
hexafluoroisopropyl-acrylate) and Cinchona-CD derivatives (19b, 20b, 23c or 24b) were added to the 
mixture and stirred at 25 °C for 168 hours. Conversion into the product was monitored by TLC in 
hexane/EtOAc (6:1) and by 1H NMR.  
General procedure for the aldol reaction  
The starting material, p-NO2-benzaldehyde were dissolved in acetone (5 eq.) and Cinchona-CD 
derivatives (1 eq., 20c or 23a) were dissolved in H2O/acetone (5 eq.) and added to the mixture and 
stirred at 25 °C for 168 hours. Conversion into the product was monitored by TLC in hexane/EtOAc 
(5:1). The reaction mixture was evaporated and crude product was purified by column 
chromatography (hexane/EtOAc 5:4). NMR and MS spectra of racemic products are in accordance 
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with the literature.167 The enantiomeric excess was measured on IA column (heptane/propan-2-ol 
90:10, λ = 235 nm, flow = 0.5 mL/min, t = 25 °C). Retention times of the products: tR = 30.0-31.0 min. 
General procedure for the Michael addition 
The starting materials, trans-NO2-styrene and dimethyl-malonate were dissolved in EtOH. Cinchona-
CD derivative (23b) were added to the mixture and stirred at 25 °C for 168 hours. Conversion into the 
product was monitored by TLC in hexane/EtOAc (1:1). The reaction mixture was evaporated and 
crude product was purified by column chromatography (hexane/EtOAc 3:1). NMR and MS spectra of 
the racemic product are in accordance with the literature.170 The enantiomeric excess was measured on 
OD-H column (heptane/propan-2-ol 70:30, λ = 230 nm, flow = 0.9 mL/min, t = 25 °C). Retention 
times of the products: tR = 11.6 min (major enantiomer), tR = 13.7 min (minor enantiomer). 
General procedure for the AAA reaction 
The starting material, MBH carbamate 32 was dissolved in ACN/H2O (for CD catalysts 19a‒19d, 
20a‒20d and 27) or toluene (for CD catalysts 23a‒23d, 24a‒24d) to achieve 0.4 M solution. 
Cinchona-CD derivatives (19a‒19d, 20a‒20d, 27, 23a‒23d, 24a‒24d) were added to the mixture and 
stirred at 40 °C for 168 hours. Conversion into the product was monitored by TLC in hexane/EtOAc 
(6:1). The reaction mixture was evaporated and crude product was purified by column 
chromatography (hexane/EtOAc 10:1). NMR and MS spectra of product 33 are in accordance with the 
literature137. The enantiomeric excess was measured on IB column (heptane/propan-2-ol 99:1, λ = 205 
nm, flow = 1.0 mL/min, t = 25 °C). Retention times of the products: tR = 9.0 – 10.5 min (major 
enantiomer), tR = 9.5 – 11.2 min (minor enantiomer).  
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10. SUPPLEMENTAL INFORMATION 
 
 
Figure S1. Distances d1 (blue) between C19 of quinine (quinuclidine part) and the primary rim of β-
CD, and d2 (green) between C19 of quinine and the secondary rim β-CD, presented the inclusion 
complex of β-CD and quinine. 
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Figure S2. Distances d3 (purple) between C10 of quinine (quinuclidine part) and the primary rim of β-
CD, and d4 (orange) between C10 of quinine and the secondary rim of β-CD and quinine, presented 
the inclusion complex of β-CD and quinine.  
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Figure S3. Distances d5 (black) between C1 of quinine (quinoline part) and the primary rim of β-
CD, and d6 (yellow) between C1 of quinine and secondary rim of β-CD and quinine, presented the 
inclusion of β-CD and quinine. 
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Figure S4. Distances d7 (light-blue) between C0 atom of methoxy group of quinine (quinoline part) 
and the primary rim of β-CD, and d8 (magenta) between C0 atom of methoxy group of quinine, 
presented the inclusion of β-CD and quinine. 
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Figure S5. Distances d1 (blue) between H76 of vinyl group of quinuclidine moiety and H-3 atoms of 
the cavity, and d2 (green) between H64 of quinoline moiety and H-3 atoms of the CD cavity, 
confirming the self-inclusion of catalyst 20a. 
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Figure S6. Distances d1 (blue) between H76 of vinyl group of quinuclidine moiety and H-3 atoms of 
the cavity, and d2 (green) between H64 of quinoline moiety and H-3 atoms of the CD cavity, 
confirming the self-inclusion of catalyst 20b. 
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Figure S7.  Distances d1 (blue) between H76 of vinyl group of quinuclidine moiety and H-3 atoms of 
the cavity, and d2 (green) between H64 of quinoline moiety and H-3 atoms of the CD cavity, 
confirming the self-inclusion of catalyst 20c. 
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Figure S8. Distances d1 (blue) and d2 (green) for the inclusion of the substituent inclusion into the 
CD cavity in catalyst 24b. 
 
